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1. Introduction 
1.1. MDR – making Cancer invulnerable? 
Cancer is the second highest cause of death in industrialized countries [1,2]. A broad range of 
diverse compounds with distinct mechanisms of anticancer activity has been developed and 
become available for treatment and is used in the clinical practice. Approved drugs include 
Vinca alkaloids (like vincristine), which depolymerize microtubules, Anthracyclines (like 
doxorubicin), that intercalate into DNA and inhibit DNA topoisomerase II, antimetabolites 
like methotrexate, DNA intercalating agents like cisplatin and several others [3]. Despite the 
diversity of drugs used for the treatment of cancer the development of drug resistance is a 
frequent reason for the failure of cancer chemotherapy [1,2]. Moreover, cells that are resistant 
to a certain cytotoxic agent can build up cross-resistance to other structurally and 
mechanistically unrelated drugs, leading to the phenotype of Multidrug Resistance (MDR) 
[3]. 
Resistance can emerge as a result of genetic changes, whereby targets are overexpressed or 
structurally modified in a manner that the binding of cytostatic agents is reduced [3–6]. An 
adaption can also consist of increased repair of damage caused by the applied drug, as for 
example in the case of DNA repair [3–5]. Signaling pathways can be modified, in order to 
overcome the dependence on the drug target [7]. An altered cellular metabolism can 
furthermore lead to an increased inactivation or decreased activation of a cytotoxic agent [3–
6]. The cellular response to drugs can also be altered as a result of decreased availability of 
the agent. This can be achieved by sequestering of drugs within cellular compartments, a 
reduced inward- or mostly active outward transport (efflux) of cytotoxic agents [3–5]. 
This efflux is energy dependent and mediated by transport proteins of the ATP-binding-
cassette (ABC) family. The human genome contains 48 genes that encode ABC transporters. 
The gene product of ABCB1, P-glycoprotein (P-gp), stands out among ABC transporters by 
conferring the strongest resistance to the widest variety of compounds [3–5,8–10]. 
Since the development of MDR is a multifactorial process, additionally to the increased 
expression of drug efflux pumps (which will be covered in detail in the next chapter), many 
other genetic changes are implicated with the MDR phenotype [3]. 
In the 1920ies Warburg discovered that the cellular energy metabolism of cancer cells is 
shifted from oxidative phosphorylation to (aerobic) glycolysis [11]. MDR cancer cells are 
reported to undergo a further metabolic shift, which results in an even higher rate of cytosolic 
glycolysis and oxygen consumption accompanied with an increased utilization of fat as a fuel 
source for the mitochondria [12,13]. As a consequence of this metabolic shift, the 
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mitochondrial membrane potential as well as the proton transfer against the gradient of the 
mitochondria are smaller in MDR cancer cells as compared to their parental cell lines [13]. 
The metabolic changes that occur during the development of resistance render the cells less 
susceptible for reactive oxygen species (ROS), DNA damage and apoptosis [13].  
Since the transport of xenobiotic or endogenous substrates imposes a considerable cost in 
energy on a cell, metabolic changes and ABC transporter mediated drug resistance are 
interconnected [14,15]. As a result of increased glycolysis the production of lactic acid is 
increased. As evidenced by drug induced increase in lactate production and extracellular 
acidification rates (ECAR) of MDR cells, the energy consumption caused by the interaction 
of a substrate with P-gp is compensated for by increased glycolysis [15–17]. Inhibition of P-
gp decreased the measured ECAR values, which furthermore correlated well with activation 
profiles of the transporter obtained by means of phosphate release measurements in inverted 
membrane vesicles for the same drugs [16,17]. 
Further metabolic enzymes like the methylglyoxal detoxifying glyoxalase system, might 
confer resistance to antitumor agents [18]. Numerous metabolic changes are mediated by 
Hypoxia inducible factor HIF-1α, as a result of PI3K/AKT/mTOR pathway stimulation 
[19,20]. Disclosing a further connectivity between metabolic changes and ABC transporters, 
this pathway is furthermore reported to upregulate the expression of P-gp either via activation 
of NFκB [21] or via HIF-1α [19,22,23]. 
The lysosomal accumulation of drugs has been suggested to differ in parental and MDR cells. 
Proton pumps like the vacuolar type H
+
-ATPase mediate intracellular pH gradients, which 
drive the lysosomal sequestration [24]. Recently the presence of P-gp in lysosomal 
membranes has been suggested as an additional mediator of the sequestration of drugs into the 
lysosome [25]. 
 
 
 
1.2. ABC transporters – stories from a family album 
The superfamily of ATP-binding cassette (ABC) transport proteins consists of seven 
subfamilies, which are classified on the basis of sequence homology and domain organization. 
They are encoded by the ABCA1-10/12/13, ABCB1-11, ABCC1-12, ABCD1-4, ABCE1, 
ABCF1-3 and ABCG1/2/4/5/8 genes [26]. 
In the context of MDR, the first discovered ABC transporter was P-glycoprotein (P-gp, 
encoded by the ABCB1 gene). Investigating Ehrlich ascites tumor cells in 1973 Dano was the 
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first to observe the active, energy dependent outward transport of the cytotoxic agent 
Daunorubicin [27]. Only three years later Juliano and Ling ascertained connectivity between 
MDR and the ABC transporter P-gp [28]. In 1992 a further ABC transporter, the Multidrug 
Resistance associated Protein, MRP1 (encoded by the ABCC1 gene), was identified to be 
linked to MDR and altering intracellular GSH levels [29,30]. As the third important 
transporter involved in MDR the Breast Cancer Resistance Protein BCRP (encoded by the 
ABCG2 gene) was discovered in 1998 [31]. These three transporters are the most important 
efflux transporters conferring MDR. 
In their structural composition they share the presence of two nucleotide binding domains 
(NBD), which are responsible for the ATP binding and hydrolysis that drives drug transport, 
and two transmembrane domains (TMD), which contain the drug-binding sides [32,33]. The 
TMDs are built by six membrane-spanning α-helixes. In case of MRP1 an additional 5-helical 
TMD is present at the N-terminus of the protein, while BCRP is a half-transporter, that needs 
to dimerize (or even oligomerize [34]) in order to function [33,35]. 
The wide substrate spectrum of compounds that is translocated across cellular membranes by 
the three presented transporters is partially overlapping. The heat-map in Figure 1 illustrates 
the structural similarity between the particular substrates. Compounds highlighted in grey are 
transported by all three transporters. Compounds that are transported by a single protein only 
are highlighted by primary colors: P-gp substrates are indicated in blue, BCRP substrates in 
red and MRP1 substrates in yellow. Substrates of two of these transport proteins are indicated 
by the mixed color, therefore compounds transported by P-gp and BCRP are highlighted in 
violet, substrates of P-gp and MRP1 in green, and BCRP and MRP1 substrates in orange.  
 
 
 
 
Figure 1: Heat-map of substrates transported by the three MDR transporters P-gp, MRP1 and BCRP. 
The coloring on the upper half illustrates the structural similarity between the compounds as calculated 
from Tanimoto coefficients with the help of the InstantJChem software [36] (as shown in the scale bar 
in the right lower corner, red indicates a coefficient of 1, which is 100% identity, while green indicates 
a coefficient of 0 with no detectable similarity). Due to the symmetry of the heat-map, in the lower 
half of the figure is indicated by which transporter the respective compound is recognized and 
transported: grey: P-gp, MRP1 and BCRP; blue: P-gp, red: BCRP; yellow: MRP1; violet: P-gp and 
BCRP, green: P-gp and MRP1, orange: MRP1 and BCRP. Data on substrate specificity were collected 
from [10,37–40]. 
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A model for a putative transport mechanism is exemplified for P-gp and illustrated in 
Figure 2. Substrates of P-gp are recognized in the context of the plasma membrane due to 
their hydrophobic character and enter the inward-facing drug binding cavity of the transporter 
[41–43]. Upon ATP binding, or ATP binding and hydrolysis, the transporter changes its 
conformation in a manner, that the drug binding domain is facing outward, enabling the 
release of the substrate [43–46]. While for most substrates, P-gp is able to establish a 
concentration gradient against the membrane, for lipophilic substrates, a renewed entry of the 
same molecule is possible, resulting in a cycle of constant efflux. This so-called “futile 
cycling” elevates the energy demand of the cell but can also inhibit the efflux of other (lower 
affinity) substrates from the pump [14,41]. 
 
 
 
Figure 2: P-gp acts as a “hydrophobic vacuum cleaner” of the membrane, preventing the entry of 
substrates into the cell – modified from [41,43]. The substrate (magenta) enters the membrane and 
diffuses into the drug binding pocket (blue) of the transporter. Upon binding and hydrolysis of two 
ATP molecules (yellow) the conformation of the transporter changes from an inward- to an outward 
facing conformation, following release of the substrate. 
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1.3. Attempts to overcome MDR 
In order to circumvent the transporter mediated resistance, inhibiting the transporters 
appeared to be a valuable approach. The first report following this idea was published in 1981 
with the discovery of P-gp inhibitory potential of the Ca
2+
-channel blocker Verapamil [47]. 
Together with further drugs, which were already approved for other medical purposes 
(Quinine and Cyclosporine A), the “first generation” of P-gp-inhibitors was born [9,48]. The 
low efficacy of these compounds together with their toxic side effects led to the development 
of “second generation” inhibitors, which were modified in a way to decrease the side effects 
caused by the interaction with the original targets of the first generation [9,48]. Despite the 
achieved improvement, second generation inhibitors like Dexverapamil and Valspodar (PSC-
833) showed pharmacokinetic interactions, that resulted in the failure of clinical trials 
[9,48,49]. In contrast, “third generation” inhibitors, like Tariquidar, Elacridar and many 
others, have been specifically designed for the interaction with the ABC transporter, and 
therefore possess P-gp inhibitory potential at low concentrations [9,48,49]. Figure 3 gives an 
overview over some reported ABC transporter inhibitors. 
 
Despite promising in vitro results, successful translation of MDR transporter inhibition to the 
clinic remains elusive [35,37,50–53]. Several factors might explain the failure in the clinical 
trials, such as the intrinsic toxicity of the modulators and the unwelcome inhibition of 
transporters residing in pharmacological barriers (blood brain barrier, placenta, GI-tract, 
liver), resulting in an altered distribution of the simultaneously administered chemotherapy 
[35,51,52]. Furthermore, many P-gp inhibitors are reported to interact with Cytochrome P450 
[35,52].
 
Genetic polymorphisms of ABC transporter genes, as represented by single-
nucleotide polymorphisms (SNPs), may have prevented optimal results from the clinical 
evaluation of their inhibitors [35,37]. A poor outcome and marginal benefit in the clinical 
trials can also be explained by insufficient preclinical evaluation [35] as well as the 
inadequate selection of patients for the enrolment of the trials: The proof that P-gp or other 
ABC transporters were the main reason for resistance of treated patients was missing [37,50].
 
The development of imaging tools to ensure that patients involved into clinical trials of ABC 
transporter inhibitors really express the transporters as main mechanisms of resistance, rather 
than as a marker of a more aggressive phenotype, is needed before the resumption of clinical 
trials [37,53]. 
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Figure 3: Inhibitors of ABC transport proteins, reported in the literature [35,37–39,52,54–64]. 
Applying the color code used in Figure 1, compounds inhibiting P-gp are marked in blue, inhibitors of 
BCRP in red, and MRP1 inhibitors in yellow. Compounds inhibiting more than one transporter are 
located in the intersections. 
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As summarized in Figure 4, further strategies to overcome ABC-transporter mediated MDR 
exist next to the inhibition of the transporters, which might “engage” the transporter. Another 
approach is, to develop compounds that do not interact with the transport protein and 
therefore “evade” it. The third strategy employs compounds, which selectively kill the MDR 
cells, “exploiting” vulnerabilities that are connected to the MDR phenotype. 
 
 
Figure 4: Strategies to overcome ABC transporter mediated MDR (top) include “engaging” the 
protein with the use of inhibitors (left), “evading” the transporter by the development of compounds 
which are not recognized (down), and “exploiting” it, by application of collateral sensitivity [9]. 
 
 
 
1.4. Collateral sensitivity – in search for the Achilles’ heel 
The term “collateral sensitivity” (CS) was first used by Szybalski and Bryson in 1952 to 
describe the increased sensitivity of Escherichia coli bacteria strains treated with a certain 
chemotherapeutic agent toward other, unrelated antibiotics [65]. 
Similarly, many reports can be found on MDR cancer cells exhibiting an – compared to their 
parental cell lines – enhanced sensitivity toward diverse compounds with distinct putative 
mechanisms of action [41,42,66]. As insinuated in chapter 1.1. the adaption processes that 
occur during the development of the MDR phenotype comprise numerous cellular changes, 
which, next to the benefit of survival in the presence of chemotherapeutic agents, may also 
provide vulnerable target points for the selective elimination of MDR cells [42]. For example, 
an increased drug metabolizing activity of MDR cells might result in a higher activation of 
xenobiotics, as observed for the natural product austocystin D. It has been shown, that the 
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enhanced P-gp expression in cell lines collateral sensitive to austocystin D is rather 
coincidental, since the selective toxicity of the compound toward MDR cell lines arises from 
its selective activation by cytochrome P450 (CYP) enzymes in specific cancer cell lines [67]. 
In contrast, in many cases ABC transporters have been reported to mediate paradoxical 
hypersensitivity by different mechanisms. One possible explanation could be that an MDR 
selective agent facilitates or stimulates the extrusion of an endogenous essential molecule 
by the transporter [66]. In case of MRP1 mediated collateral sensitivity, an enhanced toxicity 
of compounds might be explained by the (co-)transport of glutathione and glutathione-drug 
conjugates by the transporter: an enhanced export of this antioxidant will disturb the 
intracellular redox-homeostasis to a higher extent in the transporter expressing cells as 
compared to the parental cell lines, causing a higher extent of oxidative stress and cellular 
damage [68]. Since GSH is not a substrate of P-gp, this mechanism might not apply for the 
multiple cases of reported collateral sensitivity in cells, in which P-gp is responsible for the 
MDR phenotype of investigated cells [69]. 
The first reports on collateral sensitivity in P-gp expressing cells cover compounds that 
disrupt the plasma membrane, like the detergent Triton X-100 [70]. Similarly, several 
opiates induced collateral sensitivity that was related to fluidizing effects on membrane 
biophysical properties of P-gp expressing cells [71]. Since P-gp requires interaction with 
phospholipids for continuous drug-mediated ATPase activity and interaction with the 
substrate, a disruption of the plasma membrane will also affect the activity of the transport 
protein [72,73]. Even though differences in the biophysical properties of plasma membranes 
of drug-sensitive and MDR cells could be confirmed on a panel of cell lines, the increased 
toxic effect of Triton-X-100 on P-gp expressing cells could not be verified in a tetracycline-
repressible (tet-off) plasmid system, in which P-gp expression was repressed upon treatment 
with tetracycline [74]. A further example of membrane perturbing agents causing collateral 
sensitivity is given by the block-copolymers Pluronic P85 and P105. A possible interaction of 
such a polymer with the lipid raft region, the micro domain of the cellular membrane 
surrounding P-gp, is shown in Figure 5. As stated above, this interaction will inhibit the 
function of P-gp, and therefore sensitize MDR cell lines toward cytotoxic drugs [73]. 
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Figure 5: Cellular membrane with incorporated P-gp in the absence (left) and presence (right) of a 
Pluronic block-copolymer (blue / intense red). The intracellular lumen is located below the membrane, 
which is shown in Top (top) and side angle (below) view. P-gp (blue) is embedded in the membrane 
containing phospholipids with mainly unsaturated fatty acids (grey) in a micro domain called lipid 
raft. Lipid rafts contain cholesterol (red) and sphingomyelin (orange) – modified from [73]. 
 
 
In addition to the effect on the cellular membrane, Pluronic co-polymers P85 and P105 have 
been reported to decrease cellular ATP pools in MDR cells, but not in their parental 
counterparts [75,76]. The resulting sensitizing effect of Pluronics toward cytotoxic agents 
could be abolished by ATP supplementation [75]. It has been described that the block co-
polymers differentially affect the mitochondrial functions in MDR and non-MDR cells, 
evoking an increased toxicity in P-gp expressing cells [76]. Even though the lower 
mitochondrial membrane potential found in MDR cells as compared to parental cells might 
explain the intrinsically increased sensitivity of the MDR cells toward the co-polymers, two 
evidences suggest a role of P-gp in this effect [13,76]: the higher responsiveness of the 
respiratory chain of MDR cells is not only abrogated in the presence of the P-gp inhibitor 
Elacridar, but also not only observed in drug-selected MDR cells, but also in cells transfected 
with P-gp [76].  
Due to the energy dependence of the efflux by ABC transporters, P-gp-expressing cells might 
be more sensitive to compounds that interfere with cellular metabolic pathways and therefore 
cause changes in energy utilization [66]. Yet, the interaction of a compound with the cellular 
metabolic pathways does not necessarily require it’s interaction with P-gp. An increased 
sensitivity to changes in energy levels of MDR cells might explain the preferentially killing 
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of MDR cells by the antimetabolites, like 2-deoxy-d-glucose, and the electron transport chain 
inhibitors rotenone and antimycin A [66,77,78]. 
 
 
 
Figure 6: Structures of compounds with reports on CS (for details, see text). 
 
 
Since the first reports about application in MDR cancer cells due to the interaction with P-gp 
in 1981 [47], the Ca
2+
-channel blocker Verapamil has received a lot of attention. At lower 
concentrations Verapamil is a (“nontransported”) P-gp substrate, which has an ATP depleting 
effect on MDR cells due to a rapid cyclical efflux, re-entry and efflux (“futile cycling”, 
Figure 6) [14,15,41,79]. This elevated energy depletion in P-gp expressing cells might be a 
possible explanation for the differential effect on cell viability of MDR and non MDR 
Chinese Hamster ovary (CHO) cells, which was already reported as early as 1986 [80]. Also 
in other cell line models Verapamil preferentially induced apoptosis in MDR cells compared 
to drug-sensitive cells [81,82]. A biphasic effect was observed for the effect of Verapamil on 
P-gp ATPase activity and cell viability: while at lower concentrations the ATPase activity was 
stimulated (in agreement with Verapamil being transported out of the cell), at higher 
concentrations it was inhibited. Similarly the induction of apoptosis followed a biphasic trend 
[82,83]. Even though increased glycolysis has been suggested as the compensation of higher 
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energy demands due to the “futile cycling” [15–17], reactive oxygen species (ROS), which 
might occur as side products of oxidative phosphorylation, have been suggested to be 
involved in the apoptosis induction by Verapamil [82]. An increased production of ROS is a 
further suggested putative mechanism of increased toxicity toward MDR cell lines [42,66]. 
ROS might also have other sources and causes than futile cycling of P-gp substrates. For 
example the N-(2-mercaptopropionyl)glycine Tiopronin has been reported to possess 
enhanced (but still not very high) toxicity toward a subset of (but not all investigated) MDR 
cell lines expressing P-gp and MRP1 [84]. While inhibiting MRP1, Tiopronin has no impact 
on the function of P-gp [84]. In case of P-gp expressing cell lines, inhibition of the transporter 
by Tariquidar did not alter the activity of the compound [84]. Together with the cell line 
specificity of the effect this suggests, that the collateral sensitivity of MDR cells toward 
Tiopronin might be linked to other factors than P-gp. Follow up studies revealed, that the 
enhanced toxicity toward certain MDR cell lines is indeed linked to the inhibition of 
glutathione peroxidase (GPx), to which Tiopronin covalently binds [85]. In agreement with 
this, the addition of the ROS scavenger N-acetylcysteine (NAC) protected the investigated 
cells from Tiopronin induced toxicity [85]. 
Likewise, chelators might induce ROS upon formation of redox active metal complexes [86–
89]. A paradoxical hypertoxicity against the Vinblastine selected P-gp-overexpressing cervix 
carcinoma cell line KB-V1 as compared to its parental cell line KB-3-1 has been reported for 
the thiosemicarbazone metal chelator di-2-pyridylketone-4,4,-dimethyl-3-thiosemicarbazone 
(Dp44mT) [86,90]. The lysosomal accumulation of the redox active copper complex of the 
ligand might be involved in the mechanism of toxicity of this ligand [87]. It has been 
suggested, that lysosomal P-gp might contribute to this mechanism, explaining a potential 
hypersensitivity [90]. Yet, experiments performed on different cell lines suggested, that this 
effect might not be generalized, as only a weak correlation could be found between the 
sensitivity of investigated cell lines toward the P-gp substrate Doxorubicin and Dp44mT 
(based on data of Supplement from [86]). 
Further compounds with remarkably enhanced toxicity toward a P-gp expressing cell line, 
namely the Vincristine selected KB-VIN cell line, are derivatives of the natural product 
Desmosdumotin B, which was isolated from the root Desmos dumosus [91]. While the parent 
compound 5-hydroxy-7-one-6,8,8-trimethylflavone, already showed a 20-fold higher activity 
in KB-VIN cells, than in KB-3-1 cells [92], derivatives were designed in order to increase the 
selectivity. The three 6,8,8-triethyl analogues proved to be especially promising, with 4’ 
alkylated derivatives possessing up to 460-fold higher toxicity in the MDR cell line [93,94]. 
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The P-gp dependence of this effect was investigated by co-administration of Verapamil, 
which partially reversed the selectivity of Desmosdumotin B and the triethyl-derivative 
(TEDB). Despite this promising data, the effect was stated to be not generally linked to P-gp, 
but rather restricted to only a few cell lines [93,94]. 
A promising strategy to find compounds that might exploit MDR in a P-gp dependent manner 
is based on a pharmacogenomic approach which utilizes publically available data from the 
Developmental Therapeutics Program (DTP) of the National Cancer Institute (NCI) [95–97]. 
With the help of this tool, the gene expression profiles of human ABC transporters were 
correlated with patterns of drug activity within the NCI60 cell line panel [95,96]. These 60 
cell lines represent tumor types from different origin, including leukemia, colon, lung, central 
nervous system, renal, melanoma, ovarian, breast and prostate cancer [97]. 
 
 
 
 
Figure 7: Correlating publically available toxicity data (as pIC50 values) against the NCI60 cell panel 
with P-gp expression (mean centered data displayed) of the investigated cell lines for the P-gp 
substrate Doxorubicin (A; NSC123127), and the MDR selective compound NSC73306 (B).  
 
 
As illustrated in Figure 7, the toxicity of P-gp substrates show a negative correlation with 
transporter expression (Pearson correlation coefficient < -0.4), due to the efflux of the 
compounds. Panel B of the figure shows, that this approach also identified compounds toward 
which P-gp expressing cells show a paradoxical hypersensitivity (Pearson correlation 
coefficient ≥ 0.4) [95,98].  
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Figure 8: Extracted data from the drug screening against the NCI60 panel data, comparing the activity 
of known P-gp substrates (red), and reported MDR selective agents (blue) [98] in P-gp-positive 
NCI/ADR-res and P-gp-negative OVCAR-8 cells. Additionally, MDR selective Thiosemicarbazones, 
like NSC73306, are highlighted in purple, 8-hydroxyquinoline derived Mannich bases like 
NSC693871 in green.  
 
 
Within the 60 cell lines, a cell line pair with discriminative resistance status can be found, as 
the multidrug resistant NCI/ADR-res cells are derived from OVCAR-8 ovarian 
adenocarcinoma cells [99]. While the 60 cell lines in the panel are quite dissimilar to each 
other, this cell line pair shows some commonalities. Therefore comparing the activity toward 
these two related cell lines gives a further impression on the impact of MDR on the activity of 
compounds. Assuming, that P-gp expression is a major characteristic of the MDR phenotype 
in the investigated cell line (which is in agreement with the available expression data), a plot 
of activity toward the MDR cell line on the on the y-axis, vs. activity of the same compound 
against the parental cell line (X-axis), as exemplified in Figure 8, will show substrates of the 
transporter under the bisecting line. Compounds, selectively targeting MDR cells can be 
found above the bisecting line.  
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Table 1: Correlation data of the drug screening against the NCI60 panel data vs. P-gp expression as 
illustrated in Figure 7. Data are given for example compounds identified to be putatively MDR 
selective based on their Pearson correlation coefficient, as reported in [98], in comparison to the P-gp 
substrate Doxorubicin. 
 
NSC123127 
Doxorubicin 
 
Pearson correlation coefficient r: -0.45 
IC50 (OVCAR-8) / µM 0.12 
IC50 (NCI/ADR-res) / µM 1.58 
SR (OVCAR8 / NCI/ADR-res)  0.08 
NSC73306 
I-a 
 
Pearson correlation coefficient r: 0.49 
IC50 (OVCAR-8) / µM 7.56 
IC50 (NCI/ADR-res) / µM 2.09 
SR (OVCAR8 / NCI/ADR-res)  3.63 
NSC693630 
 
Pearson correlation coefficient r: 0.40 
IC50 (OVCAR-8) / µM 1.66 
IC50 (NCI/ADR-res) / µM 2.29 
SR (OVCAR8 / NCI/ADR-res)  0.72 
NSC168468 
 
Pearson correlation coefficient r: 0.46 
IC50 (OVCAR-8) / µM 2.19 
IC50 (NCI/ADR-res) / µM 0.15 
SR (OVCAR8 / NCI/ADR-res)  14.45 
NSC693871 
 
Pearson correlation coefficient r: 0.68 
IC50 (OVCAR-8) / µM 10.96 
IC50 (NCI/ADR-res) / µM 2.40 
SR (OVCAR8 / NCI/ADR-res)  4.57 
 
 
The collateral sensitivity of diverse MDR cancer cells toward the compounds identified in this 
way is abrogated in the presence of a P-gp inhibitor, suggesting that in addition to the export 
of substrates, ABC transporters may directly sensitize MDR cells to the effect of other 
compounds [95,98,100]. Based on the positive correlation of activity within the cell line panel 
with P-gp expression Türk et al. reported the potential of 64 compounds to possess MDR 
selectivity [98]. Out of this discovery set, 35 compounds were available for verification 
experiments in KB-3-1 and KB-V1 (vide supra) cells. While three compounds were not toxic 
in the test system and ten provided equal toxicity toward both cell lines, 22 of the identified 
compounds proved to be MDR selective [98]. The fraction of IC50 values obtained in P-gp 
negative vs. positive cells can serve as a quantification of CS, and is called selectivity ratio 
(SR) [41]. Table 1 gives some examples of compounds with Pearson correlation coefficients 
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calculated from the drug effects over the NCI60 cell panel against the P-gp expression, as 
well as IC50 and SR values comparing the toxicity toward ovarian carcinoma cells OVCAR-8 
(P-gp negative) and NCI/ADR-res (P-gp positive). The well-known P-gp substrate 
Doxorubicin gives a negative correlation coefficient and an inverse (< 1) SR [8,10,35,37,101], 
while the confirmed MDR selective agents NSC73306 [95,98,100,102,103] and NSC168468 
[98] show positive correlations and a SR higher than two. 
Despite of showing some degree of diversity, the compounds identified by the pharmaco-
genomic approach share the ability to chelate metal ions. Strikingly, an enrichment in isatin-β-
thiosemicarbazone structures like NSC73306 can be found (9 out of the 64 potentially MDR 
selective compounds) [95,98,100,102,103]. Several attempts have been made to identify the 
structural features of isatin-β-thiosemicarbazones that are responsible for the MDR selective 
activity. The major findings, that resulted in a pharmacophore model are summarized in 
Figure 9 [102]. The thiosemicarbazone (TSC) scaffold is required for the selective toxicity 
toward MDR cell lines: replacement of the sulfur to oxygen significantly decreases toxicity 
[102,103]. Likewise, a bulky or aromatic moiety appears to be required at the N4 of the TSC 
moiety (counting of atoms in the TSC moiety according to green numbers) [42,102,103]. This 
aromatic moiety might be substituted at positions 2’, 3’ or 4’, out of which the para 
substitution (4’) was found to be optimal, while ortho (2’) and meta (3’) substitutions have 
been concluded to be not beneficial [42]. Although the available data on ortho and meta 
substituted aromatic rings might not be sufficiently convincing, to definitely exclude the 
activity of these compounds, since many of those reported compounds show multiple 
substitutions on the aromatic ring. For chloro-substitutions, the meta substituted derivative 
was even superior to the para one, in terms of toxicity, while being equally selective [103]. 
The isatin moiety – or at least the lactam – seems to be necessary for selective activity. An 
extension of the aromatic ring system disrupts activity, while substitution at the 5th position 
might be tolerated in case of halogens or a nitro-group, but not in case of a sulfonate, which 
might be explained by a reduced cell permeability of the resulting negatively charged 
molecule [102]. 
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Figure 9: SAR / pharmacophore model on isatin-β-TSCs, created after references [42,102,103]. 
 
 
 
1.5. Putting the bite on metals – Role of Chelation in (MDR) Cancer therapy 
Chelators are investigated for their therapeutic potential in the treatment of diverse diseases 
including metal overload and diseases related to imbalanced metal homeostasis like 
hemochromatosis, β-thalassemia, Alzheimer’s or Parkinson’s diseases and cancer 
[86,88,104,105]. Several chelators display significant antitumor activity, and some were even 
shown to exhibit enhanced toxicity toward otherwise multidrug resistant cancer cell lines 
[89,95,98,100,102]. As indicated in chapter 1.4., the compounds identified by the 
pharmacogenomic approach to potentially overcome MDR by selectively targeting P-gp-
expressing cells all share the ability to bind metal ions [98].  
MDR in cancer is a highly relevant research topic, as indicated by the increasing number of 
publications per year (see numbers of PubMed search results in Figure 10). The numbers of 
publications on ABC transporter inhibition trials reflect the importance to overcome MDR. 
While the strategy to exploit vulnerabilities related to MDR by addressing the collateral 
sensitivity of cancer and the selective targeting of MDR cancer cells is relatively 
unconventional, and publication numbers on this topic might just start to rise, the increasing 
number of publications on the use of chelators as anticancer agents shows that this strategy is 
more frequently used. Due to their increased proliferation cancer cells have an altered metal 
homeostasis in order to fulfil the higher demand for metal ions that are critical for cell growth, 
cell-cycle progression and DNA synthesis [86,88,104]. The rate limiting step in DNA 
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synthesis for example is the reduction of ribonucleotides, which is catalyzed by the iron 
dependent enzyme ribonucleotide reductase (RR) [106,107].  
 
 
Figure 10: Number of articles collected in the PubMed database covering the time period from 1955 
to 2014 sorted by publication date. Search results are shown for the keywords “MDR cancer” 
(magenta), “ABC transporter inhibition cancer” (orange), “collateral sensitivity cancer / selective 
toxicity MDR cancer” (green) and “cancer chelation” (blue). 
 
 
Following alkali and alkaline earth metals, iron, zinc and copper are the most abundant 
essential metals in the human body [108]. While zinc is found to have many structure-
supporting and gene regulatory roles, the ability of iron and copper to change between two 
stable oxidation states facilitates their utilization as cofactors with catalytic function in many 
enzymes. It is estimated that at least one third of the human proteome consists of metallo-
proteins and many of them have been associated with a variety of diseases such as cancer, 
inflammatory, infectious, cardiovascular and neurodegenerative diseases [108–110]. The 
elevated demand of cancer cells especially for iron [111,112] and copper [113,114] provides 
promising target points for cancer treatment strategies [88,89,98,104,115]. 
1. Introduction  19 
 
 
The regulation of intracellular metal levels, localization and utilization is tightly regulated 
[116,117]. Figure 11 shows some of the key processes involved in iron and copper 
homeostasis (panel A) and possible interaction points of chelators (panel B).  
Iron uptake is mediated by the transferrin receptor TfR. The shuttle protein transferrin (Tf) 
has two binding sites for ferric iron (Fe
3+
). Upon iron-loading, and binding of two Tf proteins 
to the receptor, the TfR is endocytosed together with other membrane proteins like the copper 
transporter CTR1, the divalent metal transporter DMT1 and the ferrireductase STEAP3 (six 
transmembrane epithelial antigen of the prostate 3). Within the acidic endosome ferric iron is 
released from Tf and reduced by STEAP3 to its ferrous form (Fe
2+
). Fe
2+
 is exported from the 
endosome by DMT1 and becomes available in the cytosol as part of the labile iron pool. 
Recycling of the metal free Apo-Tf bound TfR receptor is achieved via exocytosis 
[88,116,118–120]. Excess of iron can either be stored in the storage protein ferritin, or 
transported out of the cell by the transporter ferroportin (FPN1) [116,118,120]. The 
mitochondrial iron transporter mitoferrin-1 (MTFR) enables utilization in the mitochondria 
for example for iron-sulfur-cluster (ISC) and heme-synthesis, which are both incorporated in 
several metallo-enzymes [119–121]. The expression of proteins involved in iron-homeostasis 
(TfR, DMT1, ferritin, FPN1, enzymes involved in ISC and heme synthesis) is regulated on 
the translational level via the IRE (iron-responsive element) - IRP (iron-regulatory protein) 
system [119,121,122]. FPN1 is additionally regulated on a systemic level via hepcidin 
[88,121]. While only a minor fraction of the intracellular transition metal content is available 
in free ion pools, the amount of metal ions bound to, or incorporated into various proteins is 
much higher [117]. Metal ions serve as cofactors in a wide range of proteins and many iron-
containing proteins have an equivalent copper protein with comparable function: Oxygen can 
be transported by the iron containing proteins hemoglobin and hemerythrin, or the copper 
containing hemocyanin; oxygenation reactions are catalyzed by iron containing cytochrome 
P-450 enzymes, or different oxygenases, as well as by the copper containing tyrosinase and 
quercitinase. Oxidases can be found with iron (peroxidases) and copper (amine oxidases, 
laccase) in their catalytic center – the same holds true for nitrite reductases. Electron transfer 
reactions are found to be mediated by iron containing cytochromes or blue copper proteins. 
Metallo proteins with antioxidative functions are iron containing peroxidases and copper 
containing superoxide dismutase (SOD) [108,114].  
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Figure 11: Cellular metal homeostasis (A) and possible interaction points of chelators (B). Created 
according to references [88,104,108,114–116,118–120,123–125], see text for details. Abbreviations: 
CDK2: Cyclin-dependent kinase 2; CP: ceruloplasmin; CTR1: copper transporter; DMT1: divalent 
metal transporter; FPN1: ferroportin; MTFR: mitotransferrin; NDRG1: N-myc downstream-regulated 
gene 1; IRE-IRP: iron-response element and iron-regulatory protein (1/2); ISC: iron sulfur cluster; Tf: 
Transferrin; TfR: transferrin receptor; STEAP3: six transmembrane epithelial antigen of the prostate 3 
(ferrireductase); ROS: reactive oxygen species.  
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In order to supply the cellular demands on copper, uptake of cuprous copper (Cu
+
) is 
regulated via the copper transporter CTR1, while cupric copper (Cu
2+
) is taken up by DMT1. 
Specific chaperones distribute copper to its target proteins: Ccs1 facilitates the incorporation 
of copper into SOD, cox11 delivers copper for the synthesis of cytochrome c oxidase and 
ATOX1 enables transportation by the ATPases ATP7A and B out of the cells or into the 
secretory trans-Golgi apparatus [116,118]. In the Golgi apparatus, copper is sequestered and 
incorporated into ceruloplasmin and exported out of the cell, where it acts as a ferroxidase 
[114,116,126,127]. 
The incorporation of metal ions in several metallo proteins provides a broad spectrum of 
possible targets for chelators. Panel B of Figure 11 summarizes some general mechanisms by 
which chelators might interfere with the metal homeostasis. Triapine, a tridentate α-N-pyridyl 
thiosemicarbazone, is a prominent example for a chelator, inhibiting the metallo-enzyme 
ribonucleotide reductase (RR). Triapine is currently undergoing different phase I and II 
clinical trials [128]. In its mechanism of inhibition the chelation by Triapine will not only lead 
to the withdrawal of the necessary iron from the enzyme, but also result in redox active 
complexes, which interfere with the intra-enzymatical electron transfer of the enzyme. The 
electron transfer from subunit R2 (which contains a tyrosyl radical and a diiron center) to 
subunit R1 (which harbors the catalytically active center) is pivotal for the function of the 
enzyme [106,129,130].  
Next to their impact on DNA synthesis, chelators have been reported to result in cell cycle 
arrest via the down-regulation of Cyclin D1 and cyclin-dependent kinase 2 (CDK2) 
[88,115,131,132]. Furthermore, they regulate tumor suppressors like p53 and metastasis 
suppressors like the N-myc downstream regulated gene-1 (NDRG1) are down 
[88,115,131,133]. Iron depletion can foster apoptosis by up-regulation of the pro-apoptotic 
protein Bax and downregulation of the anti-apoptotic Bcl-2 [131,134]. Interfering with the 
IRE-IRP system, the expression of proteins involved in iron homeostasis will be regulated 
[119,121,122]. By chelating, ligands might deprive the cells from essential metal ions and 
deplete the labile iron pool [88,115]. Apart from the depleting effect, chelators might enable 
the transfer of metal ions through membranes, and for example shuttle additional iron into 
mitochondria [125]. Interfering with mitochondrial metal homeostasis, chelators might 
influence energy homeostasis and protein synthesis. Formed complexes might also possess 
biological activity, which is partially linked to their redox properties [87,124,135,136]. 
Copper complexes have been reported to intercalate into DNA [124,137,138], act as chemical 
nucleases, cleaving DNA by oxidative [124,138–140] or hydrolytic [124,141–143] 
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mechanisms or inhibit topoisomerase [124,144] and the proteasome [124,145,146]. Forming 
redox active complexes, chelators might enhance the production of reactive oxygen species, 
which might cause cellular damage, as addressed in detail in chapter 1.5. [88,115,116]. 
Several chelator classes have been described as pan assay interference compounds (PAINs). 
In a wide range of target-based assays, covering ion channels, enzymes, and protein-protein-
interactions, these compounds have been reported to be problematic due to their reactivity, 
spectroscopic properties and the ability to form metal complexes as well as aggregates 
[147,148]. Redox active compounds might interfere with proteins, and by inactivating the 
target lead to false positive results [148]. Still in the areas of oncology, microbiology, and 
parasitology, reactive, photosensitive, and redox-active compounds may be particularly suited 
for therapeutic uses [147]. Often, in these areas the exact target of chelators is not known, and 
therefore the phenotypic drug discovery strategy is applied, where little assumptions are made 
concerning the participation of specific molecular targets and/or signaling pathways. Instead, 
compounds are investigated in complex biological systems and compound induced 
physiological responses or phenotypes are monitored in cells, tissues or whole organisms 
[149,150]. The induction of cell death upon treatment with a certain compound can be seen as 
a phenotypic effect [150]. 
 
 
 
1.6. Keeping the balance on a double edged sword – ROS 
Reactive oxygen species (ROS) appear naturally as side products in the metabolism of aerobic 
organisms [113,116,151]. The main sources for cellular ROS are the complexes I and III 
(MCX-I, MCI-III) in the mitochondrial electron transport chain [152–155], as well as NADH 
cytochrome c reductase and cytochrome P-450 enzymes in the endoplasmatic reticulum (ER) 
[153,156], and oxidases (OX) like the membrane associated NADPH oxidases (NOX) 
[152,156]. The particular reactive species that can be found are oxygen containing radicals 
like the superoxide anion (O2
-·
), hydroperoxyl (HOO
·
), or other peroxyl radicals (ROO
·
), the 
hydroxyl radical (
·
OH), nitric oxide (
·
NO), and other species like hydrogen peroxide (H2O2), 
singlet oxygen (
1
O2), hypochlorous acid (HOCl) and peroxynitrite (ONOO
-
) [151,157]. Also 
diverse radicals are formed by hydrogen abstraction (R
·
) [151]. Out of these the three most 
physiologically relevant (with increasing reactivity) are hydrogen peroxide (H2O2), the 
superoxide anion (O2
-·
) and the hydroxyl radical (
·
OH) [116]. With a reduction potential of a 
1-molar (oxidized and reduced form) solution at physiological pH of E°’ = 0.32 V, H2O2 is 
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the weakest oxidizing agent of the three. Its reactivity is comparably poor, but it is highly 
diffusible and able to cross cellular membranes, which renders it the most efficient signal 
messenger and physiological regulator [113,116,153,158]. The superoxide radical O2
-·
 cannot 
cross cellular membranes freely, but can utilize ion channels for its translocation. It has a 
redox potential of E°’ = 0.94 V and its inherent reactivity at physiological pH is relatively 
low, though it causes cellular damage mainly due to further reactions [116]. The hydroxyl 
radical, on the contrary is the most reactive of the three species, reacting on a diffusion 
limited manner [116,153,159]. With E°’ = 2.31 V its reduction potential is the highest of the 
three species [116]. 
Reactive oxygen species can cause cellular damage by oxidizing biological macromolecules, 
namely lipids, proteins, sugars and DNA [115,151–153,157]. The oxidation of lipids mainly 
occurs as a consequence of reaction with the hydroxyl-radical, leading to the most common 
final products malondialdehyde and 4-hydroxynonenal, which can furthermore react with 
DNA bases, and cause mutations and DNA damage [113,155,160,161]. Since these species 
can be deleterious especially at high concentration, cells have developed an antioxidant 
system in order to disarm them [116,151,152]. Parts of the enzymatic and non-enzymatic 
antioxidant defense system are illustrated in Figure 12. 
As indicated in chapter 1.4., metal and redox homeostasis are in tight connection 
[86,104,113]. Redox active metal ions or complexes can trigger oxidative stress by increased 
production of ROS via redox cycling [86]. On the other hand, this redox activity can be 
exploited for example in the antioxidant copper-containing enzyme superoxide dismutase 
(SOD), which catalyzes the disproportionation of superoxide (O2
-·
) to hydrogen peroxide 
(H2O2) and molecular oxygen (O2), as indicated by the green arrows in Figure 12. 
Likewise, these reactions can be catalyzed by metal ions or redox active complexes. Also the 
subsequent production of the reactive hydroxyl radical, which occurs via the Fenton (in case 
of iron) or Fenton-like (in case of other metal ions) reaction (red arrow in Figure 12), is 
catalyzed by metal ions or complexes, as depicted by the red arrow. The Fenton reaction is 
part of the so called Haber-Weiss reaction (indicated by highlighted arrows in Figure 12), that 
describes the metal ion catalyzed reaction of hydrogen peroxide with superoxide 
[86,104,113,116,121,135,151,154]. 
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Figure 12: Redox homeostasis. Redox cycling of metal ions or of redox active complexes induces 
further reactions and responses in the cellular antioxidant system. Created according to references 
[116,135,151,154,89,162]. Oxidation reactions are depicted by black arrows, reduction reactions by 
grey arrows. Green arrows represent the reactions, which are also catalyzed by the copper-containing 
superoxide dismutase (SOD), the red arrow represents the Fenton (iron) / Fenton-like (other redox 
active metal ions) reaction. The reduction of hydrogen peroxide to water is depicted by the blue arrow. 
For details, see text. Abbreviations (in alphabetical order): Cat: catalase; GPx: glutathione peroxidase; 
G6P: glucose-6-phosphate; G6PDH: glucose-6-phosphate dehydrogenase; GR: glutathione reductase; 
GRX: glutaredoxin; GSH: reduced glutathione; GS-SG: oxidized glutathione; MCX-I: mitochondrial 
complex I; NADP
+
: oxidized nicotinamide adenine dinucleotide phosphate; NADPH: reduced 
nicotinamide adenine dinucleotide phosphate; OX: oxidases; 6PGδL: 6-phosphoglucono-δ-lactone; 
SOD: superoxide dismutase; TPx: thioredoxin peroxidase; TrxR: thioredoxin reductase. Trx-S2: 
oxidized thioredoxin; Trx-(SH)2: reduced thioredoxin.  
 
 
While the reactivity of the hydroxyl radical hinders its controlled disarming, the cellular 
antioxidant system has several ways, to metabolize hydrogen peroxide to water (indicated by 
the blue arrow in Figure 12), like the enzyme catalase (cat), or the antioxidants glutathione 
(GSH) and thioredoxin (Trx-(SH)2). GSH is able to reduce hydrogen peroxide directly or with 
the help of enzymatic catalysis, namely glutathione peroxidase or glutaredoxin, which are 
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themselves reduced by GSH [116,151,154,162]. As a result of these reactions, GSH is 
oxidized to GSSG, which can be reduced by glutathione reductase (GR). The reducing power 
for this reduction comes from NADPH (nicotinamide adenine dinucleotide phosphate), which 
is itself reduced in the course of the oxidation of glucose-6-phosphate (G6P) to 6-
phosphoglucono-δ-lactone (6PGδL) by glucose-6-phosphate dehydrogenase (G6PDH) 
[116,151,154,163] (reactions on top of the blue arrow in Figure 12). 
The thioredoxin centered reducing system works in a similar manner. The reduction of 
hydrogen peroxide by thioredoxin can be mediated by Trx-(SH)2 directly or via catalysis 
through thioredoxin peroxidase (TPx). Unlike GPx, TPx can only be reduced by NADPH, like 
the oxidized thioredoxin (Trx-S2) [116,151,152,154].  
These several redox systems enable the cell to balance between oxidant and antioxidant 
forces. The term “oxidative stress” therefore describes a disturbance of this balance [113,116]. 
While ROS at high concentrations are deleterious, their important roles in cellular functions 
including activation and modulation of signal transduction pathways, as well as several redox-
sensitive transcription factors evidence the “two-faced” character of these species 
[113,116,152,155,158,159,164]. Also the duration of the oxidative stress seems to be 
important, as short lived redox changes, like transient and localized ROS production is 
involved in normal growth factor signaling, while long-lived oxidative stress often leads to 
cellular senescence [165]. 
Figure 13 illustrates some of the pathways that are activated by certain levels of reactive 
oxygen species. Lower levels of (or short term exposure to) ROS have mainly pro-survival 
effects, while increasing levels can lead to tumor promotion, proliferation and progression, 
and finally to apoptosis or even necrosis [113,155].  
Redox regulation of the pro-survival Nrf2 pathway works via disruption of the Keap1-Nrf2 
(Kelch-like ECH-associated protein 1 – Nuclear factor (erythroid-derived 2)-like 2) - complex 
that enables the translocation of Nrf2 to the nucleus, where it induces the transcription of 
antioxidant enzymes. In association with Keap1, the transcription factor is subject to 
ubiquitination and protein degradation [158,166,167]. Oxidative stress can furthermore induce 
this pathway by activation of protein kinase C (PKC), which phosphorylates Nrf2 [167]. Also 
the translocation of nuclear factor κB (NFκB) is activated by ROS. The kinases IκB-kinase 
(IKK) and protein kinase D (PKD) catalyze the disruption of the complex formed by NFκB 
with its inhibitor IκB (inhibitor of NFκB), allowing the translocation of the transcription 
factor to the nucleus (and the degradation of IκB). Genes, that are regulated by NFκB include 
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anti-apoptosis factors like BcL2, the antioxidant enzyme SOD and ABC transporters 
[21,152,158,166,167].  
 
 
 
Figure 13: Examples for ROS-induced signaling pathways. While at low concentrations pro-survival 
pathways are activated, high levels lead to apoptosis, or even necrosis. Figure created according to 
[113,152,155,158,160,161,164,166–169]. Redox-responsive transcription factors (Nrf2, NFκB, p53) 
are indicated by blue boxes, kinases are shown in boxes (green for pro-survival signaling, brown for 
apoptotic signaling). Grey boxes surround inactive protein-complexes that are activated by kinases or 
ROS. Arrows indicating pathways are colored in green for pro-survival or brown for apoptotic 
signaling. Regulation of MDR associated genes is highlighted by a star. Abbreviations (in alphabetical 
order): Akt1: threonine-protein kinase (PKB); ASK1: apoptosis signal-regulating kinase-1; Bad: Bcl-
2-associated death promoter; Bax: Bcl-2-associated X protein; GSTπ: Glutathione S-transferase π; 
IκB: inhibitor of NFκB; IKK: IκB-kinase; JNK: c-Jun N-terminal kinase; Keap1: Kelch-like ECH-
associated protein 1; mTOR: mammalian target of rapamycin; NFκB: nuclear factor κB; Nrf2: Nuclear 
factor (erythroid-derived 2)-like 2; PDK1: 3’-phosphoinositide-dependent kinase-1; PI3K: 
phosphatidylinositol-3-kinase; PKC: protein kinase C; PKD: protein kinase D; PTEN: 
phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase; Trx: thioredoxin.  
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Another pro-survival signaling induced by ROS is the activation of the threonine-protein 
kinase Akt1, which is the result of a signaling cascade starting with the oxidative inhibition of 
phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (PTEN) [152,166]. By activating 
IKK, Akt1 also induces the NFκB pathway, leading to an increased expression of P-gp [21]. 
Furthermore activation of Akt1 down-regulates pro-apoptosis factors, partially through a 
crosstalk to the apoptosis signal-regulating kinase ASK1 [21,152,166]. 
ASK1 is involved in apoptosis signaling. Under non-stress conditions it is associated to 
thioredoxin (Trx), which renders the protein inactive. Upon oxidation, Trx undergoes 
conformational changes that lead to activation of ASK1 [152,164,166,168]. As a consequence 
of ASK1 activation, mitochondrial cytochrome C is released, which activates caspases 9 and 3 
and leads to apoptosis [168]. Next to the direct mitochondrial cytochrome C release, ASK1 
can also activate p53, which in turn phosphorylates the pro-apoptotic Bcl-2-associated X 
protein (Bax), enabling it to induce cytochrome C release [168]. 
Activation of ASK1 can also lead to the activation of c-Jun N-terminal kinase (JNK), which 
leads to the decomposition of the Bax/BcL2 complex, enabling the homo-dimerization of 
Bax, and the phosphorylation and downregulation of BcL2 [152]. Similar to ASK1, JNK can 
be inhibited under non-stress conditions by forming a redox sensitive complex with 
glutathione-S-transferase-π. Upon oxidative stress JNK is released from this complex and 
activated [166]. A crosstalk between NFκB and JNK has been suggested to be of importance 
for the final cell fate in response to oxidative stress [166]. 
In comparison to healthy tissues, ROS levels have been found to be elevated in cancer 
patients. Additionally to the direct measurement of elevated levels, increased lipid 
peroxidation serves as an indirect proof [113,158]. The increase of ROS might be caused by 
oncogenic stimulation, increased metabolic activity due to the higher energy demand caused 
by rapid proliferation, or mitochondrial malfunction. Also a decrease in the antioxidant 
capacity of cancer cells has been suggested as a cause. Though, documented studies 
comparing the levels of antioxidant enzymes in cancer patients vs. healthy subjects were not 
conclusive, most probably due to huge variations in patients and control populations. Also the 
geographical location and the time of the study (data were collected over the last three or four 
decades) might have caused this variation [113].  
Figure 13 shows the different pathways favoring the cellular survival, tumor promotion, 
proliferation and progression or apoptosis in dependence of the cellular ROS levels. A higher 
oxidative stress level in cancer cells, might therefore provide the opportunity for a selective 
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targeting, since the tumor cells might be more sensitive to additionally induced oxidative 
stress as compared to normal (healthy) cells [113,155]. 
Also ABC transporter mediated multidrug resistance of cancer is partly regulated by ROS on 
several levels. Direct oxidation of the transport proteins might result in conformational 
changes that render the proteins inactive. Especially in case of MRP1, where GSH is co-
transported, ROS might influence the activity of the transporter [167]. The regulation of P-gp 
expression on the transcriptional level has first been identified on the rat paralogues mdr1a 
and mdr1b, but later been confirmed for the human protein as well [167]. As indicated in 
Figure 13, the ROS sensitive NFκB and Nrf2 pathways have been suggested to not only 
upregulate antioxidant enzymes but also the ABC transporter P-gp [167,169]. Further effects 
on P-gp expression include a ROS induced gene amplification, but also regulation of 
expression on post-translational and epigenetic levels [167]. 
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2. Objective 
 
As indicated in the introduction, the development of multidrug resistance (MDR) is a major 
obstacle in cancer treatment. One strategy to overcome this obstacle is the selective targeting 
of MDR cells by exploiting their collateral sensitivity (CS).  
As indicated in chapter 1.4, several reports can be found in the literature on diverse 
compounds with the potential to induce CS via different mechanisms. While some of these 
agents have been identified in a pharmacogenomic approach by correlating the drug activity 
to expression of the ABC transporter P-gp, the impact of the transporter on serendipitously 
found MDR selective agents seems elusive. Therefore, selected agents should be tested for 
their potential to induce MDR selective toxicity in a panel of cell lines. In order to exclude 
cell line specific effects and ensure the importance of transporter activity on the selectivity, 
transporter inhibition and P-gp-transfected cell lines should be investigated (addressed in 
chapter 3.1.1.). 
New data was released in 2010, updating the database of the National Cancer Institute (NCI) 
– Developmental Therapeutics Program (DTP), thus enabling the re-evaluation of the reported 
pharmacogenomic approach. Data analysis might lead to the identification of scaffolds that 
can be associated with P-gp-mediated MDR selective toxicity. Furthermore, the MDR 
selective anticancer potential of previously identified compound classes might be verified in 
this new data set and a preliminary structure activity relationship analysis might be 
performed. 
In order to confirm these (re-)identified scaffolds, and to gain more insight into the chemical 
features responsible for (MDR selective) toxicity of the chelators, a focused library should be 
designed. Isatin-β-thiosemicarbazones, like I-a, have been described to be MDR selective 
based on the previously reported pharmacogenomic approach. Starting from this chelator, the 
library should be intended to cover aspects of different chelator donor-atom sets and further 
variations that might be applied to fine-tune toxicity. Furthermore, the scaffold should be 
extended to closely related compound classes like hydrazino-benzothiazoles and aryl-
hydrazones (chapter 3.2.). Compounds should be investigated for their potential to overcome 
MDR in several cell lines. In case of compounds, identified to selectively kill MDR cell lines, 
the effect of P-gp should be addressed by co-administration of an inhibitor. 
On the basis of the previously reported pharmacogenomic approach, also 8-hydroxyquinoline 
derived Mannich bases might be a promising chelator class. Closely related derivatives might 
provide further insight into structural motives that render these compounds MDR selective. 
30   
 
A set of closely related compounds with varying MDR selective activity might provide a 
useful tool for the elucidation of putative mechanisms of (MDR selective) action. 
Furthermore, the comparison to a derivative with cell line specific selective toxicity that is 
independent of P-gp (identified in the library, chapter 3.2.), might be interesting. 
As described in the introduction, chelators might affect the intracellular redox homeostasis for 
example via the formation of redox active complexes, and eventually cause cellular damage 
through the formation of excess of reactive oxygen species (ROS). In order to address the 
impact of ROS on the toxicity of selected chelators toward parental and MDR cells, the ROS-
scavenger N-acetylcysteine (NAC) should be co-administered. 
Intracellular complexes might be formed with the two most physiologically relevant redox 
active metals iron and copper, therefore the impact of these two metals on the selective 
toxicity of the ligands toward MDR cell lines, should be addressed by co-administration of the 
metal salts.  
Since a putatively differential cellular response to the metal ion co-administration to MDR 
selective and non-MDR selective ligands might be caused by different chemical properties of 
the ligands and their complexes, complex stability and redox activity of the complexes formed 
with iron (III) and copper (II) should be investigated. 
In case of stable complex formation, pre-formed complexes should be investigated in vitro, in 
order to investigate the effect of supplemented metal ions at fixed metal to ligand ratios. The 
impact of redox activity of these complexes on the toxicity should be investigated by co-
administration of antioxidants in the in vitro studies. 
In order to further investigate the impact of ROS on the mechanism of (MDR selective) 
toxicity of ligands and metal complexes, techniques should be established for the 
measurement of intracellular ROS. 
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3. Results and discussion 
 
3.1. Critical evaluation of literature reports 
3.1.1. Serendipitous findings 
Based on the increasing number of literature reports on MDR in cancer, the selective targeting 
of otherwise MDR cancer cell lines seems to be a promising approach. As detailed in the 
introduction (chapter 1.4.) very diverse agents with distinct mechanisms of action have been 
reported to show hypertoxicity toward MDR cell lines.  
In order to elucidate the impact of P-gp on the activity of the reported compounds and to rule 
out cell line specific effects, several cell line models should be employed. Experimental data 
on the reported MDR selective agents are summarized in Table 2. The investigated cell line 
panel comprises pairs of MDR and parental cell lines from different origin. The ovarian 
carcinoma cell line A2780 and the uterine sarcoma cell line MES-SA were used in 
comparison to their doxorubicin-selected counterparts A2780adr and Dx5, respectively 
[24,170,171], while the cervix carcinoma cell line KB-3-1 was compared to the Vinblastine-
selected line KB-V1 [172,173]. The NCI/ADR-res and OVCAR-8 cell lines were introduced 
in chapter 1.4. as parts of the NCI60 cell line panel [99]. The impact of P-gp activity on the 
toxicity of the compounds was furthermore addressed by co-administration of the P-gp 
inhibitor Tariquidar, as well as by the usage of a genetically modified Madin–Darby canine 
kidney (MDCK-II) cell line, which was engineered to overexpress cDNA-derived P-gp. This 
cell line was established by Dr. Dóra Türk, a brief description of the cells is given in the 
methods section (chapter 5.1.) [89]. 
While a standard method to measure cellular viability is the MTT assay, this method requires 
the removal of medium before the lysing of cells (for details see methods section chapter 
5.6.1.), which might be a possible source of errors in case of agents, which might act via a 
perturbation of membrane properties. The putative loss of cells with perturbed membrane 
properties during the experiment might lead to artefacts in the measurement. Therefore the 
detergent Triton-X-100, as well as the block co-polymers pluronics P-85 and P-105 were 
measured with fluorescence based assays, namely with cell lines stably transfected with the 
fluorescent proteins eGfP or DsRed (for details, see method section chapter 5.6.3.), or by the 
application of Presto Blue reagent (for details, see method section chapter 5.6.2.). In 
comparison to the MTT reagent, this method has the advantage that a medium replacement is 
not necessary in cases, where an interaction of the test compound with the assay compound  
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Table 2: Evaluation of compounds reported to be MDR selective in the literature. IC50 values of at 
least 2 independent experiments (as specified in the applied assay-column) are listed in parental and 
MDR cell lines. Addition of the P-gp inhibitor Tariquidar is indicated as “+ TQ”. 
 
 
IC50 [µM]  
in parental cell 
IC50 [µM]  
in MDR cell 
SR  cell line pair Applied assay 
Triton X 
100 246.7 ±34.0 99.99 ±15.2 2.47 MES-SA / Dx5 Presto Blue assay 
 
209.2 ±5.16 109.6 ±23.6 1.95 MES-SA / Dx5 + TQ Presto Blue assay 
Pluronics 
P085 47.88 ± 1.29 51.54 ± 1.27 0.93 KB-3-1 / KB-V1 Presto Blue assay 
 
33.50 ± 0.563 38.48 ± 1.36 0.87 MES-SA / Dx5 Presto Blue assay 
 
5.692 ± 0.584 10.28 ± 1.60 0.56 OVCAR-8 / NCI DsRed / EGfP 
 
30.64 ± 1.04 37.61 ± 1.36 0.81 MDCK / MDCK-B1 Presto Blue assay 
   
    
  P105 7051 ± 1549 1900 ± 487 3.74 KB-3-1 / KB-V1 Presto Blue assay 
 
438.7 ± 13.6 72.91 ± 6.68 6.04 MES-SA / Dx5 Presto Blue assay 
 
10.45 ± 2.41 23.45 ± 4.26 0.44 OVCAR-8 / NCI DsRed / eGfP 
 
66.47 ± 9.75 90.76 ± 12.2 0.73 MDCK / MDCK-B1 Presto Blue assay 
         
Verapamil 6.89 ± 0.037 8.96 ± 0.25 0.50 KB-3-1 / KB-V1 MTT 
 
Isatin TSCs 
NSC73306 
(I-a) 
6.09 ± 0.94 3.59 ± 1.01 1.75 MES-SA / Dx5 MTT 
7.15 ± 0.66 7.42 ± 1.24 1.00 MES-SA / Dx5 + TQ MTT 
 
12.1 ± 3.32 4.15 ± 0.89 2.87 MES-SA / Dx5 mCherry fluorescence 
 
5.79 ± 2.13 7.67 ± 1.21 0.72 MES-SA / Dx5 + TQ mCherry fluorescence 
 
7.82 ± 2.06 3.78 ± 0.43 1.92 KB-3-1 / KB-V1 MTT 
 
7.49 ± 0.30 4.84 ± 1.21 1.60 A2780 / A2780adr MTT 
     
  
  I-c 5.32 ± 1.43 3.27 ± 0.75 1.54 MES-SA / Dx5 MTT 
 
6.99 ± 1.37 5.73 ± 1.44 1.23 MES-SA / Dx5 + TQ MTT 
 
11.3 ± 2.53 3.27 ± 0.85 3.14 MES-SA / Dx5 mCherry fluorescence 
 
16.0 ± 2.23 11.4 ± 3.73 1.47 MES-SA / Dx5 + TQ mCherry fluorescence 
 
4.44 ± 1.47 4.00 ± 0.62 1.06 KB-3-1 / KB-V1 MTT 
 
9.70 ± 1.50 8.75 ± 1.93 1.07 A2780 / A2780adr MTT 
 
      
  I-d 9.17 ± 3.64 4.74 ± 1.10 1.81 MES-SA / Dx5 MTT 
 
14.6 ± 4.54 13.0 ± 1.85 1.08 MES-SA / Dx5 + TQ MTT 
 
15.8 ± 7.57 7.56 ± 6.73 1.73 MES-SA / Dx5 mCherry fluorescence 
 
33.6 ± 7.45 21.1 ± 14.4 1.90 MES-SA / Dx5 + TQ mCherry fluorescence 
 
8.20 ± 1.52 4.58 ± 0.90 1.74 KB-3-1 / KB-V1 MTT 
 
25.7 ± 6.92 8.78 ± 2.35 3.63 A2780 / A2780adr MTT 
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can be excluded (in case of Triton-X-100 a reaction is very unlikely by chemical means, but 
generally, an interaction could by excluded by using cell-free conditions). 
 
While Triton-X-100 seemed to have a 2.47-fold increased toxicity in MES-SA/Dx5 cells as 
compared to the parental MES-SA cells, this difference seemed to be independent of P-gp 
function, as the co-administration of Tariquidar did not abolish selectivity. 
The toxicity of Pluronic P-85 was comparable throughout the investigated cell line panel. In 
NCI/ADR-res it even seemed less toxic as compared to the parental OVCAR-8 cell line. In 
contrast, the derivative P-105 showed enhanced toxicity toward MDR cells in two out of the 
four investigated cell line models. Experiments performed with the transfected MDCK-II-B1 
cells showed, that the selectivity observed in these models was not caused by the transport 
protein. 
Despite promising reports on up to 100-fold increased toxicity of Verapamil toward a P-gp-
expressing cell line in comparison to the parental line [82], these reports seem to be based on 
rather cell line dependent effects, as these observations could not be confirmed in the KB-V1 
vs. KB-3-1 cell line model (Table 2). Furthermore, Verapamil was found in the DTP database 
as NSC657799, and biodata on this compound was available on a major set of cell lines from 
the NCI60 panel. As summarized in Table 3, the Pearson correlation coefficient for the 
correlation of activity vs. P-gp expression was negative, supporting reports on the substrate 
properties of Verapamil, rather than those reporting about MDR selective activity. Since data 
for OVCAR-8 cells were not available, a selectivity ratio for the NCI/ADR-res vs. OVCAR-8 
cell line pair could not be given based on the database data. 
NSC73306 (I-a) has been identified as a putatively MDR selective agent based on the NCI60 
panel data, and confirmed in several models [95,98,100]. Even though the magnitude of the 
effect was rather small in some cases, a selective effect could be observed in all investigated 
cell line pairs. Application of Tariquidar abolished the selectivity, indicating the P-gp-
dependence of the selectivity. Two close derivatives have been reported to possess increased 
selectivity toward MDR cell lines, namely I-c and I-d [102,103]. Compound I-d indeed 
showed selective toxicity toward the investigated MDR cell lines in a P-gp-dependent 
manner, even though not in the reported magnitude. Compound I-c, in contrast, showed 
selective toxicity only in one test system, namely in MES-SA/Dx5 cells, measured by the 
mCherry assay. Since the effect could neither be verified by the MTT assay in the same cell 
lines, nor in other cell lines, other factors than P-gp might be responsible for the reported 
selectivity.  
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Furthermore, I-c and I-d were identified in the DTP database as NSC668502 and 
NSC670960, respectively. As summarized in Table 3, the available biodata and provided 
relatively low Pearson correlation coefficients against P-gp-expression data. Also the low SR 
comparing OVCAR8 and NCI/ADR-res cells, confirm (in agreement with the measured data, 
as summarized in Table 2) the suggestion that putatively observed selectivity of these 
compounds might be linked to other factors than P-gp. 
 
 
Table 3: correlation of activity within the NCI60 panel vs. P-gp expression for isatin-β-thiosemicarba-
zones in comparison to reported MDR selectivity. 
 
NSC657799 
Verapamil 
 
Pearson correlation coefficient r: -0.25 
IC50 (OVCAR-8) / µM - 
IC50 (NCI/ADR-res) / µM 100 
SR (OVCAR8 / NCI/ADR-res)  - 
NSC73306 
I-a 
 
Pearson correlation coefficient r: 0.49 
IC50 (OVCAR-8) / µM 7.56 
IC50 (NCI/ADR-res) / µM 2.09 
SR (OVCAR8 / NCI/ADR-res)  3.63 
NSC668502 
I-c 
 
Pearson correlation coefficient r: 0.01 
IC50 (OVCAR-8) / µM ≥ 100 
IC50 (NCI/ADR-res) / µM 51.29 
SR (OVCAR8 / NCI/ADR-res)  1.95 
reported SR (KB-3-1 / KB-V1) [103] 9.2 
NSC670960 
I-d 
 
Pearson correlation coefficient r: 0.20 
IC50 (OVCAR-8) / µM 1.78 
IC50 (NCI/ADR-res) / µM 3.02 
SR (OVCAR8 / NCI/ADR-res)  0.59 
reported SR (KB-3-1 / KB-V1) [103] 8.3 
 
 
Therefore, the results suggest, that the elevated toxicity of putative MDR selective 
compounds reported in the literature is often cell line dependent and not linked to P-gp, but 
rather to nonspecific factors arising during the development of the MDR phenotype. In 
contrast the selective toxicity of compound I-a, which was identified by the pharmaco-
genomic approach, could be confirmed in other test systems, and was found to be P-gp-
mediated. Therefore, it seems to be necessary to investigate several cell lines, in order to find 
P-gp-mediated MDR selective agents. The approach of correlating biodata across the NCI60 
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cell line panel against gene expression data seems to be a reliable strategy to find general 
MDR selective agents. 
 
 
3.1.2. Pharmacogenomic approach  
In 2010, a new updated dataset containing toxicity profiles of 49169 compounds across the 
NCI60 panel was released. In order to identify further MDR selective compounds, the 
previously described pharmacogenomic approach of correlating toxicity against P-gp 
expression was repeated using the new dataset. The bioinformatic analysis and biological 
testing of the identified compounds was performed by Szilárd Tóth, András Füredi, and Dr. 
Anna Lovrics. The analysis revealed 82 putative MDR selective compounds with Pearson 
correlation coefficient >0.4. Out of these, 61 compounds were already identified in the 
previously described set [174].  
Structural motives and molecular features known to be associated with MDR selective 
toxicity reappear within the 21 novel compounds. Available compounds were tested in a panel 
of MDR (KB-V1, MES-SA/Dx5) and parental cell lines (KB-3-1, MES-SA) with the 
Presto Blue viability assay. To clearly delineate the effect of P-gp on the toxicity of the 
compounds, MDCK-II-ABCB1 cells, which were engineered to overexpress cDNA-derived 
P-gp and the control MDCK-II cells, were included (see chapter 3.1.1.). Additionally the 
effect of co-administered P-gp inhibitor Tariquidar was investigated in the MES-SA cell line 
pair. 
In order to compare to previous findings, five reference compounds are included in the study 
of the newly investigated compound set (NSC693871, NSC73306, KP772, 1,10-
phenanthroline, 8-hydroxyquinoline (8OHQ)). The molecular similarity of the chemical 
structures can be quantified by Tanimoto coefficients, which are based on molecular 
fingerprints, that describe molecular structures as binary vectors [175]. These coefficients 
were calculated with ChemAxon software and hierarchical clustered into a dendrogram [36]. 
Data describing structural similarity and biological activity are illustrated in Figure 14. 
In agreement with prior observations based on the 2007 DTP data release, the newly 
identified compounds are contain a significant number of structures enabling metal chelation 
[174]. 
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Figure 14: Dendrogram and confirmatory biodata of newly identified potential MDR selective agents, 
including previously reported reference compounds NSC73306 and NSC693871. Furthermore, biodata 
of KP772, 1,10 phenanthroline and 8-hydroxyquinoline (8OHQ) were added. 
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NSC716771 was identified as a very close analogue of the isatin-β-thiosemicarbazone 
NSC73306. While the compound was not available for testing, Hall et al. report the MDR 
selectivity of this thiosemicarbazone in the KB-V1 vs. KB-3-1 cell line pair [176]. 
Also the 8OHQ derived Mannich base NSC693871 has previously been identified in the 
pharmacogenomic approach and confirmed to possess MDR selective activity [174]. In the 
updated data set six further 8-hydroxyquinoline derivatives were found with putative MDR 
selective activity. The 7-(piperidylmethyl)-8-hydroxyquinoline NSC57969 shows the highest 
similarity to with the previously reported compound NSC693871, with a piperidine-ring 
replacing the pyrrolidine-moiety. According to their structural similarity, both compounds are 
comparable with respect to their preferential targeting of MDR cell lines. Interestingly, the 
pyrrolidino derivative is less toxic than the newly identified piperidino derivative. 
NSC297366 can also be considered as a close derivative, which could be obtained by a 
similar Mannich reaction as the previously mentioned derivatives. The presence of an 
additional equivalent of formaldehyde in the synthesis process enables an additional ring-
closure between the 8-OH group and the benzyl amino-nitrogen. This compound harboring a 
fluorobenzylamine moiety has an outstandingly high selectivity for MDR cells with IC50 
values in the submicromolar concentration range and SR values between 10 and 19.  
In contrast, introduction of an aromatic moiety at the employed aldehyde resulting in 
compound NSC1014 seems to have detrimental effects on toxicity and selectivity. 
The cluster furthermore contains two 5-substituted 8OHQ derived derivatives (NSC79544 and 
NSC48892), which both show toxicity in the 1-3 µM range with only slight selectivity toward 
MDR cell lines (with SR values between 1.5 and 3). A similar behavior can be observed for 
NSC67090, which is halogenated in positions 5 and 7 and harbors a substituted styryl-moiety 
in position 2. Interestingly, the unsubstituted 8OHQ scaffold does not show MDR selective 
properties. 
The naphthol-carbaldehyde-hydrazone NSC72881 and the naphthylamine NSC15372 are 
relatively far analogues of the 8OHQ derived Mannich bases. They show comparable activity 
across the cell line panel in the range of 10 to 40 µM, regardless of the resistance status of the 
cells. Two further distantly related analogues can be found in the cluster around the 8-
hydroxyquinoline derived Mannich bases, namely the 1,4-benzopyrone derivative 
NSC609800 and the 1-(3,5-trimethoxyphenyl)-imidazole NSC733435. While the first one was 
not available for testing, the latter was not toxic in any of the investigated cell lines up to a 
concentration of 100 µM. While chelation of metal ions might be possible for NSC72881, it is 
rather unlikely for the other three far derivatives (NSC15372, NSC609800 and NSC733435). 
38   
 
The unsubstituted 8-OHQ scaffold clusters together with 1,10-phenanthroline, which has been 
reported earlier to possess MDR selective activity both as the free ligand and complexed with 
different metals [174,177]. The [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate 
complex (KP772) was included in the study as a reference compound [177]. A stock solution 
of the complex was prepared following the procedure described by Hart and Laming [178]. In 
order to be able to compare the activity of KP772 with that of the free ligand, IC50 are given 
in ligand equivalents, therefore as the IC50 value of {1/3 [La(phen)3](SCN)3} (accordingly, the 
IC50 value of the complex would be three times lower). The analysis of the pharmacogenomic 
correlation retrieved two new 1,10-phenanthroline complexes formed with either tin 
(NSC608465) or palladium (NSC676735). Since most programs, which calculate chemical 
and physicochemical properties, are mainly made for the analysis of organic compounds, and 
might not be able to cope with metal ions in a chemical structure, the complexes and the free 
ligand do not cluster together. The preferential killing effect of free ligand toward MDR cells 
is preserved in the presence of the metal ions lanthanum, tin and palladium.  
The aryl-urea derivative NSC672035 shows some degree of similarity to the TSC structures. 
However, its activity was comparably low with IC50 values ≥ 50 µM across the cell line panel 
(SR 0.6-1.2). In contrast to the 8OHQ and TSC derivatives, upon chelation this compound 
will form a 6-membered ring incorporating the metal ion, while the other chelators will form 
5-membered rings, which is considered more stable [179]. Also the diketon NSC17551 and 
the naphthol-derivative NSC72881, which display moderate toxicity in the investigated cell 
line panel (10-35 µM) will form 6-membered rings, applying either the two keto-oxygen 
atoms or the naphthol-hydroxyl group and a hydrazone-N as donor atoms. While the 
selectivity of the naphthol derivative is only significant in one cell line pair (MES-SA vs. 
MES-SA/Dx5), the diketon NSC17551 shows selective toxicity toward several MDR lines. 
One further structural connection can be seen in the newly identified compound set, namely 
between two structures with a quinoidic system (NSC13977 and NSC740469), the remaining 
molecules are quite dissimilar. Interestingly NSC13977, which is the dye Alizarin blue, shares 
the N,O-metal binding donors in the same distance as found in the 8OHQ-scaffold, yet the 
disruption of aromaticity and the presence of further substituents explain the huge distance in 
the dendrogram. Alizarin Blue NSC13977 showed a two-fold higher activity in MDR cells 
compared to the parental cells, while the derivative NSC740469 was not available for testing. 
NSC748494 and NSC726708 were not available, and the singleton NSC627452 was not toxic 
in any of the tested cell lines up to a concentration of 100 µM. 
3.1. Critical evaluation of literature reports  39 
 
 
Taken together, P-gp expressing MDR cells from different origin show enhanced sensitivity 
over their parental P-gp negative cell lines against the compounds identified by the correlative 
approach. The occurrence of this effect also in ABCB1 transfected MDCK-II cells and the 
ability of the P-gp inhibitor Tariquidar to abolish selectivity, point to the importance of 
functional transport protein in sensitizing MDR cells.  
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3.2. Development of new compounds – Design of a focused library 
Having shown that the isatin-β-thiosemicarbazones I-a and I-d show MDR selective toxicity, 
a focused library was designed around thiosemicarbazones and related chelator classes. 
 
The exploration of the chemical space around thiosemicarbazones (TSCs) with anticancer 
activity started in 1956 with first reports about a moderate antileukemic activity of 2-formyl 
thiosemicarbazone [180]. The most intensively investigated TSC is Triapine, a tridentate α-N-
pyridyl thiosemicarbazone. Triapine is a potent ribonucleotide reductase (RR) inhibitor 
currently undergoing phase I and II clinical trials [128–130]. While the clinical efficacy of 
Triapine awaits confirmation, in vitro experiments have suggested that Triapine is subject to 
MDR, as it is recognized and transported by P-gp [102,181,182].  
In accordance with these reports, the inhibition of P-gp by Tariquidar increases the sensitivity 
of MES-SA/Dx5 cells toward Triapine to that of the parental MES-SA cells, as illustrated in 
Figure 15. 
 
 
Figure 15: Dose-response curves for MES-SA (open squares) and MES-SA/Dx5 (filled squares) cells 
in the absence (black) and presence (grey) of the P-gp inhibitor Tariquidar (1 µM). Data are mean and 
standard deviation from at least three independent experiments, obtained by MTT viability assay. 
 
At the terminal nitrogen (N4) Triapine is not substituted. In contrast, substitution of the TSC 
moiety at this position was reported to increase the toxicity of TSC derivatives [102,183,184]. 
The terminally di-methylated TSC di-2-pyridylketone-4,4,-dimethyl-3-thiosemicarbazone 
(Dp44mT) has even been shown to exhibit a paradoxical hypertoxicity against the P-gp 
overexpressing cervix carcinoma cell line KB-V1 as compared to its parental cell line KB-3-1 
[86,90].  
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Yet, as shown in Table 4, correlating the activity of both compounds against the P-gp 
expression within the NCI60 cell panel partially confirmed the substrate-like properties of 
Triapine: The selectivity ratio comparing NCI/ADR-res vs. OVCAR8 is 0.28, suggesting a 
putative efflux by P-gp, while the Pearson correlation coefficient of 0.15 rather suggests that 
there is no clear trend. Likewise, the Pearson correlation coefficient for Dp44mT (0.22) 
suggests only limited impact of P-gp activity on the toxicity. Since small changes in IC50 
values can result in big changes in the selectivity ratios, these values underlie large 
uncertainties. With 1.74 the SR value comparing the activity of Dp44mT in NCI/ADR-res and 
OVCAR8 is slightly below the threshold of MDR selective activity. 
 
 
Table 4: Correlation results of activity vs. P-gp expression in the NCI60 cell line panel 
NSC663249 
Triapine 
 
Pearson correlation coefficient r: 0.15 
IC50 (OVCAR-8) / µM: 0.56 
IC50 (NCI/ADR-res) / µM: 2.04 
SR (OVCAR8 / NCI/ADR-res):  0.28 
NSC744381 
Dp44mT 
 
Pearson correlation coefficient r: 0.22 
IC50 (OVCAR-8) / µM: 0.036 
IC50 (NCI/ADR-res) / µM: 0.021 
SR (OVCAR8 / NCI/ADR-res): 1.74 
 
 
The introduction of an aromatic moiety at the N4 position has been reported to increase the 
toxicity of dipyridylketone TSCs to a similar extent as the dimethylation (these reports are 
based on studies with the human leukemia cell line HL60 and the human neuroepithelioma 
cell line SK-N-MC) [184,185]. Furthermore, based on a pharmacophore model of isatin-β-
TSCs an aromatic moiety at N4 might be necessary for MDR-selectivity [42,102]. Selectivity 
toward MDR cell lines can be further increased by the introduction of a strong electron 
donating or withdrawing substituent to that aromatic ring in para position to the TSC [103]. 
The reported isatin-β-TSCs are able to chelate metal ions via an ONS binding mode. In 
contrast, Triapine and Dp44mT are NNS chelators. A common feature of these compounds is 
the TSC scaffold, which enables metal binding. This scaffold is connected to pharmacological 
side effects, since H2S might be released from the scaffold during the metabolism of these 
compounds [186,187]. To overcome this drawback, arylhydrazones and benzothiazoles have 
been introduced as alternative entities: Since in these compound classes the sulfur is either 
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replaced by a nitrogen [187], or incorporated into a ring system [186], H2S release is 
abolished or hindered. Nevertheless, these compound classes provide metal chelation abilities 
similar to the TSCs, which has been suggested to be an important feature in their mechanism 
of action [89,188,189]. 
While the set of chelators with potential MDR selective activity identified with the previously 
described pharmacogenomic approach includes a hydrazino-benzothiazole (NSC693630, see 
introduction, Table 1 for the structure) [98], also arylhydrazones have been reported in the 
context of multidrug resistance, yet not in the context of cancer: Several pyridinyl- or 
pyrimidinylhydrazones are effective even against multidrug resistant strains of leprosy and 
tuberculosis by inhibition of the mycobacterial RR [187,190]. Pyridylphthalazinyl- and 
quinolylhydrazones have been suggested to possess anticancer activity based on the inhibition 
of human RR [191]. Further applications of arylhydrazones can be found due to their 
antibacterial, antimycobacterial, analgesic and anticancer activities [190,192–194]. 
Derivatives with pyridinyl- or pyrimidinyl moieties chelate via an NNN binding mode.  
As illustrated in Figure 16, the designed library contains ONS, NNS and NNN donor 
chelators. The first compound class (I) is built around isatin-β-thiosemicarbazones like the 
reported MDR selective NSC73306 (I-a). In view of the reported structure-activity 
relationship of the DpT series [184] and the pharmacophore model of isatin-β-TSCs [42,102] 
the library contains derivatives with an aromatic moiety at N4. Additionally, the current 
pharmacophore model suggests that either electron withdrawing or donating groups in para 
position of the aromatic ring might be beneficial for selective activity toward MDR cell lines 
[42,103]. Therefore compounds with either nitro, methyl, or methoxy groups in this position 
were included in the library. 
Incorporation of these substituted aromatic moieties into the N4-position of the pyridinyl TSC 
scaffold resulted in compound class II. Additionally, the acetaniline derivative II-p was 
prepared, which is able to chelate via an NNS binding mode like the pyridinyl TSC, but has 
an anilinic NH2 instead of the ring-incorporated pyridinyl nitrogen. 
By changing the pyridinyl moiety to a hydroxyphenyl moiety, the similarity to the MDR 
selective isatin-β-TSC compounds is increased, since these compounds, forming compound 
class III, again provide an ONS donor atom set for metal chelation. The previously mentioned 
NNN chelating arylhydrazones are embraced in compound class IV. Hydrazino-benzothiazole 
derivatives like NSC693630 can chelate via either an NNS or NNN donor atom set through 
rotation around a single bond. Therefore they share chemical features with the TSC as well as 
with the hydrazones. Benzothiazoles containing pyridine-moieties are encompassed by 
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compound class V (this class also contains the acetaniline derivative V-d), those with a 
hydroxyphenyl-moiety by compound class VI. 
 
 
 
Figure 16: Library design. The five molecules (upper panels) possessing variable MDR selective 
toxicity served as starting point for the library design around isatin-β-thiosemicarbazones (TSC, box 
I), pyridinyl TSCs (box II), hydroxyphenyl TSCs (box III), arylhydrazones (box IV), pyridinyl 
hydrazino-benzothiazoles (box V), hydroxyphenyl hydrazino-benzothiazoles (box VI), as well as 
molecules with combined chemical entities (box VII). Chelators with ONS, NNS and NNN donor 
atoms are shown in red, blue and green boxes, respectively; donor atoms of example ligands are 
highlighted. 
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In a further step chemical entities of the previously described compound classes were 
combined and resulted in the four derivatives that form class VII: In compound VII-a the 
“non-isatin moiety” of I-a is dimerized. Compounds VII-b and VII-c are hydrazino-
benzothiazoles that contain moieties of compound I-a, and compound VII-d is an isatin-
containing arylhydrazone.  
 
It is noteworthy, that calculations of the lowest energy confirmations of the free ligands 
revealed that the Schiff base double bound is in the E-confirmation, which rather suggests a 
bidentate over a tridentate binding mode [36]. Crystal structures of diverse NNS ligands like 
II-b [195] and II-g [196] or Triapine [197] confirm the calculated E-conformation. Also for 
hydroxyphenyl thiosemicarbazones like those related to class III [198,199] and for N-
heteroarylhydrazones related to class IV [200] the ligands preferably crystalize in their E-
conformations. Nevertheless, in the presence of metal ions an isomerization about the N=CH 
bond seems to occur, since these ligands form complexes with diverse metal ions in tridentate 
binding mode. Therefore, pyridinyl thiosemicarbazones like Triapine and related derivatives 
bind via NNS chelation motive [183,197,201–203] and hydroxyphenyl thiosemicarbazones 
via ONS [199,204–211]. Though some cases of hydroxyphenyl thiosemicarbazone bis-
complexes of nickel and palladium, it has been reported, that the second ligand might bind 
either via one, two or three donor atoms [212,213]. N-heteroarylhydrazones without imino 
carbon substitution [214–216], as well as substituted derivatives [200,217] bind via an NNN 
donor atom set [203]. 
Even though for the hydroxyphenyl hydrazino-benzothiazoles related to class VI ONS and 
ONN binding modes are possible, mostly complexes with ONN binding have been crystalized 
[188,189,218,219]. In analogy, the acetaniline derivative V-d has been reported to bind via an 
NNN binding mode [189,220], while in case of Cu bis-complexes rather a bi-dentate (NN) 
binding  
can be found [189]. Taken together, the review of reported crystal structures shows, that the 
assumption of a tridentate binding mode is generally valid. 
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Synthesis 
As depicted in Scheme 1, the diverse Schiff bases were obtained in an acid catalyzed 
condensation reaction of the particular thiosemicarbazide (C-1, C-2, or C-3) with the 
corresponding aldehyde or ketone. Products were obtained in good to moderate yields. 
Carbazides C-1 to C-3 were prepared from the particular isothiocyanates upon reaction with 
hydrazine in quantitative yields [103,221].  
 
 
 
 
Scheme 1: Synthesis of different Schiff bases starting from the preparation of thiosemicarbazides C-1 
(R
1
: OCH3), C-2 (R
1
: CH3), C-3 (R
1
: NO2), or 2-hydrazino-benzothiazole, respectively. Reaction 
conditions: a: MeOH, stirring at rt; b: EtOH, HCl or HOAc catalysis, refluxing. X = N for compound 
series II and V; X = C-OH for compound series III and VI. Substituents are R
1
: CH3, OCH3 or NO2; 
R
2
: H, CH3, R
3
: H, OCF3. Further compounds listed in Figure 16 were commercially available and 
purchased to complement the library. 
 
 
The synthesis of II-e, II-k, IV-b and V-c, in which the pyridine ring of the keto-component is 
substituted, required the preparation of 5-Ethylpicolinaldehyde (E-5). As illustrated in 
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Scheme 2, the product was obtained in a four step synthesis starting from 5-ethyl-2-methyl-
pyridine following a method patented by Seydel et al. with minor modifications [222].  
 
 
Scheme 2: Synthesis of 5-Ethylpicolinaldehyde. Reaction conditions: a) H2O2, glacial acetic acid, 
120 °C; b) acetic anhydride, glacial acetic acid, 120 °C; c) NaOH, THF, 70 °C; d) freshly prepared 
MnO2, CHCl3, ultrasound, 50 °C. 
 
 
The pyridine-N-oxide (E-2) was formed with hydrogen peroxide in glacial acetic acid, 
followed by alkaline reconditioning. Introduction of an acetoxy group at the methyl group of 
the N-oxide using acetic anhydride and glacial acetic acid provided 5-ethylpyridin-2-yl-
methyl acetate (E-3). The cleavage of the ester to the corresponding alcohol (step c) was 
carried out in THF, as the suggested conditions using ethanol as a solvent provided the ethyl 
ether instead. The oxidation to the desired aldehyde (step d) required a long time; and reflux 
with freshly prepared MnO2 under ultrasound was found to be an efficient oxidizing method. 
Several other methods including commercially available MnO2 [222], the application of SeO2 
and tert-butyl hydroperoxide [223], or the attempt to directly oxidize the 5-ethyl-2-methyl-
pyridine [224–226] were not successful. With the help of the modifications in the first and in 
the last steps of the original approach, the overall yield could be increased from the reported 
18% to 40%.  
 
 
Scheme 3: Synthesis of 4-hydrazinyl-6-methoxypyrimidine. Reaction conditions: Reaction conditions 
were as follows a) NaH, methanol, -10 °C to RT; b) N2H4, methanol, 65 °C. 
 
4-hydrazinyl-6-methoxypyrimidine necessary for the synthesis of the arylhydrazones IV-a-c 
and VII-d was prepared in a two-step approach starting from 4,6-dichloropyrimidine as 
shown in Scheme 3 [89,222].   
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in vitro testing 
As described in chapter 3.1. the cytotoxic activity of the compounds was investigated in a 
panel of parental (sensitive) and MDR cancer cell lines, in order to distinguish between 
compounds showing cell-specific and MDR selective toxicity. Cytotoxicity of the compounds 
was measured using the MTT viability assay. In order to avoid a putative interaction of the 
investigated compounds with the assay reagent, the medium containing the test compound 
was removed before adding the reagent. To still exclude assay dependent results, additional 
experiments were performed with MES-SA and MES-SA/Dx5 cells stably expressing the 
fluorescent protein mCherry. As shown in Figure 17, the two methods provided concordant 
results. Despite slight differences in the slopes optained in the fits for both cell lines (0.97 for 
MES-SA and 0.70 for MES-SA/Dx5), a high intercorrelation can be found between the 
assays. 
 
 
 
 
 
 
Figure 17: Correlation of pIC50 values of 
35 different compounds on MES-SA 
(black) and MES-SA/Dx5 (red) cell lines 
obtained with mCherry fluorescence 
assay and MTT assay. Data of at least 3 
independent measurements per assay and 
compound are shown. The squared 
correlation coefficient was calculated to 
be r² = 0.91 for MES-SA and 0.92 for 
MES-SA/Dx5 cells. 
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3.2.1. Thiosemicarbazones – Compound classes I/II/III 
Several isatin-β-thiosemicarbazones have been reported to show MDR selective toxicity 
[95,98,100,102,103]. According to the current SAR understanding of these compounds, 
derivatives were synthesized with aromatic moieties at N4 as summarized in Table 5. 
Compounds I-a, I-c and I-d were prepared for comparison with literature reports [42,102]. 
They are substituted in para position of the aromatic ring with an electron withdrawing nitro 
group (I-d) or with electron donating methoxy (I-a) or methyl (I-c) groups. Additionally I-b 
contains a trifluormethoxy substituent at the isatin moiety. In compound I-e (which was 
commercially available) the aromatic moiety is substituted in meta position. 
 
Table 5: Structures of investigated isatin-β-thiosemicarbazones. 
 
  R1 R2 
 
I-a 4-OMe H 
I-b 4-OMe 5-OCF3 
I-c 4-Me H 
I-d 4-NO2 H 
I-e 3-CF3 H 
 
 
The selectivity ratio, the fraction of IC50 values obtained in P-gp negative vs. positive cells, 
serves as a quantification of the MDR selective effect. The range of SR values for the five 
isatin-β-thiosemicarbazones obtained in at least three independent experiments is shown for 
the investigated cell lines in Figure 18. Even though the magnitude of the effect is slightly 
smaller than reported, the obtained results confirm literature reports on the selectivity of 
compound I-a. Also the selectivity-reverting effect of the P-gp inhibitor Tariquidar is in good 
agreement with the literature [95,98,100,102,103]. In contrast, the selective toxicity effect of 
the N4 para tolyl derivative I-c and the N4 para nitrophenyl derivative I-d is much less 
pronounced in our test system as compared to the reported SR values of 9.2 for I-c and 8.3 for 
I-d [103]. In fact, I-c is not selective in KB-V1 vs. KB-3-1 and A2780adr vs. A2780 cells. 
Together with the low Pearson correlation coefficient of activity and P-gp expression across 
the NCI60 cell line panel and the selectivity data for NCI/ADR-res vs. OVCAR-8 cells (see 
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Table 3), these data suggest that in case of I-c the putatively observed selectivity of these 
compounds might be strongly influenced by other factors than P-gp  
The pharmacophore model of isatin-β-thiosemicarbazones suggests that substituents at the 5 
position of the isatin moiety are tolerated, while meta substituents in the terminal phenyl ring 
might have a detrimental effect on selective toxicity [42,102]. The two novel TSC derivatives 
I-b, containing a trifluormethoxygroup in the 5-position of the isatin moiety, and I-e, 
containing a trifluormethyl substituent at the terminal phenyl ring support this general 
conclusion. 
 
 
 
Figure 18: Box and whiskers plot of selectivity ratios (SR) for the isatin-β-TSCs from Table 5 as 
calculated from the ratio of IC50 values of P-gp negative to positive cells (number of experiments 
indicated under the boxes). Black: Dx5 vs. MES-SA cells measured with MTT, red: Dx5 vs. MES-SA 
cells measured with mCherry fluorescence, blue: KB-V1 vs. KB-3-1 cells (MTT), green: A2780adr vs. 
A2780 (MTT); filled boxes in lighter color: Dx5 vs. MES-SA cells in presence of 1 µM TQ: grey: 
measured by MTT, light red: measured by mCherry fluorescence. Significance was calculated using 
paired t-tests of the independent experiments and is given as *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001, 
****: p ≤ 0.0001. 
 
 
Compound class II comprises the pyridinyl thiosemicarbazones and the acetaniline derivative 
II-p, as summarized in Table 6. In addition to the synthesized derivatives, compounds II-a, 
II-b, II-d, II-h, II-i, II-l, II-m, II-n, and II-o were obtained from vendors. A part of these 
derivatives or metal complexes thereof have been reported earlier to possess biological 
activity in diverse settings, including antimalarial [227], modest antibacterial [228], modest 
antifungal [202,229], and promising antitumor activity [195,196,202].  
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Table 6: Structures of investigated pyridinyl and acetaniline TSCs. 
 
 
II-a – II-o 
 
 
II-p 
 R1 R2 R3   R1 R2 R3 
II-a H H H  II-I 2-Me Me H 
II-b H Me H  II-j 4-NO
2
 H H 
II-c 4-OMe Me H  II-k 4-NO
2
 H 3-Et 
II-d 4-OMe H 2-Me  II-l 3-CF
3
 H H 
II-e 4-OMe H 3-Et  II-m 3-CF
3
 Me H 
II-f 4-Me H  H  II-n 2-CF
3
 H H 
II-g 4-Me Me H  II-o 2-CF
3
 Me H 
II-h 3-Me Me H  II-p H Me H 
 
 
The selectivity ratios obtained for these compounds in the investigated cell line panel are 
illustrated in Figure 19. The previously described P-gp substrate Triapine was included in the 
Figure for comparison. Compound II-b lacks toxicity, and does therefore not appear in 
Figure 19. In most cases, the compounds show comparable toxicity throughout the cell line 
panel. Still, a subset of compounds shows selective toxicity toward selected cell lines. 
Compound II-c is significantly more toxic for MES-SA/Dx5 as compared to MES-SA cells in 
both MTT and mCherry measurements. In the presence of Tariquidar, this selectivity seems 
retained, even though the effect is not significant. Selectivity of II-f can only be observed in 
MTT assays with the MES-SA cell line pair – II-e shows a similar trend, yet t-tests revealed 
that this trend lacks significance. In addition to the effect on the MES-SA cell line pair 
observed in MTT assays, compound II-g shows a small but significant preference for KB-V1 
over KB-3-1 cells. Yet, since this effect is not observed in mCherry measurements and in 
A2780 cells, and since Tariquidar did not abolish selectivity, this effect is probably not related 
to the activity of P-gp. 
It is striking that the compounds with a cell line dependent effect are those, in which the 
pyridinyl chelation motive, as also present in Triapine, is combined with an aromatic moiety 
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at N4, which is substituted in para position with an electron donating group, like the methoxy 
group in cases II-c and II-e, or the methyl group in cases II-f and II-g. In this compound set, 
changing the position of the methyl group from para in II-g to meta in II-h or ortho in II-j 
abrogates the cell line specific selectivity. 
 
 
 
Figure 19: Selectivity ratios (SR) for pyridinyl TSCs and acetaniline TSC II-p from Table 6. Black: 
Dx5 vs. MES-SA (MTT), red: Dx5 vs. MES-SA (mCherry), blue: KB-V1 vs. KB-3-1 cells, green: 
A2780adr vs. A2780; filled boxes in lighter color: Dx5 vs. MES-SA cells in presence of 1 µM TQ 
measured by MTT (grey) or mCherry (light red). Significance is given as *: p ≤ 0.05, **: p ≤ 0.01, 
***: p ≤ 0.001, ****: p ≤ 0.0001. 
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Taken together, while the terminally unsubstituted thiosemicarbazone Triapine is a substrate 
of P-gp, the introduction of a para-substituted aromatic moiety to the N4 of the pyridinyl TSC 
core structure (a feature associated with MDR selectivity) resulted in compounds that are not 
recognized and effluxed by the transporter. In some cases, the newly investigated compounds 
even conferred a cell line specific selective toxicity. Yet, this selectivity is linked to other 
factors than P-gp. 
 
The chelation motif was changed from the NNS donor atom set present in pyridinyl TSCs to 
the ONS set of isatin-β-thiosemicarbazones by replacement of the pyridinyl moiety by 
hydroxyphenyl. The investigated compounds are summarized in Table 7. Compound III-c 
and III-d were synthesized, while the other compounds were commercially available. 
Attempts to synthesize derivatives with nitro-substituents in position R1 did unfortunately not 
provide the desired products. 
Similar to the previously described compound classes (I and II), also hydroxyphenyl 
thiosemicarbazones (class III) form complexes with various metal ions, like the redox active 
complexes with Ru(II) [204,208] and Cu(II) [205–207]. For the free ligands and the 
complexes formed with Ni(II) [209], Cu(II), Ru(II) and Zn(II) [206–208] an antibacterial and 
antifungal activity has been reported. N4-phenyl-hydroxyphenyl TSC III-a has also been 
reported to show GABAa receptor inhibition [230], a weak (500 µM) inhibition of RR [231] 
and antitumor activity [198,207].  
 
 
Table 7: Structures of investigated hydroxyphenyl thiosemicarbazones. 
 
 
R1 R2 R3 
 
III-a H H H 
III-b 4-OMe H H 
III-c 4-Me H H 
III-d 4-Me Me H 
III-e 3-CF3 H H 
III-f 3-CF3 H 4-NO2 
III-g 2-CF3 H 4-NO2 
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As already observed for the pyridinyl TSCs, also the hydroxyphenyl TSCs show comparable 
toxicity across the investigated cell line panel. Two compounds show some degree of 
selectivity toward MES-SA/Dx5 over MES-SA cells in mCherry measurements, namely III-a 
and III-d. But due to the high deviation between assay results in case of III-d, this is rather a 
trend than a significant result. Even though the data in Figure 20 suggest, that Tariquidar co-
administration might decrease the selectivity, a closer look at the data reveals that surprisingly 
the P-gp inhibitor also affects the sensitivity of the parental cells toward these two 
compounds. For mCherry measurements, in case of III-a the averaged IC50 value is changed 
upon Tariquidar co-administration from 14.1 µM to 40.5 µM in MES-SA, and from 6.4 µM to 
41.8 µM in MES-SA/Dx5. Likewise for III-d the IC50 value is changed from 10.9 µM to 
13.0 µM in MES-SA and from 3.5 µM to 7.7 µM in MES-SA/Dx5 (yet, even though a trend 
for an initial selectivity might be observable, statistical analysis suggests that the difference in 
response of both cell lines toward III-d is not significant).  
In summary, these data suggest, that also in the set of hydroxyphenyl TSCs no new P-gp-
mediated MDR selective compound could be identified. 
 
 
 
Figure 20: Selectivity ratios (SR) for hydroxyphenyl TSCs from Table 7. Black: Dx5 vs. MES-SA 
(MTT), red: Dx5 vs. MES-SA (mCherry), blue: KB-V1 vs. KB-3-1 cells, green: A2780adr vs. A2780; 
filled boxes in lighter color: Dx5 vs. MES-SA cells in presence of 1 µM TQ: grey: measured by MTT, 
light red: measured by mCherry. Significance was calculated using paired t-tests of the independent 
experiments (number of experiments indicated under the boxes) and is given as *: p ≤ 0.05, **: p ≤ 
0.01, ***: p ≤ 0.001, ****: p ≤ 0.0001. 
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3.2.2. Arylhydrazones – Compound class IV 
Arylhydrazones have been suggested to be superior to thiosemicarbazones, since they cannot 
release H2S from their structure, which might cause several side effects in clinical 
applications [187]. Compound IV-c was suggested to have a potential to overcome MDR in 
strains of leprosy and tuberculosis [187,190]. In order to investigate the potential of this 
compound class to overcome MDR in cancer, IV-c together with its close derivatives IV-a 
and IV-b were synthesized, while compounds IV-d to IV-h were purchased from vendors.  
 
 
Table 8: Structures of investigated arylhydrazones. 
  
 
X R1 R2 R3 
 
IV-a N 6’-OMe H H 
IV-b N 6’-OMe Me H 
IV-c N 6’-OMe H 5-Et 
IV-d CH H Me H 
IV-e CH H H 2,3-benzo 
IV-f CH H Me 2,3-benzo 
IV-g CH H H 2,3-benzo,4-Me 
IV-h CH H Me 2,3-benzo,4-Me 
 
As shown in Figure 21, none of the investigated compounds is significantly less toxic in the 
MDR cell lines, as compared to their parental derivatives (an exception is compound IV-a, 
which seems to be significantly less toxic toward KB-V1 cells than to KB-3-1. Yet, despite 
being significant, the difference in toxicity toward the two cell lines is rather small), 
suggesting that they are not subject to P-gp-mediated efflux. Compounds IV-b and IV-c even 
show preferentially toxicity toward the MDR cell lines MES-SA/Dx5 and A2780adr 
compared to their parental counterparts MES-SA and A2780. The magnitude of the effect is 
much higher in case of IV-b. Yet, the effect observed in the MES-SA cell line pair with the 
MTT assay could not be verified with the mCherry fluorescence assay. Also, the P-gp 
inhibitor Tariquidar had no impact on the selectivity. 
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Figure 21: Selectivity ratios (SR) for arylhydrazones from Table 8. Black: Dx5 vs. MES-SA (MTT), 
red: Dx5 vs. MES-SA (mCherry), blue: KB-V1 vs. KB-3-1 cells, green: A2780adr vs. A2780; filled 
boxes in lighter color: Dx5 vs. MES-SA cells in presence of 1µM TQ measured by MTT (grey) or 
mCherry (light red). Significance is given as *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001, ****: p ≤ 
0.0001. 
 
 
 
3.2.2. Hydrazino-benzothiazoles – Compound classes V and VI 
Similar to arylhydrazones, also hydrazine-benzothiazoles have been suggested to be superior 
to thiosemicarbazones due to the incorporation of sulphur into a ring system, which hinders 
the release of H2S during metabolism, while retaining the compound’s activity [186]. The 
three pyridinyl V-a to V-c and one acetaniline derivative V-d summarized in Table 9 were 
synthesized. The biological application of benzothiazoles as well as their complexes includes 
– similar to that of TSCs – antibacterial and antifungal [188,189,218,220,232], as well as 
antitumor activity [186,188,203,219,233,234].  
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Table 9: Structures of investigated pyridinyl hydrazino-benzothiazole s, and acetaniline hydrazino-
benzothiazole V-d. 
 
 
 
R2 R3 
 
V-a H 
 
V-b Me 
 
V-c H Et 
 
V-d   
 
 
As illustrated in Figure 22, in the MTT measurements all derivatives show a slightly higher 
toxicity toward MES-SA/Dx5 as compared to parental MES-SA cells. Yet, even though 
significant, this effect is rather small in most cases and could not be observed in the mCherry 
measurements or in other cell lines. An exception is compound V-b, which shows a more 
pronounced selectivity ratio in the before mentioned test system. Even though not significant, 
a clear trend can also be observed in the mCherry measurements of the MES-SA cell line pair, 
as well as in the MTT measurements of the A2780 cell line pair. Co-administration of 
Tariquidar revealed, that P-gp has no impact on the observed selectivity of compound V-b. 
 
 
Figure 22: Selectivity ratios (SR) for pyridinyl hydrazino-benzothiazoles and the acetaniline 
hydrazino-benzothiazole V-d from Table 9. Black: Dx5 vs. MES-SA (MTT), red: Dx5 vs. MES-SA 
(mCherry), blue: KB-V1 vs. KB-3-1 cells, green: A2780adr vs. A2780; filled boxes in lighter color: 
Dx5 vs. MES-SA cells in presence of 1µM TQ measured by MTT (grey) or mCherry (light red). 
Significance is given as *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001, ****: p ≤ 0.0001. 
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In order to again increase the similarity of the chelation motif to that of the MDR selective 
isatin-β-thiosemicarbazones, compounds with an ONS donor atom set were investigated. 
Hydroxyphenyl hydrazino-benzothiazoles VI-a and VI-b were synthesized, while derivatives 
with substituents in para position of the phenolic OH VI-c to VI-g were commercially 
available. 
 
Table 10: Structures of investigated hydroxyphenyl hydrazino-benzothiazoles. 
 
  R R2 R3 
 
VI-a H H H 
VI-b H Me H 
VI-c H H 4-OMe 
VI-d H Me 4-OMe 
VI-e H H 4-Me 
VI-f H H 4-NO
2 
VI-g Me H H 
 
Strikingly, compound VI-g, in which the metal binding hydroxyl group of VI-a is replaced by 
a methoxy group, lacks toxic activity. Since the methoxygroup in VI-g hinders chelation in 
comparison to a free hydroxyl group, the lack of toxicity of this compound underlines the 
importance of chelation in the mechanism of toxicity of these compounds. Despite the 
deviations between the single experiments, a significant preferential toxicity toward MES-
SA/Dx5 as compared to MES-SA could be observed for compounds VI-a, VI-b, VI-d and 
VI-e. In case of VI-a and VI-b, experiments in other cell lines could not confirm this effect 
(Figure 23). Although co-administration of Tariquidar seemed to abolish the selectivity, the 
decreased selectivity in the presence of the P-gp inhibitor is not only connected to changes in 
MES-SA/Dx5 sensitivity, but also to the sensitivity of the parental MES-SA cells. This is 
comparable to the effect seen for the investigated hydroxyphenyl thiosemicarbazones. 
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Figure 23: Selectivity ratios (SR) for hydroxyphenyl hydrazino-benzothiazoles from Table 10. Black: 
Dx5 vs. MES-SA (MTT), red: Dx5 vs. MES-SA (mCherry), blue: KB-V1 vs. KB-3-1 cells, green: 
A2780adr vs. A2780; filled boxes in lighter color: Dx5 vs. MES-SA cells in presence of 1µM TQ: 
grey: measured by MTT, light red: measured by mCherry. Significance was calculated using paired t-
tests of the independent experiments (number of experiments indicated under the boxes) and is given 
as *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001, ****: p ≤ 0.0001. 
 
 
 
3.2.4. Combination of chemical entities – Compound class VII 
As shown in Figure 16, chemical entities from different classes were combined in order to 
increase the similarity of newly designed compounds to I-a. Four compounds were prepared 
under similar conditions as for the other Schiff-bases. For the dimer of the non-isatin moiety 
of I-a, namely VII-a, 4-methoxyphenylisothiocyanat was reacted with a half equimolar 
amount of hydrazine. Compounds VII-b and VII-c are combinations of I-a with hydrazino-
benzothiazole s, they were prepared by the reaction of hydrazino-benzothiazole with either 4-
methoxyphenylisothiocyanat or isatin. The arylhydrazone VII-d was obtained in an acid 
catalyzed condensation of isatin and 4-hydrazinyl-6-methoxypyrimidine. 
Compounds with combined entities of the parent compounds had only modest cytotoxicity 
with IC50 values above 50 µM. 
 
 
 
  
3.2. Development of new compounds – Design of a focussed library 59 
 
 
3.2.5. Structure activity relationships in the focused library and beyond 
Even though most of the scrutinized compounds do not show enhanced toxicity toward P-gp 
expressing MDR cell lines over their parental P-gp negative cells, the test results of the library 
disclose trends in toxicity, which are independent of the resistance status of the investigated 
cell lines. For illustration, results are summarized in the structure activity relationship matrix 
(SARM) shown in Figure 24 [235]. Numbers represent averaged pIC50 values of at least three 
independent experiments and are colored according to the color code given in the inset next to 
the matrix. 
As already mentioned in chapter 3.2.4., the combination of chemical entities resulted in 
nontoxic compounds VII-a, VII-b, VII-c and VII-d.  
Hydrazino-benzothiazoles have been described in the literature as metabolically more stable 
derivatives of thiosemicarbazones with retained pharmacological activity [186]. Indeed, 
comparison of the respective columns in the SARM confirms the retained (anticancer-) 
activity of the two scaffolds: the pyridinyl hydrazino-benzothiazole V-a shows similar 
toxicity compared to the corresponding TSC II-a. Likewise the hydroxyphenyl hydrazino-
benzothiazole VI-a is comparable to the corresponding TSC III-a. Furthermore comparing 
the columns of differently substituted N4-aromatic moieties in the investigated 
thiosemicarbazones it appears that N4-para-nitrophenyl derivatives have a lower toxicity 
compared to para-tolyl and para-methoxyphenyl substituted counterparts (I-d vs. I-a, I-c; II-
j vs. II-f; II-k vs. II-e). 
Comparing the rows of the SARM, further trends can be identified with respect to the impact 
of different donor atom sets and imino carbon substitution on toxicity of the compounds. Both 
will influence the metal binding properties of the chelators, which might be crucial in the 
mechanism of toxicity of these compounds. 
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Figure 24: SAR matrix of synthesized and purchased compounds. The average pIC50 values of at least 
three independent experiments are given for the A2780, KB and MES-SA cell line pairs. Cell lines are 
arranged according to the inset. In general, data were obtained by MTT assays, while compounds 
marked with an asterisk were measured in mCherry fluorescence assay only. 
  
R1
R2
5,13 5,33 5,02 5,05 4,61 5,05 n.tox. n.tox. A2780 A2780adr
5,12 5,40 5,38 5,40 5,11 5,35 4,26 4,17 KB-3-1 KB-v1
5,22 5,46 5,29 5,48 5,07 5,33 4,04 3,89 n.tox. n.tox. messa dx5
5,49 5,45
 5,21 5,41
5,24 5,59
pIC50 IC50 
n.tox. not toxic
 n.tox. n.tox. 4,00 100.0 µM
n.tox. n.tox. n.tox. n.tox. 4,50 31.6 µM
5,00 10 µM
5,27 5,16 5,30 5,22 5,51 5,23 5,50 3.2 µM
5,30 5,30 5,48 5,46 4,80 4,93 6,00 1.0 µM
4,94 5,32 5,42 5,46 5,43 5,39 4,63 5,02 6,50 316.2 nM
7,00 100.0 nM
5,08 5,01 7,50 31.6 nM
4,86 4,94 8,00 10 nM
5,01 5,36 4,91 5,28 8,50 3.2 nM
5,37 5,31
4,69 4,65
4,98 5,10 4,35 4,56
7,32 7,20 6,21 5,87 5,76 5,71 6,24 6,35
6,14 6,05 5,99 5,75 5,72 5,55 6,19 6,09
6,16 6,25 6,44 7,14 5,59 5,75 5,56 5,61 5,85 6,00
7,34 7,55 7,79 7,69 6,88 7,59 7,05 7,52
6,16 5,98 7,43 7,48 6,45 6,31 6,43 6,53
n.tox. n.tox. 6,47 7,85 7,77 8,77 6,58 7,04 6,66 7,91
5,89 6,21 6,09 6,23
5,10 5,05 5,91 5,81 6,03 5,94
6,38 7,20 4,97 5,09 5,82 5,96 5,50 5,73
5,33 5,38
VII-d VII-c cell lines
VI-b
IV-a V-a
O
N
S 
/ 
O
N
N I-a I-c I-d
VI-a
VII-a
I-b
VII-b
3d *
III-a * III-b III-c
IV-b V-b
II-a * II-f II-j
N
N
S 
/N
N
N 2q V-d
II-e II-k
II-b * II-c II-g
IV-c 5c
II-d *
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Strikingly, the investigated hydroxyphenyl TSCs and benzothiazoles proved to be less toxic 
than their corresponding pyridinyl counterparts. Plotting the pIC50 values of matched 
molecular pairs (MMP) of ONS and NNS donor chelators as shown in Figure 25, a significant 
difference in toxicity is visible across all investigated cell lines. Including also those 
compounds into the analysis which do not have an MMP, the same effect can be observed: In 
Figure 26 A the pIC50 values were averaged for P-gp positive and P-gp negative cell lines for 
all investigated compounds and plotted for comparison. In agreement with the earlier chapters 
(3.2.1 – 3.2.3), no overall effect of P-gp on the toxicity could be observed, explaining the 
arrangement of data points close to the bisecting line of the diagram. In contrast, the 
differently colored data-points, representing ONS (red), NNS (blue) and NNN (green) 
chelators seem to cluster. The significance of this clustering is illustrated in the boxplot in 
Figure 26 B. 
 
 
 
Figure 25: Pairwise comparison of the toxic effect (pIC50) of matched molecular pairs (MMP) of 
chelators with ONS and NNS donor sets. Different colors indicate the respective compound pairs: 
Cyan: VI-a vs. V-a, green: VI-b vs. V-b, blue: III-c vs. II-f, purple: III-d vs. II-g, orange: III-a vs. 
II-a, pink: III-e vs. II-m. Data are shown in panel A for A2780wt (open circles) and A2780adr (filled 
circles), in panel B for KB-3-1 (open triangles) and KB-V1 (filled triangles), and in panel C for MES-
SA (open symbols) and MES-SA/Dx5 (filled symbols). Data were in general obtained by MTT assay, 
except for the diamonds in panel C, which were obtained by mCherry fluorescence assay. The 
indicated significance (***p ≤ 0.001) was calculated by unpaired t-test. A list of IC50 values is 
provided in the appendix. 
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Figure 26: (A): Comparison of overall toxic activity of ONS (red), NNS (blue) and NNN (green) 
chelators with and without MMPs in P-gp (+) and P-gp (-) cells. Data for each compound was 
averaged over the investigated cell lines. (B): Box and Whiskers plot of toxicity data from mCherry 
fluorescence measurements using MES-SA and MES-SA/Dx5 cells comparing NNS, NNN and ONS 
chelators. Significance was calculated from unpaired t-tests (****: p ≤0.0000001). 
 
 
In the investigated set of compounds NNS chelators seemed to be have a higher toxic 
potential against the investigated cancer cell lines, as compared to ONS chelators. In order to 
test this hypothesis on a larger compound set, the DTP drug database, which contains the 
activity patterns of standard anticancer drugs and tens of thousands of candidate anticancer 
agents [96,97], appeared to be a useful tool. Substructure searches for NNS and ONS 
chelators were performed within the database as illustrated in Figure 27 A and 27 B. 
Altogether 1335 analogues were identified. Some of the identified compounds (221 NNS and 
74 ONS compounds) contained metal ions in their structure and were segregated following 
visual inspection. Further visual inspection revealed, that despite the presence of the putative 
donor atoms in the right distance to each other, some of the derivatives (namely 120 NNS and 
119 ONS compounds), will not be able to chelate metal ions, since the heteroatoms are 
occupied by substituents or incorporated into ring systems (an example for such a structure is 
given in Figure 27 E). Also these compounds were treated separately. Biodata was extracted 
from the database in case it was available (for this I am grateful to Dr. Anna Lovrics). 
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Figure 27: Flowchart of the identification of NNS (A) and ONS (B) donor chelators in the DTP 
database. (C): Pairwise comparison of cytotoxic activity of matched molecular pairs of ONS (data for 
X = C-OH shown in red) and NNS (data for X = N shown in blue) donor chelators across the NCI60 
cell panel. Structures of the compounds are shown below the graph. NSC95678 contains both binding 
options (purple). (D): Average toxicity of the compounds identified by the substructure search (pIC50 
values averaged over the 60 cell lines). (E): outstandingly toxic non chelating ONS molecules, 
derivatives of Trabectedin / ecteinascidin-743 (NSC648766, NSC648767, NSC648768, NSC648769). 
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Within the set of compounds with available biodata, three matched molecular pairs (MMPs) 
could be identified with ONS and NNS donor atom sets. Figure 27 C shows the available 
biodata of these compounds across the NCI60 panel. The structures of these pairs are 
displayed below the data with X representing C-OH for the ONS donor chelators (data in red), 
or N for the NNS donor chelators (data in blue). The three additional MMPs confirm a higher 
toxicity of NNS chelators over their ONS counterparts irrespective of the investigated cell 
line. Interestingly, NSC95678, which is able to chelate in either NNS or ONS binding mode, 
has a moderate toxicity between that of the other NNS and ONS chelators. 
In order to compare the activity of the 385 compounds for which biodata were available, the 
average pIC50 value over the NCI60 panel was determined for each compound. The boxplot in 
Figure 27 D shows that the superior activity of NNS over ONS chelators found in the DTP 
database is significant. This is especially interesting, since the identified compounds display a 
high diversity that is presumably associated with different mechanisms of toxicity. 
A similar trend could also be observed for the diverse metal complexes. Though, it has to be 
noted, that the identified complexes contain different metal ions, which might lead to 
misleading conclusions, since not only the properties of the ligand, but also the nature of the 
metal ions that are incorporated into the complex, will affect its biological activity.  
The lack of activity of the non-chelating derivative VI-g within the designed library suggested 
a huge impact of chelation on the toxicity of the investigated compounds. Indeed, non-
chelating derivatives identified in the DTP, despite their structural diversity, show a 
significantly decreased toxicity. Within the non-chelating derivatives there is no difference in 
toxicity between NNS and ONS containing structures. In comparison to the chelating 
derivatives these compounds are generally less potent. Nevertheless, within this non-chelating 
subset, four compounds show an outstandingly high toxicity. The structural scaffold of these 
compounds is shown in Figure 27 E (within the four derivatives R is differing). It is apparent, 
that despite the putative metal-binding substructure motive, by which they were identified, 
their structure is very different from the other compounds: they are derivatives of the marine 
natural product Trabectedin (ecteinascidin-743, Figure 27 E), which is currently undergoing 
clinical trials (phase III) in the USA, while it is approved for cancer treatment in Europe 
[236–238]. 
Since chelation seems to be crucial for the activity of the investigated compounds, the 
superior activity of NNS (and NNN) donor atom chelators over ONS donors might be related 
to different metal binding preferences. Chelators with distinct donor atoms show a binding 
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preference for certain metal ions, and stabilize different oxidation states of these ions, 
according to the principle of hard and soft acids and bases (HSAB) [239,240]. 
The common donor atoms in the thiosemicarbazone and hydrazino-benzothiazole compound 
classes are a sulfur atom as a soft electron donor and a hydrazinic nitrogen as a hard donor. 
The third Lewis base is either a borderline pyridine nitrogen donor in case of the pyridinyl 
derivatives, or a hard oxygen donor in case of the hydroxyphenyl derivatives [239–241]. 
Therefore the hydroxyphenyl compounds prefer harder metal ions than the pyridinyl 
derivatives [241]. A study comparing the stability of several metal complexes formed by the 
N4 unsubstituted hydroxyphenyl- and pyridylcarbaldehyde TSCs supports this general trend 
[242]. The different chelating properties of the ligands might not only influence the stability 
of complexes formed with diverse metal ions, but also their redox properties. For example, 
ONS donors prefer higher oxidation states of iron and copper as compared to NNS donors 
[241]. Therefore the mechanism of action of hard donor atom containing chelators might be 
dominated by the depletion of metal ions (as it is exploited in the case of iron overload 
disease), while soft donor atom chelators are more capable of enhancing the production of 
ROS upon complexation with metal ions like iron [123,243].  
Next to the nature of the donor atoms alone, also steric factors will affect the ligands’ ability 
to chelate a metal ion. The impact of steric effects on the biological activity is evident from 
the comparison of the two investigated acetaniline compounds II-p and V-d to their 
respective pyridinyl counterparts II-c and V-b (see SARM, Figure 24). The latter show a 
greater toxic potential. This might be explained by a combination of steric and electronic 
reasons that have an impact on the complexation of metal ions. 
 
Another observation that can be made upon comparison of rows within the SARM (Figure 24) 
is, that compounds methylated at the imino carbon of the Schiff base might be more toxic 
than those which are derived from the corresponding aldehyde and do not possess a 
methylgroup in this position. Examples for this observation are the MMPs II-f vs. II-g, IV-a 
vs. IV-b, and V-a vs. V-b. Together with further MMPs that are not included in the SARM, 
the toxicity of compounds with and without methyl group at the imino-carbon is compared in 
Figure 28 in dedicated panels for NNS (panel A), NNN (panel B) and ONS (panel C) 
chelators. Literature data suggest, that the imino carbon of thiosemicarbazones [227], 
aroylhydrazones [244], arylhydrazones [89] and benzothiazoles [203,233] might be a 
sensitive position for the fine-tuning of the biological activity of these Schiff bases. Variations 
in this position might influence the chelation behavior. 
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As apparent from panel A, in two of the four NNS donor MMPs methylation of the imino 
carbon results in increased toxicity (these two are the previously mentioned pairs II-f vs. II-g 
and V-a vs. V-b). For the MMP consisting of N4-ortho-trifluormethylphenyl TSCs, the 
imino-methylated derivative II-o showed a higher toxicity than the desmethyl counterpart II-
n in MES-SA cells, while MES-SA/Dx5 cells reacted to both compounds with the same 
sensitivity. In contrast, for the N4-meta-trifluormethylphenyl TSC MMP the methylated 
derivative II-m was actually less toxic than the desmethyl derivative II-l.  
 
 
Figure 28: Effect of imino methylation on toxicity. Pairwise comparison of pIC50 values from MMPs 
of chelators containing N NS (A), NNN (B) and ONS (C) donor atom sets obtained in A2780wt (open 
circles), A2780adr (filled circles), KB-3-1 (open triangles), KB-V1 (filled triangles), MES-SA (open 
squares), MES-SA/Dx5 (filled). Cyan: II-f vs. II-g, green: IV-a vs. IV-b, blue: V-a vs. V-b, black: 
VI-a vs. VI-b, purple: III-c vs. III-d, bordeaux: II-n vs. II-o, pink: II-l vs. II-m, orange: IV-e vs. IV-
f, red: IV-g vs. IV-h, brown: VI-c vs. VI-d. A list of IC50 values is provided in the appendix. 
 
 
For the investigated NNN donor containing chelators, toxicity of the arylhydrazones IV-e and 
IV-g was comparable to that of their corresponding imino carbon methylated counterparts IV-
f and IV-h (Figure 28 B). Here, increased toxicity upon methylation could only be observed 
for the pyrimidinylhydrazone IV-b over IV-a, which was already identified from the SARM. 
The three investigated ONS donor atom chelator MMPs showed comparable toxicity of imino 
carbon methylated and demethylated derivatives (Figure 28 C). Including also those 
compounds into the analysis, which do not have a MMP confirmed the lack of effect of imino 
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carbon methylation on the toxicity of hydroxyphenyl containing chelators, while the activity 
of the imino carbon methylated pyridinyl compounds was found to slightly but significantly 
surpass that of the unsubstituted derivatives (Figure 29). Together with the pairwise 
comparisons, these data suggest that methyl substitution of the imino carbon may influence 
the toxicity of NNS donor atom chelators.  
 
 
 
Figure 29: Box and Whiskers plot of toxicity data on MES-SA-mCh and MES-SA/Dx5-mCh cells 
comparing chelators with different donor atoms with and without methylation at the imino carbon. 
NNS/NNN chelators with imino methyl group are depicted in blue, without methyl group in cyan, 
ONS chelators with methyl group are depicted in red, without Me in orange (p=0.045).  
 
 
Since the observed trend was not conclusive, the set of NNS and ONS donor atom chelators 
identified in the DTP database was revisited. The search results were refined, separating 
molecules with unsubstituted and methylated imino carbons as shown in Figure 30 A. 
Comparison of the available biodata of further 12 imino methylated and 17 demethylated 
ONS chelators confirmed our finding that a methyl substitution of the imino carbon does not 
significantly influence the activity of these chelators. For the NNS donor chelators biodata 
was available for 62 methylated and 62 demethylated derivatives. In agreement with the 
finding on the designed library, also in this compound set the methylated derivatives tended to 
be more toxic than the demethylated derivatives (Figure 30 B). 
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Figure 30: The NNS and ONS chelating compounds from 
Figure 27 were analyzed with respect to imino carbon 
substitution. (A): Flowchart of the refinement of search results 
from Figure 27, (B): Available biodata for 62 NNS chelators 
with methyl-substituted imino carbon (blue), 62 NNS chelators 
with unsubstituted (H) imino carbon (cyan), 12 ONS chelators 
with methyl-substituted (red) and 17 ONS chelators with 
unsubstituted (H) imino carbon (orange). pIC50 values were 
averaged over the 60 cell lines for all compounds (p=0.039). 
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3.3. Having a closer look at the 8-hydroxyquinoline scaffold 
Revisiting the set of MDR selective compounds, which were identified by the 
pharmacogenomic approach on the DTP data (chapter 3.1.), two compound classes seemed 
enriched in both, the already published (reference [98]) and the new discovery set. One cluster 
is formed by thiosemicarbazones, which were derivatized as presented in chapter 3.2.1. – the 
other cluster is formed around hydroxyquinoline derived Mannich bases. The 8-
hydroxyquinoline scaffold is a privileged structure in medicinal chemistry which has various 
applications next to its anticancer activity, including neuroprotective, anti-HIV and antifungal, 
antileishmanial, antischistosomal activity, as well as inhibitory potential against 2-
oxoglutarate, iron dependent enzymes and other metallo-proteins, mycobacterium 
tuberculosis and butolinum neurotoxin [245]. In the new discovery set, the piperidine 
Mannich base NSC57969 (Q-3) and the ring-closed dihydro-[1,3]-oxazine derivative 
NSC297366 (Q-4b) were identified based on their high Pearson correlation coefficients 
(≥ 0.4). A structural similarity search in the database disclosed available biodata for further 
derivatives. Two closely related compounds are the morpholino Mannich base (NSC662298, 
Q-2) and the unsubstituted 8-hydroxyquinoline core structure (NSC2039, Q-1). While the 
Pearson correlation coefficient for Q-1 is close to zero, for Q-2 it is 0.37, and therefore just 
closely below to the set threshold of 0.4. Data in the NCI/ADR-res and OVCAR-8 cell line 
pair confirms the trend from the 60 cell line data, as illustrated in Figure 31.  
The structural similarity of these compounds suggests a similar metal binding mode. Due to 
the varied spectrum of selective toxicity toward MDR cell lines that is represented by these 
four compounds, they seem to provide a promising tool to address questions regarding the 
link between metal binding properties and their biological activity. The compound set was 
furthermore expanded by three additional compounds in order to address the impact of 
chelation. Q-4 is a close derivative of Q-4b, in which the dihydro-[1,3]-oxazine ring is 
opened. It was included to study the similarity of Q-4b to the 8-hydroxyquinoline metal 
binding motive in terms of biological and metal binding properties. In contrast, Q-5 and Q-6 
represent analogues, which share some degree of similarity to the compound set, but are 
unable to chelate metal ions. While Q-1 was commercially available, larger quantities of Q-2 
and Q-3 were synthesized by the group of Dr. Tibor Soós in the framework of a collaboration 
with the Institute of Organic Chemistry, Hungarian Academy of Sciences, Research Centre 
for Natural Sciences Budapest, Hungary), Q-4 to Q-6 were synthesized by the group of Prof. 
Ferenc Fülöp, in the framework of a collaboration with the Institute of Pharmaceutical 
Chemistry, University of Szeged, Hungary. 
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Figure 31: 8-hydroxyquinoline derivatives investigated on the basis of DTP screening data. Four 
derivatives were found in the DTP with increasing MDR selectivity: Numbers in brackets indicate the 
Pearson correlation coefficients obtained from the correlation of activity against the P-gp expression 
across the NCI60 cell line panel. The activity is shown as pIC50 values in P-gp positive NCI/ADR-res 
and P-gp negative OVCAR-8 cells for the 8-hydroxyquinoline scaffold (NSC2038, Q-1), the Mannich 
bases NSC662298 (Q-2) and NSC57969 (Q-3) and the dihydro-[1,3]-oxazine derivative (Q-4b). 
Structures of further investigated compounds Q-4 to Q-6 are shown. 
 
 
Having shown that the MDR selective effect of Q-3 and Q-4b is not restricted to single cell 
line pairs, but mediated by active P-gp (chapter 3.1.), the following mechanistic studies 
focused on the MES-SA and MES-SA/Dx5 cell line pair. Table 11 summarizes biodata of the 
8-hydroxyquinoline derivatives obtained in the absence and presence of the P-gp inhibitor 
Tariquidar. 
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Table 11: IC50 values in µM as determined by MTT assays. The left part of the table summarizes 
results in the absence, the right part in the presence of 1 µM of the P-gp inhibitor Tariquidar (TQ). The 
median SR value (quotient of parental vs. MDR cell IC50) is determined from Boxplots of the SR 
values from the indicated number of independent experiments. Significance was calculated using 
paired t-tests and results are given as *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001, ****: p ≤ 0.0001. 
 
 
MES-SA MES-SA/Dx5 median SR 
MES-SA  
+ TQ 
MES-SA/Dx5  
+ TQ 
median SR  
+ TQ 
Q-1 4.13 ± 1.11 2.37 ± 1.03 1.78 (10)  ** 5.06 ± 0.72 2.87 ± 0.99 1.59  (3)  * 
Q-2 6.76 ± 2.62 3.24 ± 0.59 1.81  (8)  *** 4.56 ± 1.38 5.40 ± 1.54 0.87  (3)  * 
Q-3 3.95 ± 1.78 0.83 ± 0.39 4.86  (18)  **** 2.86 ± 1.35 3.02 ± 1.38 0.96  (4) 
Q-4b 2.58 ± 1.58 0.24 ± 0.14 11.78  (18) ****    
Q-4 2.71 ± 0.70 0.19 ± 0.08 13.76  (11) **** 2.20 ± 0.54 3.24 ± 0.77 0.54  (3) 
Q-5 > 50 > 50     
Q-6 > 50 > 50     
 
 
As apparent from Table 11, the non-chelating compounds Q-5 and Q-6 lose their toxicity in 
comparison to their chelating counterparts Q-4 and Q-4b. The selectivity obtained with the 8-
hydroxyquinoline derivatives increases in the following order: Q-1 < Q-2 < Q-3 < Q-4b = Q-
4. The application of the P-gp inhibitor Tariquidar (TQ) shows the influence of the functional 
transporter on the toxicity of the selective compounds (Q-2,) Q-3, Q-4b and Q-4. Considering 
the precision of the assay, a selectivity threshold could be set at around 2. Applying this 
threshold, Q-1 and Q-2 would not count as MDR selective agents. Additionally, the P-gp-
inhibitor TQ does not significantly affect the toxicity of Q-1, while it increases the toxicity of 
Q-2 in MES-SA/Dx5 cells. Taking this into account, Q-2 might be considered as a weak 
MDR selective compound with borderline selectivity. 
 
Q-4 was included in the study, in order to enable comparison of the dihydro-[1,3]-oxazine 
derivative Q-4b to the 8-hydroxyquinoline based Mannich bases. Indeed, the in vitro activity 
of Q-4 and Q-4b shows a remarkable similarity with regard to toxicity and selectivity toward 
the MDR cell line counterpart. 
 
Since the physico-chemical properties, like the pKa values of potential chemotherapeutic 
agents, have a basic influence on the compounds pharmacokinetics and metal binding 
abilities, a detailed study on the proton dissociation processes of the promising compound set 
was performed in collaboration with Prof. Éva A. Enyedy from the Institute of Inorganic and 
Analytical Chemistry, University of Szeged, Hungary. I am grateful for the opportunity to 
perform the experiments in her laboratory and for her work on the data analysis using the 
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program PSEQUAD (as detailed in chapter 6.2.). For this purpose UV‒Vis spectrophoto-
metric titrations were applied at a concentration of 50 µM (in the presence of 0.5% (v/v) 
DMSO). 
 
 
 
 
Figure 32: Time-dependent UV‒Vis spectra of 50 µM solution of Q-4b at a pH of 10.63 (measured at 
T = 25.0 °C; I = 0.20 M KCl, l = 1 cm). 
 
 
The studies performed with the aim to characterize the proton dissociation processes of the 
ligands revealed, that the in vitro similarity of compounds Q-4 and Q-4b might be explained 
by the inherent instability of the latter in solution. Time-dependent UV‒Vis spectra, as shown 
in Figure 32, show a relatively fast decomposition process at alkaline pH. Even though at 
lower pH values the observed spectral changes were slower, after 24 h of incubation ESI-MS 
spectra of Q-4b solutions at different pH values (2.5, 7.4 and 10.6) suggest a decomposition 
of Q-4b to compound Q-4 via the opening of the dihydro-[1,3]-oxazine ring. Similar reactions 
were observed in the literature for other compounds containing the dihydro-[1,3]-oxazine 
moiety [246]. 
 
Therefore, data obtained with Q-4b concerning ligand properties and interaction with metal 
ions might not be reliable due to this decomposition reaction. Opposed to that, spectra 
recorded with ligands Q-2, Q-3 and Q-4 at diverse pH values did not show time dependent 
changes. The deprotonation processes on the contrary, resulted in characteristic spectral 
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changes, that could be observed in the pH-dependent UV‒Vis spectra recorded between pH 2 
and 11.5 (representative spectra are shown exemplarily for ligands Q-2 and Q-3 in Figure 33). 
 
 
Figure 33: UV-Vis absorption spectra of ligands Q-2 (A) and Q-3 (B) recorded at different pH values 
of solutions containing 50 µM of ligand (T = 25.0 °C; I = 0.20 M KCl; l = 2 cm). 
 
Deconvolution of the measured spectra revealed the molar absorbance spectra of the 
individual ligand species in the different protonation forms, as shown in Figure 34. On the 
basis of these data the concentration of the ligand species in the different protonation states 
could be calculated as a function of pH as shown in Figure 35. The pKa values were assigned 
to the deprotonation processes as shown in Scheme 4. The newly investigated ligands were 
compared to the reference compound Q-1, for which literature data was available [247]. 
Based on the obtained and published data the ligand species present at physiological pH could 
be calculated. While Q-1 is present as HL only, this is also the predominant species for Q-2 
with 93%. The second species present is the deprotonated H2L
+
 (7%). The predominant 
species for Q-3 is L (70%), accompanied by HL
+
 (30%). Q-4 is mainly present as HL (92%), 
with 8% of L
-
. 
Spectral changes and deprotonation behavior of the newly investigated ligands were 
compared to those of the reference compound Q-1 [247]. The process resulting in the most 
pronounced spectral changes is the deprotonation of the hydroxyl functional group of the 8-
hydroxyquinoline moiety. The observed development of new strong bands with higher λmax 
values due to the more extended conjugated π-electron system in the deprotonated form is 
characteristic for this process and has been described for Q-1 in the literature [247]. Similar 
changes could be observed also for the 7-substituted 8-hydroxyquinoline derivatives Q-2, Q-3 
and Q-4. The deprotonation of the other moieties of the studied ligands results in smaller 
alterations in the spectra. 
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Figure 34: Calculated UV-Vis molar absorption spectra of the individual ligand species of ligands  
Q-1 (A), Q-2 (B), Q-3 (C), Q-4 (D). Measurements for Q-2 and Q-3 were performed with 50 µM 
solutions, those for Q-4 were performed with 10 µM solutions, data of Q-1 (A) are taken for the 
calculations from reference [247]. 
 
 
Figure 35: Calculated concentration distribution curves of the ligands Q-1 (A), Q-2 (B), Q-3 (C) and 
Q-4 (D). Data of Q-1 are taken for the calculations from reference [247].  
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As highlighted in red in Scheme 4, the corresponding pKa values attributed to the 
deprotonation of the phenolic OH are pK2 for Q-1 [247], pK3 for Q-2, pK2 for Q-3 and pK1 
for Q-4. In comparison to Q-1, the morpholino-substituent in 7-position of Q-2 increases the 
pKa value of the phenolic-OH functional group by almost one order of magnitude possibly 
due to the formation of a hydrogen bond between the OH and the morholine-N in the HL form 
of the ligand that hinders the deprotonation. In contrast, the protonated (thus positively 
charged) amine moiety of the piperidine of Q-3 decreases the proton dissociation constant of 
the OH group by 2.5 orders of magnitude compared to that of Q-1. Lower pKa values were 
also reported for numerous hydroxamic and carboxylic acids due to the electron withdrawing 
effect of the protonated piperidinium moiety [248]. A hydrogen bond which might form 
between the phenolate and the piperidinium NH
+
 in the L form of Q-3 can additionally 
contribute to the diminished pK2 value due to the stabilization of the conjugated base (L). In 
Q-4 the pKa value of the phenolic OH is by 4.4 orders of magnitude smaller than in Q-1. The 
two factors contributing to that are the protonated benzylamine moiety, together with the 
electron withdrawing effect of the chlorine substituent. 
As indicated in blue in Scheme 4, the pK1 values of ligands Q-1 (reference [247]), Q-2 and Q-
3 were assigned to the deprotonation of the quinolinium-NH
+
 moieties of these ligands. 
Compared to the 8-hydroxyquinoline scaffold Q-1, the substitutions in R7 significantly 
decrease the pKa values of the quinoline-NH
+
 by more than 2 orders of magnitude. This might 
be explained by the electron withdrawing effect of the methylene linked protonated amine 
moieties of the Mannich bases. In case of ligand Q-4 the deprotonation of the quinolinium-
NH
+
 moiety could not be observed in the applied experimental conditions, since it most 
probably takes place at lower pH values (accordingly, the predicted pKa value for the 
quinolinium-NH
+
 in Q-4 using ChemAxon software is 0.98 [36]). Additionally to the 
protonated benzylamine in R7, the Chloro substituent in para position to the hydroxyl group 
causes this significant decrease in the pKa value due to the negative inductive effect of the 
halogen atom. Consequently, pK1 of ligand Q-4 was attributed to the deprotonation of the OH 
group, while pK2 to the secondary amine.  
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Scheme 4: Proton dissociation constants (pKa) of the studied ligands in comparison to published data 
for Q-1 (panel A, reference [247]). pKa values describing the deprotonation of the quinoline nitrogen 
are highlighted in blue, those of the hydroxyl group in red. Values for Q-2 (panel B), Q-3 (panel C) 
and Q-4 (panel D) were obtained from the data of the UV–Vis spectrophotometric titrations. 
 
 
As apparent from the structures of ligands Q-2, Q-3 and Q-4, the differFent substituents on 
the 8-hydroxyquinoline scaffold do not only affect the pKa values of the phenolic-OH and 
quinolinium-NH
+
 moieties, but also result in additional proton dissociation processes (Scheme 
4 B-D). These additional processes could be observed in case of Q-2 (pK2) and Q-4 (pK2). In 
contrast, the deprotonation of the piperidinium-NH
+
 of Q-3 could not be detected in the 
studied pH range, as its pKa value is probably higher than 11.5.  
As summarized in Table 12, the experimental results are (more or less) in agreement with 
calculations performed with ChemAxon software [36]. The calculated values confirm the 
order of deprotonation processes concluded from the measurements. 
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Table 12: Comparison of experimentally determined and calculated values. Calculations were done 
with ChemAxon software [36]. 
a
 experimental data for compound Q-1 was taken from reference [247], 
the pK value indicated with 
b
 characterizes the deprotonation process of Mannich base related 
nitrogen. Values indicated with 
c
 could not be measured within the applied experimental setup. 
 
 pK1  
- 
measured 
pK2  
- 
measured 
pK3  
- 
measured 
pK1  
- 
calculated 
pK2  
- 
calculated 
pK3  
- 
calculated 
Q-1 4.99 a 9.51
 a  3.93 9.36  
Q-2 2.59 6.25 b 10.37 2.29 7.21 b 8.25 
Q-3 2.69 6.99 > 11 b,c 2.28 7.45 10.20 b 
Q-4 < 2 c 5.16 8.54 b 0.91 7.14 9.22 b 
 
 
In order to investigate whether the pKa values might affect the (MDR selective) cytotoxicity, 
correlation diagrams are shown in Figure 36. In the investigated compound set, compounds 
with a lower pKa value of the phenolic OH tend to show an increased toxicity in P-gp 
expressing MES-SA/Dx5 cells, while the effect on the parental MES-SA cell line is minor. 
This suggests, that there might be a tendency in affecting the selective toxicity of the 8-
hydroxyquinoline derived ligands. Yet, the size of the investigated data set does not allow a 
general conclusion about the multifactorial correlation between chemical properties and the 
biological effect. Between the biodata and pKa values of the quinolinium NH
+
 moieties of 
these ligands no clear relationship was found. 
 
 
 
Figure 36: pIC50 values obtained in MES-SA (open symbols) and MES-SA/Dx5 cells (filled symbols) 
as a function of experimentally determined phenolic-pKa (A), or quinolinium-pKa (B). Circles: Q-1, 
triangles: Q-2, diamonds: Q-3, squares: Q-4. Since the quinolinium-pKa for Q-4 could not be 
determined in the applied measurement conditions, the calculated value (Table 12) was plotted instead.  
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3.4. Elucidation of putative mechanism(s) of action 
 
3.4.1. Impact of ROS  
Since the ligands might form redox active metal complexes inside the cells, the involvement 
of reactive oxygen species (ROS) resulting from redox cycling of these complexes (see 
chapters 1.5 and 1.6), might be involved in the toxicity mechanism of the 8-hydroxyquinoline 
derivatives. In order to test this hypothesis, the cytotoxicity experiments were repeated in 
presence of the ROS-scavenger and potent antioxidant N-acetylcysteine (NAC). As shown in 
Figure 37, a different behavior could be observed for the non-MDR selective Q-1, the 
“weakly MDR selective” agent Q-2, and the MDR selective compounds Q-3 and Q-4.  
 
 
Figure 37: Effect of the ROS scavenger NAC on the toxicity of the 8-hydroxyquinoline derived 
ligands. pIC50 values obtained in MES-SA (open columns) and MES-SA/Dx5 (filled columns) cells 
are shown in absence (black) and presence (blue) of 5 mM NAC. Significance was calculated using 
paired t-tests in the comparison of MES-SA and MES-SA/Dx5 cells treated in the same experiment 
and unpaired t-tests for the comparison of co-incubation experiments that have partly been performed 
in independent experiments. 
 
In case of the non-MDR selective Q-1 core structure, NAC protects both, the P-gp negative 
cell line MES-SA and the P-gp positive MES-SA/Dx5 cell line from the toxic effect of the 
ligand. In case of the “borderline MDR selective” agent Q-2, a protective effect of NAC could 
only be observed for the P-gp negative MES-SA cells, while there was no significant effect on 
MES-SA/Dx5 cells. On the contrary, the toxicity of the MDR selective compounds Q-3 and 
Q-4 is not significantly influenced by NAC in either of the investigated cell lines. 
3.4. Elucidation of putative mechanism(s) of action 79 
 
 
These results indicate that the production of ROS by the ligands or by putatively formed metal 
complexes might play a role in the toxicity of Q-1 and Q-2. The lack of protective effect of 
NAC on the toxicity of the MDR selective agents, as compared to their structurally closely 
related derivatives, might be suggestive of a different mechanism of action, which might be 
connected to the complex interplay with the intracellular redox homeostasis. 
 
 
 
Figure 38: Effect of the ROS scavenger NAC on the toxicity of selected MDR selective 
thiosemicarbazones I-a and I-d (A) and cell line dependently selective compounds II-g, IV-b, V-b 
(B). pIC50 values obtained in parental (open columns) and MDR (filled columns) cells are shown in 
absence (black) and presence (blue) of 5 mM NAC. The cellular test system is indicated below the bar 
diagram. Significance was calculated as in 37.  
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For comparison, compounds from the focused designed library (chapters 3.2.1. – 3.2.5.) were 
co-administered to cells with NAC. As shown in Figure 38, comparably to the effect of the 
MDR selective 8-hydroxyquinoline Mannich bases Q-3 and Q-4, also the toxicity of the 
MDR selective isatin-β-thiosemicarbazones I-a and I-d was not affected by the ROS-
scavenger. In contrast, compounds that showed an increased toxicity toward single MDR cell 
lines in a P-gp independent manner behaved differently. The toxicity of the pyridinyl thio-
semicarbazone II-g, the pyrimidinyl hydrazone IV-b, and the hydrazino benzothiazole V-b 
was attenuated in the presence of NAC. Despite the parallel that can be drawn to the non-
MDR selective Q-1, in contrast to the effect on the 8-hydroxyquinoline scaffold, the (relative) 
protective effect of the antioxidant against IV-b is more pronounced in the drug resistant cells 
as compared to their sensitive counterparts. 
 
 
 
3.4.2. Impact of metals – co-incubation with FeCl3 and CuCl2 
Since the formation of redox active metal complexes might be a source of ROS, the biological 
activity of metal binding compounds is often modified upon complex formation with metal 
ions [87,129]. Therefore in the next step the toxicity of the ligands was compared in the 
absence and in the presence of increasing iron (III) and copper (II) concentrations (0.5 µM, 
5.0 µM, 50 µM). The metal salts alone did not influence the cell viability within the 
timeframe of the assay, indicating that the observed effects are not additive. 
Iron (III) co-incubation did not influence the toxicity of the 8-hydroxyquinoline core structure 
Q-1 (Figure 39 A). In contrast, for the weakly MDR selective agent Q-2 in the presence of 
50 µM FeCl3 a significant protective effect could be observed for the MDR cell line MES-
SA/Dx5, while the P-gp negative parental cell line MES-SA was not affected (Figure 39 B). 
In sharp contrast, both cell lines were significantly protected from the toxic effect of the two 
MDR selective derivatives Q-3 and Q-4 in the presence of 5 and 50 µM FeCl3 
(Figure 39 C,D). Though, the magnitude of this effect is much higher in the P-gp positive 
MES-SA/Dx5 cell line, resulting in a decrease of selective toxicity of the ligands in the 
presence of FeCl3. 
Contrary to these results, the rescuing effect of FeCl3 was more pronounced in MES-SA as 
compared to MES-SA/Dx5 cells in case of the P-gp independently MDR selective pyrimidi-
nylhydrazone IV-b, resulting in an enhanced selectivity in the presence of iron (Figure 39 E). 
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Figure 39: Effect of increasing concentrations of FeCl3 on toxicity of the 8-hydroxyquinoline 
derivatives Q-1 (A), Q-2 (B), Q-3 (C) and Q-4 (D) in comparison to the arylhydrazone IV-b (E). 
pIC50 values of the ligands were obtained by the MTT assay after 72 h incubation of MES-SA (open 
squares) and MES-SA/Dx5 (filled squares) cells with the compounds in absence or presence of 
constant metal ion concentrations. Data represent mean and standard deviation obtained in at least 
three independent experiments. Significant differences between results in presence and absence of 
metal ion were calculated with unpaired t-test. 
 
A rescuing effect of iron co-administration might imply an influence of iron depletion in the 
toxicity mechanism of the applied chelators. Another conceivable explanation might be that 
the added excess of iron (III) prevents the binding of the chelators to either the target or to 
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other metal ions (like copper) and therefore leads to protection of the cells. The different 
response of P-gp positive and negative cells to this effect, as observed for the MDR selective 
ligands Q-3 and Q-4, supports the hypothesis of an altered metal homeostasis in MDR vs. 
sensitive cancer cells [42,89]. 
 
The presence of copper (II) increased the toxicity of ligands Q-1 and Q-2 in a dose dependent 
manner (Figure 40 A,B). A similar effect could be observed for the pyrimidinylhydrazone IV-
b (Figure 40 E). In contrast, P-gp positive MES-SA/Dx5 cells seem unresponsive to 
copper (II) co-administration to the MDR selective ligands Q-3 and Q-4. Yet, in the parental 
MES-SA cell line an increase in toxicity could be observed upon copper (II) co-administration 
(Figure 40 C,D). It is worth mentioning, that the sensitizing effect starts at higher metal ion 
concentrations as compared to the non-MDR selective ligands Q-1, Q-2 and IV-b, and that it 
is more pronounced for the ligand with the higher selectivity ratio (Q-4). Due to the 
difference in the response of MES-SA and MES-SA/Dx5 cells toward the co-administration 
of copper, the selectivity in the toxic effect toward P-gp expressing cells vanishes upon metal 
co-administration in case of the MDR selective ligands Q-3 and Q-4. 
The increase in toxicity caused by copper, as observed in both cell lines for Q-1, Q-2 (and IV-
b), as well as in MES-SA cells for Q-3 and Q-4 might be explained by the formation of redox 
active copper complexes. In an “activation by reduction” mechanism, following Fenton-like 
chemistry, these complexes can produce harmful reactive oxygen species (ROS) – in 
particular the hydroxyl-radical – which might lead to cell death [86,89,116,135].  
The lack of response on copper co-administration in the P-gp positive MES-SA/Dx5 cells 
might be explained by several factors. Similar to the different response of the investigated P-
gp positive and negative cells to the co-administration of iron (III), also the effect induced by 
copper (II), might point to an altered metal homeostasis in MDR vs. sensitive cancer cells 
[4,8]. Since the metal homeostasis is tightly connected to intracellular redox homeostasis, also 
an altered redox state of the cells might possibly be involved in the mechanism of (MDR 
selective) toxicity [88,89,116].  
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Figure 40: Effect of increasing concentrations of CuCl2 on toxicity of the 8-hydroxyquinoline 
derivatives Q-1 (A), Q-2 (B), Q-3 (C) and Q-4 (D) in comparison to the arylhydrazone IV-b (E). 
pIC50 values of the ligands were measured by the MTT assay after 72 h incubation of MES-SA (open 
squares) and MES-SA/Dx5 (filled squares) cells with the compounds in absence or presence of 
constant metal ion concentrations. Data represent mean and standard deviation obtained in at least 
three independent experiments. Significant differences between results in presence and absence of 
metal ion were calculated with unpaired t-test. 
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3.4.3. Investigation of Fe(III) and Cu(II) complexes – stabilities and stoichiometries 
Characterization of the ligands’ metal binding ability, and the most plausible chemical species 
formed in aqueous solution in the biologically relevant pH range might give further insight 
into the mechanism of action of metal binding compounds [89]. Therefore the stoichiometry 
and stability constants of the complexes of the ligands Q-2, Q-3 and Q-4 in the presence of 
iron (III) and copper (II) were determined by means of UV‒Vis spectrophotometry. These 
studies were performed in collaboration with Prof. Éva A. Enyedy from the Institute of 
Inorganic and Analytical Chemistry, University of Szeged, Hungary. The solution speciation 
data were furthermore compared to those of the reference compound Q-1 [249,250]. The 
complex formation processes could be followed by the characteristic changes of charge 
transfer (CT) bands, which are partially overlapping with the ligands’ bands. In case of 
iron (III), additional changes of the d-d bands could be monitored. In case of copper (II) the d-
d bands could not be detected under the applied conditions due to their fairly low molar 
absorptivities.  
In the spectra obtained during titrations with both metal ions the absorbance values tend to 
decrease at pH > ~8. In case of the iron (III) complexes the hydrolysis of the metal ion, which 
might occur at alkaline pH values, might suppress the complex formation. Compared to the 
titrations in the presence of iron (III), the decrease in absorbance seems to be even more 
pronounced in the case of the copper (II) complexes. This might be explained by a 
precipitation of the formed neutral complexes, which also becomes visible in form of yellow 
precipitates at pH > ~9. Thus, only data collected at pH < 8 were evaluated in all cases.  
In the case of the iron (III) complexes the spectral changes upon complexation detected in the 
350-750 nm wavelength range were most useful for the calculations since bands located in 
this range are relatively well-separated from the ligands’ bands. Representative spectra are 
shown for the ligands Q-2 (Figure 41 A) and Q-3 (Figure 41 B) in the presence of 
0.33 equivalents of iron (III). The arrow indicates the shift of the peak maxima λmax upon 
alkalization of the solution. Molar absorbance spectra were computed by the deconvolution of 
UV-Vis spectra recorded at different pH values and revealed that the shift in absorbance 
maxima is indicative for the consecutive coordination of the ligands to the metal ion. The 
coordination sphere of iron (III) is octahedral, therefore with the (Nquinoline,O
-
) bidentate 8-
hydroxyquinoline derivatives the formation of mono-, bis- and tris-ligand complexes is 
expected [251]. A shift in λmax values upon filling of the metal coordination-sphere, as 
indicated by the arrows in Figure 41, has also been reported for the complexes of Q-1 [250]. 
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The stability data resulting from the deconvolution of the spectra are summarized in 
comparison to the previously reported data on the Q-1 core structure in Table 13 [250]. 
 
 
 
Figure 41: Recorded spectra at different pH values for samples in iron (III) to ligand ratio 1:3 for Q-2 
(A) and Q-3 (B). The arrow indicates a shift in the absorbance maxima upon alkalization of the 
solution. Dotted spectra at high pH values were excluded from calculations (see text for details). 
 
 
Based on the determined stability constants (Table 13), concentration distribution curves of 
the species formed with the ligands Q-1 to Q-4 in the presence of given concentrations of 
metal ions could be calculated as functions of pH or ligand concentration. These calculations 
disclosed the species that are likely present at physiological pH (7.4) at the respective IC50 
values obtained in the experiments presented in chapter 3.4.2. (Figures 39, 42). 
While at low metal ion concentrations (0.5 µM), the major fraction of the investigated ligands 
is not bound to metal ions, at higher metal concentrations, the ligands are incorporated to 
metal complexes. Similarly to Q-1, the predominant species of Q-2 is the tris-ligand complex 
[FeL3]. While Q-1 also forms small fractions of bis complex [FeL2], in case of Q-2 the 
protonated tris complex [FeL3H] is present in small fractions. Presumably, the proton can be 
attributed to the non-coordinating tertiary amine of the morpholinium moiety. In contrast, the 
presence of the bis complex is more pronounced in the case of Q-3 (accompanied by a small 
fraction of tris complex). Complexation of iron by Q-4 results mainly in mono complex 
[FeL], accompanied by the protonated bis complex [FeL2H]. Similar to the protonated 
complex of Q-2, the protonation is most likely to be found at the secondary amine, which is 
not taking part in the coordination of the metal ion. The predominance of the mono complex 
might be explained by the sterical hindrance caused by the aromatic moiety. 
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Predominant species are comparable at the IC50 values measured against MES-SA and MES-
SA/Dx5 cells in general. Though, a difference can be observed in case of the complexes 
formed by ligand Q-4 at the respective IC50 values in the presence of 0.5 µM iron (III). While 
at the IC50 value in MES-SA cells, around 70 % of the ligand is free, at the IC50 value in 
MES-SA/Dx5, 90 % of the ligand is incorporated into metal complexes (mainly [FeL]). 
 
 
 
Figure 42: Calculated distribution of ligand fractions in the species formed at pH 7.4 at the ligand-
IC50 values in MES-SA and MES-SA/Dx5 upon co-incubation with 0.5, 5, or 50 µM FeCl3 
(experiments from Figure 39). The color code of the single species is given on the left side, charges 
are omitted for clarity. 
 
 
In order to compare the metal binding ability of the four investigated chelators, the pM values, 
representing the negative decadic logarithm of the free metal ion concentration found at 
physiological pH (at cM = 1 µM; cL/cM = 10), were computed using the experimentally 
determined stability constants. Higher pM values indicate a more favored complex formation. 
Since iron(III) tends to hydrolyze at physiological pH, its hydroxido species were also taken 
into account (pM* = −log ([Fe] + Σ[Fei(OH)j])), providing data that are comparable to those 
of other metal ions. As summarized in Table 13, according to both pM and pM* values, the 
iron binding effectivity of the investigated ligands at pH 7.4 follows the order Q-1 ≈ Q-2 > Q-
3 > Q-4. This reflects the inverse order of selectivity in the toxicity of the ligands toward 
MES-SA/Dx5 vs. MES-SA cells. Figure 43 shows the cytotoxicity of the ligands toward both 
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cell lines and the selectivity ratios as a function the p(Fe)* values reflecting complex 
stabilities at pH 7.4. 
 
 
Figure 43: Impact of iron (III) binding capacity of the ligands (expressed as p(Fe)*) on their 
cytotoxicity (expressed as pIC50) in MES-SA (open symbols) and MES-SA/Dx5 (filled symbols) cells 
(A) and on the selectivity ratio (SR) between the investigated cell lines (B). Results of the different 
ligands are depicted as circles for Q-1, triangles for Q-2, diamonds for Q-3 and squares for Q-4. 
 
In the investigated compound set, toxicity toward MES-SA/Dx5 cells and accordingly also 
MDR-selectivity seem to increase with decreasing iron (III) complex stability.  
 
The complex stabilities and stoichiometries were also investigated for complexes formed with 
copper (II). Novel (CT) bands with higher wavelength maxima relative to the spectra of the 
ligands also appeared in the UV-Vis spectra recorded in the presence of the metal ion 
(Figure 44). While the consecutive coordination of iron (III) resulted in a decrease in λmax 
values (Figure 41), the bis-ligand copper (II) complexes, which form upon alkalization of the 
sample, possess somewhat higher λmax values compared to those of the mono species, as 
indicated by the arrow in Figure 44. 
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Figure 44: Recorded spectra at different pH values for samples in the copper to ligand ratio 1:2 for  
Q-2 (A) and Q-4 (B). The arrow indicates a shift in the absorbance maxima upon alkalization of the 
solution. 
 
 
For Q-1 the formation of square planar bis complexes via a (Nquinoline,O
-
) bidentate 
coordination mode has been reported [252]. In agreement with this report, distribution curves, 
calculated on the basis of the determined stability data, suggest a favored formation of bis 
complexes (and protonated) bis complexes for the ligands Q-1 to Q-4 under conditions of 
ligand excess in solution (predominant species at physiological pH are [CuL2] for Q-1, [CuL2] 
and [CuL2H]
+
 for Q-2, [CuL2]
2+
 for Q-3 and [CuL2H]
2+
 for Q-4). In the protonated 
complexes, the protons can presumably be attributed to the non-coordinating amine. On the 
contrary, calculations performed to disclose the species, present at the IC50 values obtained in 
the co-incubation experiments presented in chapter 3.4.2. (Figure 40) are shown in Figure 45. 
These data reveal that in the presence of 5 and 50 µM CuCl2, where toxicity was significantly 
increased in a cell line dependent manner, the only species present at the concentration of the 
IC50 values is [CuL] (for all ligands - regardless of the cell line).  
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Figure 45: Calculated distribution of ligand fractions in the species formed at pH 7.4 at the ligand-
IC50 values in MES-SA and MES-SA/Dx5 upon co-incubation with CuCl2 (experiments from 
Figure 40). The color code of the single species is given on the left side, charges are omitted for 
clarity. 
 
 
Comparably to the calculations done for iron (III), also for copper (II) co-incubation with a 
concentration of 0.5 µM a clear difference can be seen for the predominant species formed at 
the IC50 values of Q-4 in the different cell lines. While at the IC50 value in the MDR MES-
SA/Dx5 cells the predominant species is still the [CuL] complex, at the IC50 value of the 
parental cell line most of the ligand is unbound, while approximately 40% are incorporated in 
the [CuL2] complex. Also in case of Q-3 a difference in species formed at the respective IC50 
could be observed: Similar to Q-4 also here [CuL] is present at the IC50 value in the resistant 
cell line, but not at the IC50 value of the parental counterpart. Even though in a smaller 
fraction, this can also be observed in case of the non MDR selective ligand Q-1. 
 
In order to compare the copper (II) binding ability between the investigated ligands and to the 
previously described iron (III) binding ability, pM values were also computed for the 
copper (II) systems based on the experimentally determined stability constants. The relative 
copper (II) chelating ability of the ligands at physiological pH follows the order Q-2 > Q-
1 > Q-3 > Q-4 (Table 13). Compared to the iron binding abilities, the order is similar, with 
the exception, that for iron (III) binding Q-2 and Q-1 were equally potent. Like in case of 
iron (III), the biological data can be correlated with the p(Cu) values, revealing a higher 
toxicity and selectivity for ligands with lower p(Cu) values (Figure 46). 
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Figure 46: Impact of copper (II) binding capacity of the ligands (expressed as p(Cu)*) on their 
cytotoxicity (expressed as pIC50) in MES-SA (open symbols) and MES-SA/Dx5 (filled symbols) cells 
(A) and on the selectivity ratio (SR) between the investigated cell lines (B). Results of the different 
ligands are depicted as circles for Q-1, triangles for Q-2, diamonds for Q-3 and squares for Q-4. 
 
 
Comparing the binding abilities of the ligands toward the two investigated metal ions, the 
higher p(Cu) values over the p(Fe)* values indicate a preference of the ligands for copper(II) 
binding over the complexation with iron(III) at pH 7.4. Interestingly, this preference is much 
more pronounced in case of the MDR selective ligands Q-3 and Q-4 as compared to the non-
MDR selective derivatives Q-1 and Q-2 (Figure 47). 
 
 
 
Figure 47: Selectivity ratio (SR) between MES-SA and MES-SA/Dx5 cells as a function of 
preferential binding toward copper over iron (expressed as the fraction of pM* values). Results of the 
different ligands are depicted as circles for Q-1, triangles for Q-2, diamonds for Q-3 and squares for 
Q-4. 
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The pyrimidinylhydrazone IV-b showed MDR selective toxicity in a cell line dependent 
manner. Similar to Q-1 and further cell line dependently selective agents, namely the 
pyridinyl TSC II-g and the pyridinyl hydrazino-benzothiazole V-b, its toxicity was attenuated 
in the presence of NAC (see chapter 3.4.1.). Since metal complexes might be involved in this 
process, the metal binding properties of IV-b were investigated in similar experiments, in 
order to compare its metal binding properties to that of the presented 8-hydroxyquinoline 
derivatives. pK values were determined and are given in the Scheme in Figure 48. In contrast 
to the 8-hydroxyquinoline compound set, which binds to metal ions via an (Nquinoline,O
-
) 
bidentate coordination mode [252], ligand IV-b binds to metal ions via an NNN coordination 
mode (see chapter 3.2.). 
Upon metal binding, well-defined charge transfer bands appear in the visible wavelength 
range of the pH-dependent UV‒Vis spectra shown in Figure 48 D and E. While the CT bands 
considerably overlap with the ligand bands, the d-d bands are too weak to be detected in the 
applied concentration of 50 µM. Deconvolution of the spectra suggests the formation of mono 
and bis complexes with iron (III), with a predominance for the bis-complex [FeL2]
3+
 in the 
physiologic pH range, although the hydrolysis of the metal ion suppresses the complex 
formation at alkaline pH values. Surprisingly, at alkaline pH values (pH > ~ 8.5), the 
development of CT bands in the 510–610 nm wavelength range could be detected. These 
bands are characteristic for the formation of Fe (II) complexes formed with ligands consisting 
of aromatic nitrogen donor atoms. Also at lower pH values, the formation of minor amounts 
of iron (II) complexes might be possible, but the redox process of the complex seems to be 
pH-dependent and much faster in the basic pH range. Thus data collected at pH > 7.5 were 
not used for the complex stability calculations. The pM value of the ligand allows the 
comparison of its iron (III) binding ability to that of other ligands. With a pM of 17.6, the 
iron (III) binding ability of IV-b can be settled between that of the borderline MDR selective 
ligand Q-2 and the MDR selective agent Q-3. 
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Figure 48: UV-Vis absorption spectra recorded at different pH values for 50 µM ligand IV-b (A) 
alone or in the presence of 20 µM FeCl3 (D), or 50 µM CuCl2 (E). The molar absorption spectra for 
the ligand species (B) and pH dependent species distribution of the ligand (C) were calculated from 
the spectral data, and pK values were assigned as indicated in the Scheme. Data of IV-b were 
published in reference [89]. 
 
 
Also in case of copper complexation, the formation of mono-, protonated mono- and bis-
complexes could be observed, although the formation of the [CuL2]
2+
 complex seems less 
pronounced as in the case of iron (III). With a pM value of 8.6 calculated for the copper 
binding ability, IV-b is a much weaker copper chelator compared to the 8-hydroxyquinoline 
set of chelators Q-1 to Q-4. A further difference to the 8-hydroxyquinolines can be seen in the 
metal binding preference: While in case of the MDR selective ligands Q-3 and Q-4 a clear 
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preference for copper (II) binding over iron (III) was concluded, ligand IV-b, which shows 
cell line specific selective effects, seems to preferentially bind iron (III) over copper (II). 
 
 
Table 13: Overall stability constants (logβ) of the copper (II) and iron (III) complexes of ligands Q-1 to 
Q-4 and VI-b determined by UV–vis spectrophotometric titrations and pM values calculated at pH 7.4. 
Charges of the complexes are omitted for clarity. L is singly negatively charged in case of Q-1, Q-2 
and Q-4 and neutral in case of Q-3 and IV-b. Data of IV-b were published in reference [89]. 
 
 Q-1 Q-2 Q-3 Q-4 IV-b 
logβ [FeLH]  19.80 ± 0.04  18.46 ± 0.04  
logβ [FeL] 13.7 a 16.90 ± 0.04 11.11 ± 0.02 14.31 ± 0.05 15.69 ± 0.07 
logβ [FeL2H2]    34.44 ± 0.04  
logβ [FeL2H]  35.18 ± 0.04  28.50 ± 0.06  
logβ [FeL2] 26.3 
a  20.32 ± 0.03  21.71 ± 0.06 
logβ [FeL3H]  49.03 ± 0.03    
logβ [FeL3] 36.9 
a 42.49 ± 0.03 25.42 ± 0.07   
pM b 21.1 21.1 16.0 14.8 17.6 
pM*f 13.0 13.0 8.0 6.8 9.5 
logβ [CuLH]    16.87 ± 0.03 12.16 ± 0.09 
logβ [CuL] 12.1d 16.54 ± 0.04 10.60 ± 0.1 10.96 ± 0.07 7.39 ± 0.01 
logβ [CuL2H2]    32.54 ± 0.06  
logβ [CuL2H]  34.67 ± 0.04  26.94 ± 0.06  
logβ [CuL2] 23.0 
d 27.50 ± 0.10 19.40 ± 0.1  12.35 ± 0.03 
pM b 15.1 17.4 14.9 13.0 8.6 
a
 Data taken from reference [250]. 
b
 pM = ‒log [M] calculated at pH = 7.4, cM = 1 µM; cL= 10 µM. 
c
 pM*
 = ‒log ([Fe] + Σ [Fei(OH)j] calculated at pH = 7.4, cM = 1 µM; cL= 10 µM. 
d 
Data taken from reference [253]. 
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3.4.4. In vitro testing of preformed complexes – and the impact of P-gp on their toxicity 
Following the characterization of the iron (III) and copper (II) binding ability of the selected 
ligands, complexes were prepared in solution in order to test their antitumor potential in vitro. 
Since metal complexes of these ligand types are reported to be poorly soluble in water [254], 
for the biological tests, 10 mM stock solutions of ligands were prepared in DMSO in presence 
of 1, 0.5 and 0.33 equivalents of the respective metal ion. In contrast to the co-incubation 
experiments (presented in 3.4.2.), a constant metal-to-ligand ratio is ensured over the 
investigated concentration range by the application of preformed complexes. In order to avoid 
misinterpretation due to different amount of ligand present in the respective complexes, 
concentrations are expressed as ligand equivalents. Therefore in the 1:3 metal-to-ligand ratio, 
the IC50 values were in general viewed as 1/3 [ML3]. In order to compare the activity of the 
free and complexed ligands, fold changes upon metal binding were calculated as the fraction 
of the average IC50 values of free vs. complexed ligands with negative values representing a 
decrease in toxicity, while positive values are indicating an increase in toxicity upon metal ion 
complexation. The results are summarized and illustrated in Figure 49 A-D for the 8-hydroxy-
quinoline compound set. In agreement with the co-incubation data (chapter 3.4.2.), the 
iron (III) complexes of Q-1 behaved very similar to the free ligand – the only significant 
difference is a slight increase in toxicity in MES-SA cells at 1:1 ratio. Comparably, the 
toxicity of Q-2 upon iron (III) complexation was slightly increased in MES-SA cells in the 
metal-to-ligand ratios 1:3 and 1:2, and significantly decreased in MES-SA/Dx5 cells at the 1:1 
ratio. While the tris complex [FeL3] of the MDR selective ligand Q-3 was more toxic in MES-
SA cells, the bis and mono complexes ([FeL2]
+
 and [FeL]
2+
) were less toxic than the free 
ligands in MES-SA/Dx5 cells. This is in agreement with the protection of MES-SA/Dx5 cells 
against the toxicity of Q-3 by co-incubated FeCl3. Also the bis- and mono-complexes of 
ligand Q-4 were found to be less toxic than the free ligand. 
On the contrary, complexation with copper generally seemed to increase the toxicity of the 
ligands. While for Q-1 a significant effect could only be observed for the mono complex in 
both cell lines, for Q-2 complexation in the metal to ligand ratios 1:3 to 1:1 resulted in 
increased toxicity in both cell lines, with a higher magnitude in MES-SA as compared to the 
MDR MES-SA/Dx5 cells. For the MDR selective ligands Q-3 and Q-4 a significant increase 
could be observed upon complexation with copper (II) in all investigated metal-to-ligand 
ratios in MES-SA cells, but not in P-gp-expressing MES-SA/Dx5 cells. 
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Figure 49: Fold change in toxicity of ligands Q-1 (A), Q-2 
(B), Q-3 (C), Q-4 (D) and IV-b (E) upon complexation with 
0.33 (orange), 0.5 (red), or 1 (bordeaux) equivalents of FeCl3, 
or with 0.33 (cyan), 0.5 (green), or 1 (blue) equivalents of 
CuCl2. Changes in toxicity against MES-SA (open 
arrowheads) and MES-SA/Dx5 (filled arrowheads) cells were 
calculated as described in the text. Statistical significance of 
the difference toward the free ligands’ behavior was 
calculated with t-test. Obtained p-values are given under the 
arrows with numbers in brackets indicating the number of 
independent experiments and are indicated with *: p ≤ 0.05, 
**: p ≤ 0.01, ***: p ≤ 0.001, ****: p ≤ 0.0001. 
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Similar to the 8-hydroxyquinoline set, the compound IV-b, which showed enhanced toxicity 
only toward a subset of investigated MDR cells, also showed decreased toxicity upon 
complexation with iron (III), yet, the magnitude of the change was remarkably big. 
Copper (II) complexation at the 1:2 metal-to-ligand ratio slightly increased toxicity in MES-
SA cells only (Figure 49 E). 
 
The comparison of the toxicity data of the complexes obtained in P-gp positive MES-SA/Dx5 
and P-gp negative MES-SA cells reveals that the complexes of ligands without MDR 
selective activity (Q-1, circles in Figure 50 A) or with a very low selectivity (Q-2, triangles in 
Figure 50 B) do not show a preferential toxic effect in P-gp expressing cells, either. In 
contrast, iron (III) and copper (II) complexes formed with the MDR selective ligands Q-3 
(diamonds in Figure 50 C) and Q-4 (squares in Figure 50 D), show enhanced toxicity toward 
the P-gp expressing MES-SA/Dx5 cells as compared to the P-gp negative parental cell line 
MES-SA. 
 
 
 
Figure 50: Comparison of the toxic activity of ligands (black) and complexes in P-gp negative (MES-
SA, x-Axis) and P-gp positive (Dx5, y-Axis) cells. Non-MDR selective ligands: Q-1 (circles, panel 
A), Q-2 (triangles, panel B) and their metal complexes. MDR selective ligands: Q-3 (diamonds, panel 
C), Q-4 (squares, panel D) and their metal complexes. The pIC50 values of the ligand at different metal 
to ligand ratios are shown in different colors: 1/3 [FeL3] (orange), 1/2 [FeL2] (light red), [FeL] 
(bordeaux), 1/3 [CuL3] (green), 1/2 [CuL2] (cyan) and [CuL] (blue). 
 
 
The impact of P-gp on the toxicity of the complexes was furthermore followed up by co-
incubation experiments with the P-gp inhibitor Tariquidar. The results of these experiments 
suggest that the described behavior is dependent on the function of the transporter (Figure 51). 
As expected, the presence of TQ had no impact on the toxicity of any ligands or complexes 
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toward the P-gp negative MES-SA cells, which were included as a control (Figure 51 E-H). In 
MES-SA/Dx5 cells also the toxicity of Q-1 and its iron (III) and copper (II) complexes 
remained unaffected in the presence of the P-gp inhibitor (Figure 51 A). In case of ligand Q-2 
results look similar, with one exception of the iron (III) complex at 1:1 ratio (bordeaux 
triangle, Figure 51 B). Here the presence of the inhibitor significantly increased the toxicity 
by a factor of 2.4, suggesting that the [Fe(Q-2)] complex might be a weak substrate for the 
transporter. In contrast, the complexes formed by the MDR selective ligands Q-3 
(Figure 51 C) and Q-4 (Figure 51 D) show a significantly decreased toxicity in the presence 
of the P-gp inhibitor. The magnitude of the selective toxic effect of the complexes is bigger 
for Q-4 compared to Q-3, reflecting the MDR selective properties of the ligands. These 
results suggest that the iron (III) and copper (II) complexes of the MDR selective ligands 
show a MDR selective toxicity pattern similar to their free ligands and are not transported by 
P-gp. 
 
 
Figure 51: Comparison of the toxic activity of ligands (black) and complexes in the absence and 
presence of the P-gp-inhibitor Tariquidar (TQ) in MES-SA/Dx5 cells (A-D) and MES-SA cells (E-H). 
The pIC50 values of the ligand at different metal-to-ligand ratios illustrated by different colors: 1/3 
[FeL3] (orange), 1/2 [FeL2] (light red), [FeL] (bordeaux), 1/3 [CuL3] (green), 1/2 [CuL2] (cyan), [CuL] 
(blue) and L (black). Data shown for Q-1 (A, E), Q-2 (B, F), Q-3 (C, G) and Q-4 (D, H).  
98   
 
3.4.5. Redox activity of complexes 
 
3.4.5.1. Cyclic voltammetry 
Having shown that the formed complexes are stable and active in the in vitro setting with a 
similar selective toxicity profile against the investigated drug sensitive and MDR cancer cell 
lines as the free ligands, the putative influence of reactive oxygen species in their (selective) 
mechanism of toxicity should be addressed in the next step. Since ROS might evolve as a 
result of Fenton like reactions, which involve redox active metal complexes, the redox 
properties of iron and copper complexes were investigated using cyclic voltammetry. Since 
the low water solubility of the complexes did not allow a sufficiently concentrated aqueous 
solution, studies were performed in a 90% (v/v) DMSO-water mixture. The electrochemical 
data obtained for ligands Q-1 to Q-4 as well as IV-b in the presence of FeCl3 and CuCl2 are 
summarized in Table 14.  
In most cases, the cyclic voltammograms recorded for the metal salts or in the presence of 
ligand at different metal-to-ligand ratios appear to be significantly different due to the 
formation of various complex species, as shown in representative voltammograms for 
complexes of Q-3 and the cell line specific agent IV-b (Figure 52). However, for the ligand  
Q-4 the voltammograms of the metal ions in the absence of the ligand were quite similar to 
those in the presence of Q-4 in the case of both metal ions. This might be a result of the 
relatively low stability of the complexes; thus cathodic and anodic peaks could only be 
identified for the aqua metal ions formed from the metal chlorides in solution. In contrast, the 
addition of ligands Q-1, Q-2 and Q-3 to iron (III) results in the appearance of a new set of 
peaks at lower potentials compared to the aqua ion peaks. The detected redox process due to 
the iron complex formation were found to be quasi-reversible under the applied conditions 
and the formal reduction potential values (E, Table 14) might be assigned to the tris-
complexes, in which the coordination sphere of the metal ion is saturated. The highest shift in 
the E° value in comparison to the free metal ion is obtained for Q-1, followed by Q-3 and Q-
2. Thus, the formal potential of the iron complexes does not seem to follow the trend in 
selective toxicity of these three ligands. All determined E values are higher than that of the 
biological reductant GSH, which is reported to have the formal potential of the GSSG/GSH 
couple at -0.26 V at pH 7.4 [255]. Compared to dehydro-L-ascorbic acid, another important 
antioxidant, the iron complex formed with Q-3 has a similar potential (+0.05 V at pH 7.4 
[256]), while the redox potential of the iron complexes of Q-2 is more positive. 
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The complexation of iron by ligand IV-b in contrast results in the appearance of a new set of 
peaks with a more positive potential as compared to the aqua complex. This positive shift of 
the formal potential indicates a preference of the complex for the Fe (II) oxidation state, 
which has already been suggested in the UV-Vis spectrophotometric titrations (chapter 
3.4.4.). 
 
 
Figure 52: Cyclic voltammograms of iron (A, C) and copper (B, D) complexes of ligands Q-3 (A,B) 
and IV-b (C,D) vs. Ag/AgCl/KCl (1.0 M) for ligand concentrations of cL =1.0 mM. Solutions were 
prepared in 90% (v/v) DMSO/H2O with an ionic strength of I = 0.01M (TBACl). Measurements were 
performed with a glassy carbon working electrode at a temperature of T = 25 °C with a scan rate of 
100 mV/s. Data are shown for the ligand alone (dashed grey), for FeCl3 (dotted brown), iron 
complexes at the M:L ratios 1:1 (solid bordeaux), 1:2 (solid red) and 1: 3 (solid orange), as well as for 
CuCl2 (dotted dark blue), and copper complexes at the M:L ratios 1:1 (solid blue), 1:2 (solid green) 
and 1:3 (solid cyan). 
 
 
While the voltammograms recorded for the copper aqua complexes, formed in the solution of 
CuCl2, display a reversible redox process, for its complexes formed with the 8-
hydroxyquinoline derivatives Q-1 to Q-3 only irreversible redox processes could be observed 
under the applied conditions, in which only the reduction peaks could be seen (cathodic peak 
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potentials in Table 14). Upon complexation of the copper ion, two reduction peaks appeared 
at much lower potentials compared to the copper aqua complexes. Based on the changes of 
their intensity ratio with increasing ligand excess they can be assigned to the mono- and bis-
ligand complexes. It is noteworthy that the consecutive coordination of the ligands to the 
metal ion results in progressive shifts in the reduction potential as compared to the aqua 
complex. In the case of the copper-Q-3 system a further oxidation peak appears at the 1:3 metal 
to ligand ratio, which can be assigned to the presence of unbound ligand. Since the formal 
reduction potential values could not be calculated for the copper complexes due to the 
irreversible electrode reactions, to this state, an estimation of behavior of the copper species in 
the presence of intracellular antioxidants is not possible; however it should be noted that their 
cathodic peak potentials are significantly lower than those obtained for the aqua copper ion 
and for the iron complexes. 
 
 
Table 14: Electrochemical data for the iron and copper complexes formed with ligands Q-1 to Q-3, as 
well as IV-b, in comparison to the metal chlorides. Cyclic voltammograms were recorded for 90% (v/v) 
DMSO/H2O solutions of the ligands in concentrations of cL =1.0 mM with an ionic strength of I = 0.01 
M (TBACl). Measurements were performed with a glassy carbon working electrode against an 
Ag/AgCl/KCl (1.0 M) reference electrode at a temperature of T = 25 °C with a scan rate of v = 100 
mV/s scan rate. Data of IV-b were published in reference [89]. 
 
 MClx Q-1 Q-2 Q-3 Q-4 IV-b 
ligand        
Eox vs. NHE / V    0.916   
Ered vs. NHE / V  -0.412  
(0.687) 
-1.004  < - 1a -0.774 
[FeL3]      [FeL2] 
Eox vs. NHE / V 0.466 0.049 0.262 0.068 free FeCl3 0.823 
Ered vs. NHE / V 0.241 -0.484 0.007 -0.058 “ 0.558 
E° vs. NHE / V 0.354 -0.218 0.134 0.005 “ 0.691 
∆E (E°ML3 – E°M)  -0.572 -0.220 -0.349  +0.337 
[CuL]        
Eox vs. NHE / V 0.709 - - - free CuCl2  
Ered vs. NHE / V 0.481 0.101
b -0.355 -0.076 “   
[CuL2]       
Eox vs. NHE / V 0.709 - - - free CuCl2 0.244
a 
Ered vs. NHE / V 0.481 -0.440 -0.491 -0.076 “ 0.070 
E° vs. NHE / V      0.157 
∆E (E°ML3 – E°M)      -0.438 
a
 broad peak, not complete in measurement, 
b
 very low peak intensity 
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On the contrary copper complexes formed with the arylhydrazone IV-b display a quasi-
reversible redox process as shown in Figure 52 and Table 14. The formal potential of the new 
set of peaks is shifted by 0.44 V to the negative potential range. With 0.16 V against the 
normal hydrogen electrode, the potential is still more positive than that of the biological 
reductants glutathione and ascorbate, therefore the reduction by these agents is 
thermodynamically possible [116,255]. 
 
 
3.4.5.2. Reactivity with antioxidants 
The formal potentials that were derived from cyclic voltammetry experiments provide 
information about the thermodynamic possibility of interactions with intracellular 
components. The potential of the formed metal complexes to undergo intracellular redox 
reactions can furthermore be investigated by monitoring the reactions with biologically 
relevant antioxidants. Glutathione (GSH) is the predominant intracellular reducing agent with 
a lower formal potential compared to that of dehydro-L-ascorbic acid (ASC). The formal 
potential of the GSSG/GSH and the dehydro-L-ascorbic acid/ASC redox pairs at pH 7.4 are -
0.26 V and +0.05 V, respectively [255,256]. Oxidation of ASC or GSH are often monitored 
by measuring the changes in absorbance at their λmax values (265 and 262 nm, respectively) 
over a given time period [185,257–262]. Since many compounds – free ligands as well as 
metal complexes – show absorbance at the required wavelengths themselves, an alternative 
strategy is, to follow the changes in the characteristic regions of the compounds’ spectra upon 
reaction with the antioxidants under strictly anaerobic conditions [89,263]. Monitoring the 
interaction of the investigated compounds with biologically relevant antioxidants addresses 
one half of the redox cycling. The other half, namely the oxidation reaction, is often 
monitored by the benzoate hydroxylation assay [185,257,259–261]. The emission of the 
fluorescent products that occur in that assay can be measured at 410 nm upon excitation at 
308 nm [185,257,259–261]. Also this assay may be hampered by the spectral properties of the 
investigated compounds, since they might show intrinsic fluorescence. In order to still be able 
to address the whole redox cycle, and to investigate, if observed reductions were reversible, 
hydrogen peroxide was added at the end of the reaction with the antioxidant [89]. 
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Figure 53: Time-dependent UV–Vis spectra of the [CuL] complexes of Q-1 (A), Q-2 (B), Q-3 (C) 
and Q-4 (D) upon addition of 5 equivalents of GSH. Black dashed line denotes the initial spectrum 
before addition of GSH, grey dashed line the spectrum upon addition of H2O2.  
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Even though the formal redox potentials obtained from cyclic voltammetric studies of the 8-
hydroxyquinoline set suggested a putative reduction by GSH, spectral changes were not 
observed in any of the investigated iron complexes upon addition of GSH (tmax = 90 min). 
This suggests that under the applied conditions the formed iron complexes of ligands Q-1 to 
Q-4 seem to be redox inert. 
In contrast, moderately fast redox reactions were observed in case of the copper (II) 
complexes when GSH was added. As illustrated in Figure 53, the recorded time-dependent 
spectra revealed a significant decrease of the absorbance values at the respective λmax of the 
copper (II) complexes of ligands Q-1 to Q-4 during the reaction with GSH. Additionally, the 
absorbance at the λmax values of the free ligands (~ 304 nm) seemed to increase with 
progressing time, indicating a possible ligand release of ligand upon re-organization of the 
coordination sphere in the reduced copper (I) complexes. In order to investigate the 
reversibility of the observed reaction, H2O2 was added to the samples. The oxidant restored 
the spectra obtained with the original copper (II) complexes, showing the reversibility of the 
redox process. 
Comparing the rates of the reduction reactions (as on the right side on the Figure 53), it 
seems, that the reduction of the [Cu(Q-4)] complex, which possessed the highest MDR 
selectivity among the studied systems, shows the slowest reaction. Yet, the investigation of 
two further compounds with high MDR selectivity did not follow that trend (data not shown), 
suggesting that this observation might not be an explanation for the selectivity. 
 
As for the 8-hydroxyquinoline ligand set, also the kinetic runs of the [CuL]
2+
 complex formed 
with ligand IV-b were performed at pH 7.40, while in case of the [FeL]
3+
 complex the pH was 
lowered to 5.45 in order to avoid metal ion hydrolysis and the possible formation of the Fe 
(II) species in the Fe (III) - ligand system in the basic pH range (see chapters 3.4.3. and 
3.4.5.1.). In line with the high redox potential observed for [Fe(IV-b)]
3+
 (chapter 3.4.5.1.), 
this complex was reduced by ascorbate, as shown in Figure 54 B. Addition of hydrogen 
peroxide at the end of the kinetic run resulted in only negligible changes in the spectra, even 
after 30 min, suggesting that the observed reduction is not reversible, and that the complex is 
therefore unlikely to undergo intracellular redox cycling. Surprisingly, a ten-fold excess of the 
stronger reducing agent GSH did not provoke spectral changes in the [Fe(IV-b)]
3+
 system 
within 90 min. This suggests that this reaction might be kinetically hindered. A similar trend 
in the reduction kinetics of the two reducing agents has been reported for the reactions of 
vanadium complexes [262,263]. 
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Furthermore, the formal potentials of both reducing agents are pH-dependent, which might 
also explain the lack of GSH-induced reduction of the iron complex at pH 5.45. Based on 
studies on the pH dependence of the redox potentials, it can be estimated that in comparison 
to the potentials at a pH of 7.4, at the lower pH (5.45) the redox potential of GSH is shifted by 
116 mV, while that of ASC is shifted by 52 mV only [255,256,264]. Together these reasons 
might explain why ASC was able to reduce the complex, while GSH was not. 
 
 
Figure 54: Time-dependent UV–Vis spectra of [Cu(IV-b)]2+ (A, C – pH 7.40) and [Fe(IV-b)]3+ (B, D 
– pH 5.45) in the presence of 10 equivalents of ASC (A, B) and GSH (C, D). Red lines denote spectra 
obtained upon addition of H2O2. These data of IV-b were published in reference [89]. 
 
 
In contrast, the addition of ascorbate did not provoke changes in the spectra of the  
[Cu(IV-b)]
2+
 complex at a (pH of 7.4) within 75 min, suggesting that the complex is not 
reduced under the applied conditions (Figure 54 D). The reaction of the complex with 
glutathione on the contrary seemed to happen relatively fast, as the decrease in the λmax value 
of the Cu (II) complex (408 nm) during the redox reaction suggests. In parallel, an increase in 
absorbance at the λmax of the free ligand (~310 nm) could be observed, which is most 
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probably the result of the decomposition of the generated instable Cu (I) complex 
(Figure 54 C). Furthermore, addition of hydrogen peroxide at the end of the kinetic run 
restored the original spectrum, suggesting that the complex can undergo a reversible redox 
process, which might contribute to the toxicity of the compound. 
 
 
 
3.4.6. Relevance of redox activity of the complexes for toxicity 
The differential behavior of P-gp positive and negative cell lines in response to co-treatment 
with the 8-hydroxyquinoline derivatives Q-1 to Q-4 and the antioxidant N-acetylcysteine 
(NAC) suggested a putative influence of ROS on the (selective) toxicity mechanism of the 
compounds. Having shown that the ligands form stable and redox active complexes with 
iron (III) and copper (II), experiments were designed to evaluate the impact of the metal 
complexes on this behavior. Therefore cells were co-incubated with the preformed metal 
complexes and three antioxidants with varying reduction power. NAC is considered to be an 
intracellular precursor for GSH, since the availability of cysteine is rate-limiting for 
glutathione re-synthesis [265], but NAC also has reducing activity itself based on its thiol 
group. The redox potential of NAC is by 68 mV more positive than that of the GSH/GSSG 
redox pair, therefore at pH 7.4 it is at ‒192 mV [255,266]. At this pH, the reduction of 
pyruvate to lactate is characterized by a potential of ‒200 mV [267], while dithiothreitol 
(DTT) has a reduction potential at ‒345.6 mV [268,269]. 
Results that showed significant changes upon co-incubation with one of the antioxidants are 
summarized in Figure 55. The protective effect of NAC for MES-SA and MES-SA/Dx5 cells 
toward the toxicity of Q-1 was also found in case of mixtures of the ligand with one 
equivalent of iron (III) or 0.33 equivalents of copper (II), though the relative observed 
protection was smaller than in case of the free ligand. In case of the ligand Q-2, NAC 
protected MES-SA and MES-SA/Dx5 from the iron (III) complexes formed in all metal to 
ligand ratios. The magnitude of this protective effect is much more pronounced in the P-gp 
expressing MES-SA/Dx5 cells than in MES-SA cells. In case of the MDR selective ligands 
Q-3 and Q-4, significant protection could only be observed for the P-gp expressing MES-
SA/Dx5 cells against the iron (III) complexes formed at the metal-to-ligand ratio of 1:1. 
Pyruvate and DTT did not affect the toxicity of any investigated compound toward the 
parental MES-SA cells. Yet, a protective effect could be observed in MES-SA/Dx5 cells for 
the iron complexes of Q-2 ([FeL] and [FeL2] for pyruvate; [FeL], [FeL2] and [FeL3] for DTT). 
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DTT additionally protected MES-SA/Dx5 cells from the free ligand Q-1 and the iron (III) 
complex formed with Q-3 at 1:1 ratio. 
These results seem to be contradictory to the lack of observed interaction with GSH in the 
monitored reactions (chapter 3.4.5.2.). Though, this ostensible contradiction might show a 
weakness of the model, since it has to be kept in mind that the (intracellular) redox reactions 
depend on actual concentrations and are also not independent of pH. Furthermore, it has been 
reported that the reduction by GSH in the model might be kinetically hindered in some cases. 
Accordingly, for some metal complexes that did not show reactions with GSH, a reduction by 
the weaker antioxidant ascorbate has been reported [262,263].  
 
 
 
Figure 55: Significant fold changes in toxicity upon co-incubation with the indicated antioxidants 
(concentrations were 5 mM for NAC, 5 mM for pyruvate (pyr) and 100 µM for DTT). Ligands are 
indicated in the boxes. Changes in toxicity against MES-SA (open arrowheads) and MES-SA/Dx5 
(filled arrowheads) cells were calculated as the fraction of IC50 values in the presence vs. the absence 
of the antioxidant. Thereby positive values indicate an increase in toxicity, while negative values 
indicate a decrease in toxicity. Results obtained with free ligands are shown in black, that of [FeL3] in 
orange, [FeL2] in red, [FeL] in bordeaux, [CuL3] in cyan, and [CuL] in blue. Statistical significance 
was calculated with t-test, three independent experiments were performed. Obtained p-values are 
given under the arrows and are indicated with *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001, ****: p ≤ 
0.0001. 
 
 
In contrast, for the copper (II) complexes, the only significant change upon co-incubation was 
observed for [Cu(Q-4)]
2+
. Even though this observation could not be found with the other 
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antioxidants pyruvate and DTT, the toxicity toward MES-SA/Dx5 cells was found to be 
slightly increased in the presence of NAC.  
Taken together, these observations underline the “Janus-face” like character of the 
antioxidant: while on one hand it can scavenge reactive oxygen species, on the other hand, it 
might induce a mechanism of “activation by reduction” [86,116,135], and increase the 
oxidative stress leading to increased cellular damage. The lack of effect of antioxidants on the 
toxicity of most copper complexes might therefore either mean a real lack of effect, or be 
caused by parallel processes that counteract each other. 
The different reactivity of MES-SA and MES-SA/Dx5 cells toward the combination of 8-
hydroxyquinoline derivatives of different MDR selectivity, or metal complexes thereof, with 
antioxidants might again imply a different redox homeostasis of the parental and drug 
resistant cells.  
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4. Establishing techniques to measure ROS 
 
4.1. DCFDA  
The inherent instability and reactivity of most ROS and their very low steady state levels 
render the precise determination of their intracellular levels challenging [270]. The most 
frequently used method to measure intracellular ROS is based on the membrane permeable 
reagent 2’7’-Dichlorofluoresceindiacetate (DCFDA). As detailed in the methods section 
(Chapter 5.8.1.), upon cleavage of the ester bonds by intracellular esterases, the membrane 
impermeable, but still non-fluorescent Dichlorofluorescin (DCF-H) is formed, which is 
oxidized by ROS to the fluorescent Dichlorofluorescein (DCF) [271,272]. Even though being 
membrane impermeable in principle, studies revealed, that it is a substrate for the ABC-
transporters MRP1 and BCRP. In contrast it is not recognized and exported by P-gp, allowing 
the application in the test setup of MDR selective compounds [273]. 
As summarized in Table 15, different protocols can be found for the application of the DCF-
DA dye in the literature. The dye can be used for measurements of ROS levels within tumor 
spheroids [274], primary cells [275], as well as in suspension [135,276,277] and adherent cell 
lines [278–282]. Applicable methods for the measurement of intracellular fluorescence of the 
dye include flow cytometry, microscopy and spectrofluorimetric measurements. Often, the 
effect of test compounds on the cellular redox homeostasis is investigated. In these cases, 
three different experimental setups can be found with respect to the incubation protocols. The 
treatment of the cells can occur in parallel (Table 15, entry 2, [278]), prior to (Table 15, 
entries 3-6, [276,279–281,283]) or after loading of the cells with the DCFDA-reagent (Table 
15, entries 7-10, [135,271,275,277,282]). 
In order to establish a measurement system, the assay protocol was optimized using hydrogen 
peroxide (H2O2) and tert-butyl hydroperoxide (
t
BHP) as positive controls. Furthermore, cell 
free controls were used, to detect interactions of the dye with the oxidants as well as 
background reactions that might occur in solution (in the absence of the oxidants) due to 
hydrolysis and subsequent oxidation by atmospheric oxygen. Changes in fluorescence were 
investigated over a time period of one to four hours. A simultaneous incubation of cells with 
the test compounds and the DCFDA dye did not seem to be a preferential method, as high 
background signals were observed, which caused an unsatisfactory signal-to-noise ratio. 
In a next step, cells were seeded to plates, attached overnight and treated with the
 
oxidants.  
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Table 15: Different protocols used for the measurement of reactive oxygen species with the DCFDA-
dye in the literature. 
 
 
loading with DCFDA 
treatment with 
compound 
measurement 
method 
medium  Ref.  
1 multicellular tumor 
spheroids 
no compound 
treatment 
confocal laser 
scanning 
microscopy 
HEPES-
containing 
buffer 
[274] 
2 simultaneous incubation with DCFDA and 
test compound; trypsinization of adherent 
cells after incubation 
flow cytometry not specified [278] 
3 after treatment,  
test-compound not 
removed during 
loading, 
trypsinization after 
loading 
cells attached,  
compound treatment 
prior to DCFDA 
loading  
flow cytometry 
after washing with 
cold buffer 
culture 
medium  
[279] 
[280] 
4 after treatment,  
test-compound not 
removed during 
loading 
suspension cells, 
treatment prior to 
DCFDA-loading 
flow cytometry not specified [276] 
5 after treatment, 
putatively in the 
presence of test 
compound  
(not specified) 
prior to DCFDA 
loading 
measurement of 
cell-lysates at 
spectrofluorimeter; 
cell free controls 
added 
not specified [283] 
6 a) after treatment, 
test-compound 
not removed, 
trypsinization 
after loading 
b) attached cells, 
simultaneously 
with treatment 
a) cells attached, 
treatment prior 
to DCFDA 
loading. 
 
b) attached cells, 
simultaneously 
with DCFDA-
loading 
a) flow cytometry 
after washing 
with buffer 
 
 
b) laser 
cytometry on 
attached cells 
a) buffer 
 
 
 
 
b) serum-
free 
culture 
medium 
[281] 
7 cells attached on a 
chip, DCFDA-loading 
prior to treatment 
treatment after 
loading, DCFDA not 
removed 
fluorescence 
microscopy 
culture 
medium 
[282] 
8 suspension cells, 
labeling prior to 
treatment  
treatment after 
loading 
 
flow cytometry not specified 
([277]) / HBSS 
buffer ([135]) 
[277] 
[135] 
9 freshly isolated 
glomeruli, 
loading prior to 
treatment 
treatment after 
DCFDA-loading and 
removal of loading 
medium  
plate reader  
(note: cell free 
control missing) 
culture 
medium 
[275] 
10 loading of suspended 
cells in buffer prior to 
treatment, removal 
of loading buffer for 
treatment 
treatment after 
loading, following a 
recovery time for 
esterases 
not specified (amine-free) 
buffer 
[271] 
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Before incubation with the dye, the test compounds were removed. After loading with the 
dye, recovery times of 0 min, 30 min, 60 min, or 120 min were applied before trypsinization 
and subsequent measurement of the cell suspensions by flow cytometry. Differences in the 
fluorescence of treated and untreated cells were minor; the overall signals decreased with an 
elongated recovery time. Since the process of trypsinization might represent a certain stress 
for the cells, which might elevate the overall ROS levels, the protocol was modified for 
measurement with the microplate reader. However, this modification did not result in a 
reliable method either, since only one of four investigated cell lines showed small changes in 
fluorescence upon treatment with the oxidants.  
Therefore the protocol was further modified, shifting the loading of the cells with the dye 
prior to the treatment with the oxidants in the schedule of the experiment. After staining with 
DCFDA for 30 min at 37°C, cells were washed and seeded to 96 well plates in a density of 
20.000 C/W. Basal fluorescence levels were determined prior to the addition of test 
compounds and the measured data could be expressed as fold change toward the basal levels 
and the untreated controls (see methods part, chapter 5.8.1. for details).  
 
Figure 56 shows results obtained with the optimized protocol using the oxidant 
t
BHP. The 
induced signal was found to be dose dependent and increasing over time. MES-SA and MES-
SA/Dx5 cells showed a comparable behavior in the assay. 
 
 
 
Figure 56: Using the DCFDA assay for the measurement of intracellular 
t
BHP. (A): representative 
kinetic curve of an experiment showing the measured fluorescence signal of stained, but untreated 
(grey) MES-SA (open squares) and MES-SA/Dx5 (filled squares), with the cell-free control (stars) in 
comparison to the treatment condition with 5 mM of 
t
BHP. (B): Dose-dependence of induced signal by 
t
BHP after 60 min of incubation. Average and standard deviation of 6 independent experiments 
performed in duplicates are shown. 
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Being able to detect the addition of the peroxide 
t
BHP, which can be considered as a ROS 
itself, the next step was, to test the established system with a compound that is able to induce 
reactive oxygen species as a cellular response. One example for such a compound is the 
natural occurring naphthoquinone Plumbagin, which is used in Traditional Chinese Medicine. 
It has antitumor activity, which is reported to involve the formation of ROS via its copper 
complexes [284–287]. 
 
Prior to the experiments, the impact of ROS in the mechanism of cytotoxicity of Plumbagin 
was investigated by co-incubation with N-acetylcysteine. As shown in Figure 57, the ROS-
scavenger was able to protect MES-SA and MES-SA/Dx5 from the toxic effect of Plumbagin 
in a dose-dependent manner, confirming a role of ROS in the activity of the compound. 
 
 
 
Figure 57: Involvement of ROS in the toxicity mechanism of Plumbagin. Dose response curves 
showing average and standard deviation of 5 independent experiments with MES-SA (A) and MES-
SA/Dx5 (B) cells in the absence (black) and presence of 1 mM (green) and 5 mM (blue) NAC. 
Resulting IC50 values are summarized in panel C. 
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As apparent from Figure 58, Plumbagin was able to induce a fluorescence signal in the 
DCFDA-assay in both MES-SA and MES-SA/Dx5 cells. Furthermore, co-administration of 
the ROS-scavenger NAC attenuated the intensity of the signal, confirming a connection 
between signal intensity and ROS production. 
 
 
Figure 58: ROS induction of 
t
BHP and Plumbagin as measured by DCFDA assay in the absence 
(black) or presence of 1mM (green) NAC. Data represent the mean and standard error (SEM) of 
compound induced change in fluorescence after 1 h obtained in 5 independent experiments performed 
in duplicate. Cell free controls are shown in striped columns, while open columns show the signals 
obtained with MES-SA and filled columns that in MES-SA/Dx5 cells. 
 
 
It is noteworthy, that also in cell-free conditions, an increased fluorescence could be observed 
for the measurements with 100 µM of Plumbagin. Its quinoidic substructure enables the 
compound to redox cycle and consequently take part in chemical reactions with the dye. This 
indicates, that results obtained with the assay, might have to be interpreted with caution in 
some cases. Still, the difference between cell free and cellular samples is significant and 
relatively high. Therefore the established assay seems to provide a powerful tool for the 
measurement of ROS in cellular systems. 
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In a next step, a set of 8-hydroxyquinoline derivatives Q-1, Q-3 and Q-4, as well as their 
iron (III) and copper (II) complexes were investigated for their potential to induce reactive 
oxygen species in a cellular context. As shown in Figure 59, the pronounced signal induction 
in cell free conditions does unfortunately not allow a reliable conclusion in the cases of the 
MDR selective compounds Q-3 and Q-4.  
 
 
 
 
Figure 59: ROS induction of 8-hydroxyquinoline derivatives Q-1 (A), Q-3 (B) and Q-4 (C) and their 
metal complexes in comparison to 
t
BHP as measured by the DCFDA assay. Changes in fluorescence 
after 1h of treatment with 100 µM of the indicated compounds are shown. Cell free controls are shown 
in striped columns, while open columns show the signals obtained with MES-SA and filled columns 
that in MES-SA/Dx5 cells. Free ligands are shown in black, iron complexes FeL in bordeaux and 1/2 
[FeL2] in bright red, copper complexes CuL in blue and 1/2 [CuL2] in green. 
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In chapter 3.4. the set of 8-hydroxyquinoline derivatives with varying MDR selective activity 
was compared to the arylhydrazone IV-b, which showed enhanced toxicity toward a subset of 
MDR cell lines, yet in a P-gp independent manner. It has been shown, that – similar to the 8-
hydroxyquinolines Q-1 to Q-4 – compound IV-b is able to form stable and redox active 
complexes. Cellular antioxidants could interact with the formed complexes of iron (III) and 
copper (II). Furthermore protection of cells against the toxic effect of IV-b and its metal 
complexes by the ROS-scavenger NAC indicates an involvement of ROS in the toxicity 
mechanism of the ligand and its complexes. 
In order to characterize the extent of ROS formation, the newly established assay was applied. 
Figure 60 summarizes the fold changes in fluorescence obtained after 80 min of incubation 
with either 50 or 100 µM of the ligand or the indicated complexes. In contrast to the 8-
hydroxyquinoline derivatives, IV-b and its complexes showed only minor interaction with the 
DCFDA dye in cell free conditions, rendering the obtained results more reliable. The ligand 
alone did not provoke a ROS-related increase in fluorescence, suggesting that the presence of 
metal ions is necessary for the induction of ROS. In contrast, complexation with iron (III) in 
both metal-to-ligand ratios ([FeL]
3+
 and [FeL2]
3+
) resulted in a dose dependent ROS induction 
in equal measure in MES-SA and in MES-SA/Dx5 cells. The presence of NAC prevented the 
signal induction (Figure 60 A). In case of the copper complexes, ROS induction could be 
observed in the 1:1 metal-to-ligand ratio in both investigated cell lines, but not in case of the 
1:2 ratio, in which the Cu-coordination sphere of the formed complexes is saturated 
(Figure 60 B). Interestingly, the effect of NAC on the observed ROS-induction of [CuL]
2+
 
depended on the concentration of the complex. While at 50 µM concentration NAC reduced 
the fluorescent signal, an increase in fluorescence could be observed at 100 µM. The 
diminishing effect of NAC on the signal, induced by 50 µM of the complex is in agreement 
with a scavenging activity of the antioxidant. In contrast, the augmenting effect of NAC at the 
higher concentration could also be observed in the cell free condition, suggesting that a direct 
oxidation of the DCF-H is possible under this condition [288,289]. Still, it is possible that 
NAC initiates redox cycling of the formed complex within the cellular context, which – 
following Fenton-like chemistry (see Chapter 1.6.) – will increase the formation of reactive 
oxygen species by a mechanism of “activation by reduction” [89,135]. 
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Figure 60: ROS induction of arylhydrazone IV-b and its iron (III) (A) and Cu (II) (B) in comparison 
to 
t
BHP, as measured by the DCFDA assay. Changes in fluorescence after 80 min of treatment with 
indicated concentrations are shown. Co-incubation with 1 mM NAC is indicated in the table and 
highlighted with a grey background. Cell free controls are shown in striped columns, while open 
columns show the signals obtained with MES-SA and filled columns that in MES-SA/Dx5 cells. Free 
ligands are shown in black, iron complexes FeL in bordeaux and 1/2 [FeL2] in bright red, copper 
complexes CuL in blue and 1/2 [CuL2] in green. 
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The application of DCFDA for the measurement of reactive oxygen species is frequently 
used, since it is based on an easy principle; it is cheap and enables the detection of a broad 
range of ROS [288,289]. Despite these advantages, the method has certain limitations, which 
have to be kept in mind analyzing the data obtained with this system: several intracellular 
enzymes have been reported to interact with the ROS mediated oxidation of DCFH to DCF, 
such as diverse oxidases [288,290], peroxidases [288,290], catalase [288] and superoxide 
dismutase [288], but also non-enzymatic interaction partners can be found like hematin, 
hemoglobin, myoglobin [283] and cytochrome c [283,288,289,291]. Furthermore an 
artifactual increase in fluorescence can also be the result of photochemistry (followed by 
oxidation of the semiquinone radical) [288,289,292,293]. The DCFDA reagent (or derived 
intermediates) can also directly interact with the investigated compounds, metal ions and 
metal complexes [289,293]. This could be observed in the cases of the 8-hydroxyquinoline 
derivatives Q-1, Q-3 and Q-4 as well as for Plumbagin and the copper (II) complex of 
compound IV-a, underlining the importance of cell free controls in the application of the 
method. A rational use of the DCFDA probe requires an increased awareness for the possible 
pitfalls of the assay, which are related to possible mechanistic interactions and pathways 
[293]. The number of compounds which might theoretically interfere with DCFDA 
emphasizes the importance of proper controls and a careful interpretation of the results. It has 
been suggested to use the assay rather as a marker of the cellular oxidative stress, than as 
quantitative indicator for the formation of certain reactive oxygen species [270,271,288]. 
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4.2. HyPer - A genetically encoded sensor for H2O2
 
In order to overcome the drawbacks of artifactual side reactions observed with redox-sensitive 
probes [159], a recently developed method allows the selective quantification of transient 
fluxes of intracellular H2O2 utilizing the genetically encoded fluorescent sensor protein HyPer 
[294]. HyPer is a fusion protein consisting of the circular permuted yellow fluorescent protein 
cpYFP and an OxyR-RD domain. The latter is a well-known regulatory domain of a 
physiological sensor in Escherichia coli, which undergoes conformational changes upon 
oxidation by H2O2 [294–296]. Its selectivity toward H2O2 results from the localization of the 
oxidation side, which is situated in a hydrophobic pocket of the protein and is therefore 
inaccessible for charged oxidants such as superoxide anion [297]. Insertion of cpYFP to 
OxyR-RD with a short three amino acid linker resulted in the ratiometric probe HyPer [295]. 
As shown in Figure 61, the excitation spectrum of the protein has two maxima, one at 420 nm 
and one at around 500 nm. Upon oxidation by H2O2, the intensity of the peak at 420 nm 
decreases, while that of the peak at the higher wavelength increases, enabling a ratiometric 
readout of the probe [295,297]. Applying this method, artefacts associated with cell 
movement or differences in the sensor expression level between cells can be avoided [297]. 
 
 
Figure 61: Spectral properties of the ratiometric probe HyPer, modified from [295]. (A): excitation 
and emission spectra; spectral changes upon H2O2 addition, enabling the ratiometric measurement are 
shown for the pure protein (B) and for HyPer expressing E. coli cells in suspension (C). 
 
 
A further advantage of HyPer over fluorescent redox sensitive dyes is the reversibility of the 
protein oxidation, which enables the visualization of dynamic changes in intracellular H2O2 
levels [298,299]. Furthermore, HyPer is not prone to autoxidation, more photo-stable and 
retained very well within the cells [298]. Unspecific signals might be possible for compounds 
which interfere with the spectral properties of the sensor, or with compounds that significantly 
change the pH of the sample, since HyPer is pH sensitive [295,298,300]. In order to exclude 
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those unspecific signals, the mutant HyPerC121s, in which a single amino acid exchange 
disables the signal induction upon H2O2 stress, serves as a valuable control [156]. 
 
For the investigation of the effect of ROS in short and long term experiments, cell lines stably 
expressing the sensor protein would be beneficial, as transiently transfected cells should 
usually be assayed within 24 to 48 h after transfection [301]. The plasmids for HyPerC and 
HyPerC121s were kind gifts of Dr. Miklós Geiszt (Semmelweis University, Budapest, 
Hungary). The attempt to create stably HyPer expressing cells, by selection of transiently 
transfected cells with the antibiotic G418 (see chapter 5.8.2.1.4. for details) failed to provide 
stably expressing clones. Therefore a lentiviral transfection protocol was applied. I am 
grateful for the work of Nóra Kucsma and Áron Szepesi on creating the following stably 
transfected cell lines: MES-SA-259.75, MES-SA-259.200, MES-SA/Dx5-259.75, MES-
SA/Dx5-259.200 (with 259 encoding the viral supernatant of HyPerC, and the number behind 
the applied volume in µL), MES-SA-260.75, MES-SA-260.200, MES-SA/Dx5-260.75, MES-
SA/Dx5-260.200 (with 260 encoding the viral supernatant of HyPerC121s, and the number 
behind the applied volume in µL). 
 
 
Figure 62: Histograms of transfected MES-SA-HyPerC cells after sorting detected using two filters to 
address the two excitation maxima (A: 405 nm, B: 488 nm). The auto-fluorescence of non-transfected 
MES-SA cells is shown in magenta, cells transfected with 75 µL viral supernatant (MES-SA-HyPerC-
75 / messa.259.75) are shown in violet, cells transfected with 200 µL (MES-SA-HyPerC.200 / 
messa.259.200) are shown in green.  
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Due to their basal fluorescence, the transfected cells could be sorted by flow cytometry. 
Exemplarily, Figure 62 shows histograms of sorted MES-SA cells transfected with two 
different volumes of HyPerC viral supernatant in comparison to the non-transfected cells. 
Transfection with the mutant HyPerC121s and of MES-SA/Dx5 cells resulted in comparable 
histograms, as shown in the methods part (Chapter 5.8.2.1.5). 
 
Due to the ratiometric use of the sensor, the results should not depend on the transfection 
efficiency [297]. Since initial trials incorporating all eight cell lines were in agreement with 
this, in the following studies only those cells transfected with 200 µL supernatant were used. 
As MES-SA and MES-SA/Dx5 are adherent cell lines, the signal induction of H2O2 on the 
transfected cells was initially investigated on cells that were allowed to attach to 96 well 
plates overnight. In order to optimize fluorescence intensity, the cell number was adjusted to 
reach confluency for the time of the measurement (40.000C/W were used). In order to avoid 
putative disturbance through the components of the medium, measurements were performed 
in PBS buffer. Upon baseline measurement, H2O2 was added, and changes in emission at 
525 nm upon excitation at 420 and 490 nm were followed. Figure 63 A shows the fold change 
of the ratio between both measurements compared to the baseline over time for a 
representative experiment upon treatment with 200 µM H2O2. While a signal is induced in 
cell lines transfected with HyPerC, cell lines transfected with the mutant HyPerC121s served 
as the negative control and did not show signal induction. The induced oxidative stress is 
compensated for by the antioxidant system of the cells, provoking a decrease of intracellular 
H2O2 levels and concordantly in signal intensity over time. 
In Figure 63 B the dose-dependent signal inductions in MES-SA and MES-SA/Dx5 cells are 
compared at the time point of 5 min. Based on the three independent experiments (performed 
in duplicate) presented in this figure, no significant difference can be observed between the 
cell lines. Even though the measurements performed with the plate reader appeared 
promising, a drawback of this method is the time shift between the measurements of each 
sample with the different excitation wavelength, that provide data for one ratiometric data 
point. This time-shift is not negligible and might cause an uncertainty in kinetic 
measurements when fast changes occur.  
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Figure 63: (A): kinetic of a representative experiment using MES-SA and MES-SA/Dx5 cells 
transfected with 200 µL of HyPer containing virus. Cells were seeded to a 96 well plate 
(40.000 cells/well), and allowed to attach overnight. Before addition of the compound, culture medium 
was replaced by PBS buffer. Fluorescence was followed at 525 nm upon excitation at 420 and 490 nm 
prior to and after addition of H2O2 (200 µM are shown in the figure). MES-SA cells are depicted with 
open symbols, MES-SA/Dx5 with filled symbols. Results of HyPerC transfected cells are shown in 
black, results of the mutant HyPerC121s transfected cells in red. (B): Increases in fluorescence ratio 
values are shown for the time point of 5 min incubation with the indicated concentration of H2O2. Data 
of 3 independent experiments performed in duplicates are shown. 
 
 
A more reliable measurement can be achieved with a spectrofluorimeter, with which two 
wavelengths can be measured almost simultaneously. While the microplate reader allowed the 
measurement of attached cells, in this method, cells are measured in suspension. The cell 
density was optimized to 1.5 Mio cells per milliliter. In order to allow a more physiologic 
condition, HPMI buffer was applied (containing Ca
2+
, Mg
2+
 and glucose, see chapter 5.1.). 
Representative measurement curves with this system are shown in Figure 64 for the single 
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wavelengths (panel A) and the ratiometric evaluation (panel B) of transfected MES-SA cells. 
As in the previous setup, cells transfected with the mutant HyPerC121s served as a negative 
control, and did not show any change in signal upon addition of H2O2. Furthermore it can be 
seen in panel B, that the ROS scavenger NAC is able to attenuate the signal induced in MES-
SA-HyPerC cells. 
 
 
 
Figure 64: Representative curves showing the kinetic of the response of transfected MES-SA cells to 
50 µM H2O2. Panel A shows the changes in fluorescence at 525 nm upon excitation with the single 
wavelengths (490 nm is shown in red, 420 nm is shown in blue), panel B shows the changes in the 
ratiometric evaluation for the same measurement of MES-SA. HyPerC cells (black) in comparison to 
the mutant MES-SA.HyPerC121s (red). Furthermore the effect of NAC on the signal induced in MES-
SA.HyPerC is shown (green). 
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The real time monitoring measurement technique using the spectrofluorimeter opens up new 
readout possibilities for the investigation of the kinetics of the intracellularly induced H2O2 
levels in different cell lines. To quantify observed differences in curve kinetics, the Hill 
equation was applied as a mathematical model to describe the decay of the induced signal. 
Curve parameters were defined as indicated in Figure 65. Due to the fast response to the 
addition of H2O2, for the increase in signal no reliable fit could be found.  
 
 
Figure 65: The Hill equation was used to describe the time dependent decay of the signal. Definition 
of curve parameters for a representative response to treatment with 50 µM H2O2: The amplitude is 
described by the value max, the inflection point of the curve, which is showing the time dependence in 
seconds is described by k. Further variables in the equation are the endpoint end and a slope related 
factor n. 
 
 
As stated above, the ratiometric measuring mode makes the signal independent of HyPer-
protein expression levels. Different cell densities were applied in order to investigate the 
effect of cell numbers on signal reproducibility. While the curve parameters describing the 
amplitude (max), the endpoint (end) and the slope (n) of the curve were not markedly 
influenced, the inflection point k seemed to depend on the cell number, as shown in Figure 66. 
The high values of k in the figure result from the plot of time in the SI unit seconds. 
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Figure 66: Impact of the applied cell number on the inflection point k in the response of HyPerC 
transfected MES-SA (open symbols) and MES-SA/Dx5 cells (filled symbols) toward 50 µM H2O2.  
 
 
The dependence of k on the cell density can be explained by the ability of a higher number of 
cells to metabolize externally added H2O2 in a shorter time. Therefore, in the following 
measurements the cell number was kept constant at 1.5 Mio cells per milliliter. MES-SA and 
MES-SA/Dx5 cells transfected with HyPerC can be compared with regard to their response 
toward H2O2 analyzing the introduced curve parameters. Figure 67 provides an overview over 
the characteristics of the response of the two cell lines toward 50 µM H2O2. As Figure 66 
already suggests, there is a significant difference in k values between the sensitive and MDR 
cell line. The inflection point k represents the time, that the cells need, to cope with half of the 
induced stress. Comparing a number of independent experiments performed with MES-
SA.HyPerC (33) and the MDR MES-SA/Dx5.HyPerC cells (45), the MDR cell line seems to 
be able to cope with the induced stress in a shorter time window compared to the sensitive 
counterpart (Figure 67 A). Co-administration of the antioxidant NAC, added some minutes 
prior to H2O2, accelerates the H2O2 metabolism in MES-SA cells, but seems to have no 
significant effect on the speed of metabolism in MES-SA/Dx5 cells. In contrast, the amplitude 
of the induced signal (max, Figure 67 B) is attenuated by NAC in both cell lines. Similar to 
the differences observed in the inflection point, also the slope related factor n and the 
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endpoint of the measurement (end) seem to be different between MES-SA and MES-SA/Dx5 
cells, yet, these differences are rather small (Figure 67 C,D). These differences, especially in 
the time, needed to cope with induced stress (k) and in the degree of induced signal (max) that 
could be observed between the cell lines and upon co-incubation with NAC, suggest a 
different redox homeostasis of the sensitive and MDR counterpart. In agreement with this, 
Wartenberg et al. reported a negative correlation between intracellular ROS levels and P-gp 
expression [22,274,302,303]. 
 
 
 
 
Figure 67: Curve parameters comparing HyPerC transfected MES-SA (open symbols) and MES-
SA/Dx5 cells (filled symbols) in their response to 50 µM H2O2. Additionally, the effect of 1 mM NAC 
added prior to H2O2 is shown (green symbols). Significance was calculated from unpaired t-tests. The 
number of the independent experiments is indicated in brackets. 
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In order to test, whether the observed differences in the cellular response to H2O2 between 
MES-SA and MES-SA/Dx5 cells was dependent on the function of P-gp, the effect of 
Tariquidar was investigated. The inhibitor was administered either directly before the 
measurement (Figure 68 A,B) or cells were incubated with TQ for 72 h (Figure 68 C,D). As 
seen from the curve parameters k and max of these experiments, the currently available data 
do not allow a conclusion. Surprisingly, the curve parameters also changed in case of MES-
SA cells. Further experiments would be needed to draw conclusions. 
 
 
 
Figure 68: Curve parameters k and max comparing HyPerC transfected MES-SA (open symbols) and 
MES-SA/Dx5 cells (filled symbols) in their response to 50 µM H2O2. The effect of 1 or 10 µM TQ, 
added 5 min (A, B) or 72 h (C, D) prior to H2O2 is shown (grey symbols). The 72 h treatment was 
performed on 6 well plates, the untreated samples in this experiment are given as control values in 
these panels (in case of MES-SA cells in the presence of TQ over 72 h, a reliable curve fitting was 
only possible for one prepared sample). Significance was calculated from unpaired t-tests. The number 
of the independent experiments is indicated in brackets. 
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While the addition of extracellular H2O2 was able to provoke a signal in the experimental 
setup, the 8-hydroxyquinoline derivatives Q-1 to Q-4 as well as some of their investigated 
iron and copper complexes did not induce signals of comparable patterns. In some cases, 
slight changes in signal intensity could be observed over a longer measurement time, yet these 
effects were not reliably reproducible. 
 
Plumbagin (PG) proved to be a good control reagent for intracellular ROS induction in the 
DCFDA assay (Chapter 4.1.). Though, the species responsible for the induced oxidative stress 
is not specified in the literature. As shown in Figure 69, cells react to Plumbagin in a similar 
pattern as to the extracellularly added H2O2. The concentration that was needed to induce a 
curve of similar shape to the H2O2 positive control was as low as 2.5 µM, suggesting that the 
naphthoquinone is a very potent inducer of oxidative stress. This for the first time identifies 
the reactive oxygen species induced by Plumbagin to be H2O2. Unspecific effects could be 
excluded by the application of cells transfected with the mutant HyPerC121s. Furthermore, 
the presence of NAC attenuates the signal.  
Even though the MDR selective ligands and their metal complexes did not result in an 
increase in intracellular H2O2 levels, the application of Plumbagin shows, that the system is 
able to detect intracellularly induced changes in H2O2 levels.  
 
 
Figure 69: Intracellular H2O2 levels measured with HyPer system upon addition of 2.5 µM PG: MES-
SA.HyPerC cells (black), in presence of NAC (green), MES-SA.HyPerC121s cells (grey), in presence 
of NAC (blue). 
  
4. Summary  127 
 
 
4. Summary 
The development of the multidrug resistant phenotype is a multi-factorial process [3]. The 
multiple changes that endow MDR cells with benefits in survival might also create 
vulnerabilities that can be exploited to selectively target resistant cancer cells [42]. Therefore, 
the application of such MDR selective agents appears to be a promising approach to 
overcome multidrug resistance in cancer. 
 
In order to find P-gp mediated MDR selective agents, a panel of several cell lines and the 
application of a P-gp inhibitor should be considered: 
Analysis of reported compounds, that were serendipitously found to have higher toxicity 
toward MDR as compared to sensitive cell lines, revealed that the reported selectivity seems 
to be related to cell-line specific alterations other than the expression and function of P-gp 
(chapter 3.1.1.). In contrast, compounds that were identified as a result of data analysis from 
several cell lines of different P-gp expression levels proved to be more potent in MDR cell 
lines as compared to their sensitive counterparts (chapter 3.1.2. – common project with 
Szilárd Tóth, András Füredi, and Dr. Anna Lovrics). Furthermore, the selectivity of those 
compounds could be abrogated in the presence of the P-gp inhibitor Tariquidar, confirming 
that the activity of the transport protein is indeed responsible for the increased toxicity. 
 
Chelation is necessary for MDR selective anticancer activity – but not sufficient:  
Despite some degree of chemical diversity, a commonality between the identified MDR 
selective agents is their ability to chelate metal ions. Especially thiosemicarbazones (like I-a) 
and 8-hydroxyquinoline derived Mannich bases (like Q-3) are prevalently found scaffolds. 
Modification of the compounds’ scaffold in a way that disables the binding of metal ions leads 
to inactive compounds, with a lack of anticancer toxicity regardless of the resistance status of 
investigated cells. Nevertheless, by far not every chelator shows an enhanced activity toward 
MDR cell lines.  
A focused library around the chemical space of the chelator I-a was designed and tested for 
the potential to overcome MDR (chapter 3.2.). While most of the scrutinized compounds from 
the focused library show a comparable toxicity throughout the investigated cell line panel, 
single compounds show an enhanced toxicity toward certain P-gp expressing cell lines. 
Though, this effect appears to be restricted to single cell line pairs and not reversible in the 
presence of the P-gp inhibitor Tariquidar. 
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Despite the lack of new generally MDR selective compounds in this library, structure-activity 
relationships can be observed with respect to the toxicity of the investigated compounds. In a 
comparison of chelators with different metal binding motives – namely pyridinyl TSCs 
(NNS), hydroxyphenyl TSCs (ONS), arylhydrazones (NNN), pyridinyl hydrazino-
benzothiazoles (NNS) and hydroxyphenyl hydrazino-benzothiazoles (ONS) – NNS and NNN 
donor atom chelators show a superior activity over ONS chelators. Analysis of larger 
compound sets in the DTP database could confirm this trend. A putative explanation might be 
the preferential binding of these different chelators to certain metal ions, and the stabilization 
of different oxidation states of these ions according to the principle of hard and soft acids and 
bases (HSAB) [239,240]. Furthermore, a tendency could be observed for higher toxicity 
among NNS donors with imino carbon methylation. Though, a pairwise comparison of 
matched molecular pairs did not always follow this trend. For the ONS donor chelators, 
methylation of the imino carbon did not significantly influence the toxicity of the investigated 
compounds. 
 
Differences between MDR selective and non-MDR selective chelators from a bioinorganic 
chemical viewpoint: 
Experiments were designed and performed in order to find characteristics, which discriminate 
those chelators that show a preferential toxicity toward P-gp expressing cells from other non-
MDR selective chelators.  
In particular, a set of four structurally related compounds with a range of P-gp mediated MDR 
selectivity (Q-1 < Q-2 < Q-3 < Q-4) was investigated in detail and compared to a compound 
with cell-line specific selectivity, identified in the library (IV-b). Despite the limited size of 
this compound set, that does not allow general conclusions, differences and trends could be 
observed, that are promising starting points for follow up studies on larger compound sets.  
As implied in the introduction, chelators can have a wide range of various targets within 
biological setups including the inhibition of metallo-proteins, interfering with gene regulation 
and cell cycle progression [115,116]. By binding to intracellular metal ions chelators can 
deplete the labile ion pools, but also form biologically active complexes with a broad range of 
possible activities [124]. Since these complexes might be redox-active, also a disturbance of 
redox homeostasis and an interaction with the cellular antioxidant network is possible. 
In order to investigate a putative involvement of reactive oxygen species (ROS) in the 
mechanism of (selective) toxicity of the compounds, the ability of the ROS-scavenger and 
potent antioxidant N-acetylcysteine (NAC), to protect cells from the toxic effect of the 
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compounds was investigated. Remarkably, NAC had different effects on the cellular response 
toward MDR selective and non-MDR selective compounds (chapter 3.4.1.). While the toxicity 
of the not MDR selective core structure Q-1 was attenuated in the presence of NAC in both, 
MES-SA and MES-SA/Dx5 cells, NAC had no effect on the toxicity of the MDR selective 
agents Q-3 and Q-4. The same trend could be observed in a subset of structurally unrelated 
chelators. The toxicity of the two MDR selective isatin-β-thiosemicarbazones I-a and I-d was 
not influenced by co-administration of NAC. In contrast, cells were significantly protected 
against the toxic effect of the pyridinyl TSC II-g, the arylhydrazone IV-b and the pyridinyl 
hydrazino-benzothiazole V-b, which showed a cell-line specific selective toxicity.  
These results might suggest a different interaction of MDR selective and non-MDR selective 
chelators with the intracellular redox homeostasis, which could be a consequential 
characteristic involved in the selective targeting of MDR cells.  
In those cases, were NAC offered protection, redox active metal complexes might cause 
oxidative stress, which is antagonized by the ROS-scavenger. On the other hand, antioxidants 
might not only protect, but also sensitize cells to the toxic effect of metal complexes via an 
“activation by reduction” mechanism, following Fenton-like chemistry, that will increase the 
ROS levels and therefore cause cellular damage [86,116,135]. Since these two processes 
might occur in parallel, they might counteract each other, which might be a hypothetical 
explanation for the lack of detectable effect of NAC on the toxicity of MDR selective ligands. 
 
The differential response of MDR selective and non-MDR selective ligands to the co-
administration of NAC might be caused by different properties of the putatively formed metal 
complexes. In order to investigate this theory, complexes formed with iron (III) and 
copper (II) were characterized with regards to stability and redox activity. 
The spider-net diagrams in Figure 70 summarize some characteristics that describe the metal 
binding and biological activity of the 8-hydroxyquinoline derivatives Q-1 to Q-4 and the 
pyrimidinylhydrazone IV-b (chapters 3.3. / 3.4.3.). A correlation of chemical properties like 
the pKa values and metal binding abilities (expressed as pM* values) with toxicity and 
selectivity can be found in the set of 8-hydroxyquinolines. While MDR selectivity seems to 
increase with decreasing pKa and pM* values, a clear tendency can be seen that derivatives 
with higher MDR selectivity show a higher preference for copper (II) over Fe (III) binding. 
The trend in copper binding preference seems to follow the trend of MDR selectivity. Though 
the size of the investigated compound set does not allow a general conclusion, these results 
might indicate an impact of copper chelation on the mechanism of (selective) toxicity.  
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Figure 70: Bioinorganic chemistry in a spider diagram – comparison of biological and metal binding 
activity of the 8-hydroxyquinolines Q-1 to Q-4 (A) and the pyrimidinyl-hydrazone IV-b (B). The 
illustrated pKa values were determined experimentally, except for the pKa(NquinH
+
) of ligand Q-4, 
which was calculated using ChemAxon software [36]. pM* values represent the free metal ion 
concentration at physiological pH, which is present in a solution of 1 µM metal salt in a ten-fold 
excess of ligand. As detailed in the text and methods part data characterizing the bioinorganic 
chemistry of compounds was obtained in collaboration with Prof. Éva A. Enyedy (Institute of 
Inorganic and Analytical Chemistry, University of Szeged, Hungary). 
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Since IV-b does not share the same scaffold, its pKa values, on which the ligands’ ability to 
bind to metal ions highly depends, belong to different chemical entities. Therefore this 
compound is shown separately in panel B of Figure 70. Remarkably, for this cell line 
dependently selective pyrimidinylhydrazone IV-b, a clear difference in the metal chelating 
properties could be observed in comparison to the 8-hydroxyquinoline set, since IV-b shows a 
slight preference for iron (III) over copper (II) binding. Thus, these observed trends in metal 
binding preferences (chapter 3.4.3.) provide a promising starting point for further 
investigations on larger compound sets. 
 
In order to address the impact of iron and copper on the toxicity of the compounds, the 
toxicity of the ligands was investigated in the presence of non-toxic, fixed concentrations of 
FeCl3 or CuCl2 (chapter 3.4.2.). Depending on the investigated ligand, MDR and parental cell 
lines responded differently toward the co-administration of the metal ions. 
Upon iron co-administration, the MDR cell line MES-SA/Dx5 was protected from the toxic 
effect of the MDR selective ligands Q-2, Q-3 and Q-4 in a dose dependent manner. The fold 
protection appeared to follow the trend of MDR selectivity, since in the presence of the 
highest applied FeCl3-concentration (50 µM) MDR and parental cell lines were comparably 
sensitive to the toxic effect of the investigated ligands. In contrast, iron co-administration had 
no significant effect on the toxicity of the non-MDR selective core structure Q-1. Furthermore 
the sensitivity of parental MES-SA cells to the investigated 8-hydroxyquinoline set was 
comparable in the presence and in the absence of FeCl3.  
In contrast, FeCl3 offered protection to MES-SA cells against the pyrimidinylhydrazone IV-b, 
while it did not affect the sensitivity of the MDR cell line MES-SA/Dx5 against IV-b. 
The rescuing effect of iron that could be observed in MDR cell lines in case of MDR selective 
ligands might indicate an involvement of iron-depletion in the mechanism of toxicity, which 
might be more pronounced in the MDR cell line as compared to the parental counterpart. On 
the other hand, an excess of iron (III) might also prevent the binding of the chelators to its 
target or to other metal ions (like copper) and therefore result in protection of the cells. 
 
Also in the case of copper co-administration, differences could be observed in a cell line and 
compound specific manner. Both, parental and MDR cells, became more sensitive to the 
ligand in the presence of copper for the non-MDR selective quinoline Q-1, the “borderline” 
derivative Q-2, and the cell line dependently selective pyrimidinylhydrazone IV-b. In 
contrast, copper co-administration only sensitized the parental MES-SA cells toward the 
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MDR selective ligands Q-3 and Q-4, while the MDR cell line MES-SA/Dx5 did not show an 
increase in sensitivity.  
Similar to the rescuing effect of FeCl3, also the differential response of the two cell lines 
toward the sensitizing by CuCl2 causes a loss in selectivity in the presence of the highest 
applied the metal ion concentration (50 µM). In contrast to the protection by iron, a 
sensitizing effect of copper co-administration might be explained by an involvement of redox 
active complexes. The redox cycling of the complexes in Fenton-like reactions can harm the 
cells by the production of reactive oxygen species (ROS) – in particular the hydroxyl-radical 
[86,116,135]. 
 
The application of preformed complexes in fixed metal-to-ligand ratios confirmed the 
observations made on the co-incubation with a fixed metal concentration (chapter 3.4.4.): 
While iron complexes show a lower toxicity as compared to the free ligand (partially more 
pronounced in the parental cell line), copper complexes have an increased toxicity (especially 
in the MDR cell line). Furthermore, the inhibition of P-gp had similar effects on the toxicity 
of the complexes, as it had to the free ligands. While metal complexes formed with Q-1 were 
comparably toxic in the presence and in the absence of the inhibitor Tariquidar, the enhanced 
activity of both iron (III) and copper (II) complexes formed with the MDR selective ligands 
Q-3 and Q-4 seemed to require the activity of the transporter. 
Taken together these results might point to an altered metal homeostasis in MDR vs. sensitive 
cancer cells [42]. Since the metal homeostasis is tightly linked to intracellular redox 
homeostasis, also an altered redox state of the cells might be a possible explanation for the 
differential response of the cells toward MDR selective ligands [88,116]. 
 
The redox properties of the iron (III) and copper (II) complexes formed with the respective 
ligands might result in a different ability to induce ROS, and therefore cause the differential 
cellular response toward the complexes in the presence of the ROS scavenger. Therefore the 
redox behavior of the complexes was investigated by cyclic voltammetry (chapter 3.4.5.1.) 
and by monitoring reactions with intracellular antioxidants (chapter 3.4.5.2.). 
All formed complexes occurred to be redox active. In case of the iron complexes formed with 
the 8-hydroxyquinoline derivatives Q-1 to Q-4, the redox potential was shifted to the negative 
direction in comparison to the iron-aqua complex, indicating a preferential stabilization of the 
ferric (III) oxidation state. In contrast, the redox potential of iron complexes formed with the 
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NNN-donating pyrimidinylhydrazone IV-b was more positive than the aqua complex, 
indicating a stabilization of the ferrous (II) oxidation state. 
The reactions of the copper complexes were irreversible (Q-1 to Q-4) or quasi-reversible  
(IV-b) under the applied conditions. Yet, reduction potentials were found to be (much) more 
negative than that of the copper aqua complex. 
Monitoring of reactions with intracellular antioxidants in a buffered solution serves as a 
model of intracellular conditions. While under the applied conditions, GSH was not able to 
reduce the investigated iron (III) complexes, it underwent redox reactions with the copper 
complexes formed with the investigated ligands. The observed re-oxidation upon addition of 
H2O2 suggests the reversibility of the reaction, enabling intracellular redox cycling of the 
investigated copper (II) complexes and Fenton-like chemistry. 
 
In order to investigate the relevance of the redox activity of the complexes in vitro, co-
incubation experiments were performed with NAC, pyruvate and DTT. The toxicity of some 
iron complexes (mostly of Q-2) was markedly reduced in the presence of the antioxidants 
(chapter 3.4.6.). This ostensible contradiction to the lack of observed interaction with GSH in 
the monitored reactions might show a weakness of the model, since many factors will 
influence the intracellular redox reactions (e.g. actual concentrations and pH). 
In case of the copper-complexes, the cellular response to most complexes was not affected by 
the addition of antioxidants. An exception is the [Cu(Q-4)] complex, which exhibits a slightly 
increased toxicity toward MES-SA/Dx5 cells in the presence of NAC.  
These observations might underline the “Janus-face” like character of the antioxidant: while 
on one hand it can scavenge reactive oxygen species, on the other hand, it might induce a 
mechanism of “activation by reduction”, and increase the oxidative stress leading to increased 
cellular damage. While the lack of effect of antioxidants on the toxicity of most copper 
complexes might of course mean a real lack of effect, it might also be caused by parallel 
processes that counteract each other. 
It is noteworthy, that both effects of the antioxidants (protection against iron-complexes and 
sensitization against the copper-complex of Q-4) seem more pronounced in MES-SA/Dx5 
cells as compared to the parental MES-SA cells. 
 
Techniques for the measurement of ROS were established: 
In order to further investigate the hypotheses about the involvement of reactive oxygen 
species (ROS) on the toxicity of the investigated ligands and complexes, and the differential 
134   
 
response of parental and MDR cell lines, the detection and monitoring of ROS on a cellular 
level would be eligible. 
Therefore, two complementary measurement techniques were established (chapter 3.5.). 
While the application of the redox-sensitive dye DCFDA can detect a broad range of ROS, it 
is also prone to artefacts (as discussed in chapter 3.5.1.). Due to an interaction of compounds 
with the assay reagent, the ROS induction by the free ligands as well as the complexes formed 
with ligands Q-1 to Q-4 could not reliably be investigated. In contrast, IV-b and its 
complexes did not show unspecific interactions with the reagent. For this ligand and its 
complexes an involvement of ROS in the mechanism of toxicity of the complexes formed 
with the pyrimidinylhydrazone could be concluded from the measurements. The two-faced 
character of NAC becomes apparent from its effect on the induced fluorescent signal upon 
treatment with different concentrations of the [Cu(IV-b)]2+ complex. While NAC reduces the 
signal intensity up to concentrations of 50 µM of the complex, at higher complex 
concentrations, the co-administration of NAC increases the signal. This indicates a higher 
ROS production, which might putatively be the result of the “activation by reduction” 
mechanism. 
The application of the fluorescent sensor protein HyPer provides a more specific 
measurement method [156,295,300]. Upon selective oxidation by hydrogen peroxide the 
spectral properties of the sensor change in a way that the fluorescence intensity in one 
maximum (emission 525 nm / excitation 500 nm) increases while it decreases in the other 
(emission 525 nm / excitation 420 nm). This property enables a ratiometric measurement of 
intracellular H2O2 levels in real-time. As detailed in the methods part (chapter 5.8.2.), cell 
lines stably expressing HyPerC and the mutant HyPerC121s, which can serve as a control to 
exclude unspecific effects [156], were created with the help of Nóra Kucsma, Áron Szepesi 
and Zsuzsana Nagy (plasmids were kind gifts of Miklós Geiszt, Semmelweis University, 
Budapest, Hungary). Stably transfected MES-SA and MES-SA/Dx5 cell lines were 
characterized and their differential response to H2O2 was investigated using a plate reader and 
a spectro-fluorimeter measurement setup. The “half-live” of the induced signal (k) and its 
amplitude (max) were defined as important characteristics describing the cellular response 
toward intracellular H2O2 (-induced stress). Comparison of multidrug resistant MES-SA/Dx5 
to parental MES-SA cells revealed, that the antioxidant system of both cell lines might be 
different, enabling the resistant counterpart to cope with induced stress faster than their 
sensitive counterpart.  
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These results show the previously suggested difference in redox homoeostasis of the two 
investigated cell lines. In comparison to MES-SA cells, the higher capability of MES-SA/Dx5 
cells to cope with oxidative stress might be indicative of a stronger antioxidant system.  
 
Following a mechanism of “activation by reduction” of formed copper complexes 
[86,116,135], the potentially stronger antioxidant system of MES-SA/Dx5 (in comparison to 
the parental MES-SA cells) cells might therefore result in a more pronounced production of 
ROS following the Fenton-like chemistry of formed metal complexes with the MDR selective 
ligands.  
The toxicity increasing effect of copper co-administration only in MES-SA cells, but not in 
the MDR MES-SA/Dx5 cells, might be in agreement with this. Also the metal binding 
preference of MDR selective ligands for copper over iron and the observed ability of the 
copper complexes to redox cycle in biologically relevant conditions are in line with this 
theory. 
The respective preferences in metal binding and the redox properties of the formed complexes 
might be relevant descriptors of the MDR selective ligands. In order to find out, if these 
descriptors are putative discrimination factors of MDR vs. non-MDR ligands, a higher 
number of compounds should be investigated. 
 
While experiments investigating the effect of P-gp activity and MDR selective compounds on 
the intracellular H2O2 levels with the HyPer measurement system did not provide conclusive 
results so far, the naphthoquinone Plumbagin, which was reported to have anticancer activity 
via ROS formation, induced a signal that was comparable to that of H2O2 already in the low 
micro-molar concentration range. This shows that an intracellular response in H2O2 levels can 
be provoked by the addition of compounds. Therefore the established measurement system 
provides a useful tool for further investigation of the impact of MDR selective compounds on 
the H2O2 levels and on the intracellular antioxidant network. This tool also enables the 
cellular monitoring over longer incubation time periods. 
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5. Tumor models and biological methods 
 
5.1. Cell lines, media and buffer  
The human ovarian carcinoma cell lines A2780 and the Doxorubicin selected multidrug 
resistant counterpart A2780adr were obtained from ECACC, UK, (A2780: No. 93112519, 
A2780adr: No. 93112520) [304], and cultivated in RPMI (Sigma Aldrich, Germany) 
supplemented with 10% fetal bovine serum and 50 unit/mL penicillin and streptomycin, 
respectively (Sigma Aldrich, Germany).  
The human uterine sarcoma cell lines MES-SA and the Doxorubicin selected MES-SA/Dx5 
were obtained from ATCC (MES-SA: No. CRL-1976™, MES-SA/Dx5: No. CRL-1977™) 
and cultivated in Dulbecco’s Modified Eagle Medium (DMEM, Sigma Aldrich, Hungary) 
[24,171]. 
The Madin–Darby canine kidney (MDCK-II) cell line was genetically modified by Dr. Dóra 
Türk, to overexpress cDNA-derived P-gp. by the Sleeping Beauty (SB) transposon-based gene 
delivery system, using the 100x hyperactive SB transposase [305]. Cells were co-transfected 
with the SB transposon vector containing the wild type human MDR1 cDNA [306] and the 
SB transposase vector construct, using the Lipofectamine 2000 reagent (Life Technologies) in 
accordance with the manufacturer’s instructions. Transfected cells were sorted by flow 
cytometry (FACS Aria High Speed Cell Sorter, Beckton-Dickinson) based on the cell surface 
expression of MDR1/ABCB1. Protein expression was measured by antibody labeling using 
the human MDR1/ABCB1 specific monoclonal antibody MRK16 (Abnova). In order to 
obtain homogenous transgene positive cell population, sorting procedure was repeated 4 times 
in 2-week intervals [89]. MDCK-II and MDCK-II-ABCB1 cells were cultured in DMEM 
medium. 
The human cervix carcinoma cell line KB-3-1 and the Vinblastine selected KB-V1 as well as 
the human ovarian carcinoma cell line OVCAR-8 and the Doxorubicin selected counterpart 
NCI/ADR-RES stably expressing fluorescent label proteins (see chapter 5.6.3.) were kind gifts 
of Dr. Michael M. Gottesman, National Institutes of Health [172,307]. KB-3-1 and KB-V1 
cells were cultivated in DMEM. OVCAR-8 and NCI/ADR-RES cells were maintained in RPMI 
medium (Life Technologies, Hungary) supplemented with 10% fetal bovine serum, 5 mmol/L 
glutamine, and 50 unit/mL penicillin and streptomycin, respectively (Life Technologies, 
Hungary). 
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DMEM media (Sigma Aldrich, Hungary) were supplemented with 10% fetal bovine serum, 
5 mmol/L glutamine, and 50 unit/mL penicillin and streptomycin, respectively (Life 
Technologies).  
 
 
The most frequently applied buffers in the biological testing were phosphate-buffered saline 
(PBS) and HPMI. Buffers were prepared in 10x concentrated stock solutions and diluted for 
usage. The pH was adjusted to 7.4 using NaOH and HCl. The ingredients are given in Table 
16 [308]. 
 
Table 16: Composition of PBS and HPMI buffers [308]. 
 PBS HPMI 
conc 
mmol/L 
g/L for 
10x stock 
conc 
mmol/L 
g/L for 
10x stock 
NaCl 136.89 80.00 119.77 70.00 
KCl 2.68 2.00 5.00 3.73 
Na2HPO4  9.86 14.00 5.00 7.10 
KH2PO4 1.41 2.00   
MgCl2   0.85 0.81 
CaCl2·2H2O   0.04 0.06 
HEPES   10.00 23.83 
NaHCO3   10.00 8.40 
Glucose   10.00 18.00 
 
 
 
5.2. Cell culturing 
All cell lines were cultivated under aseptic conditions using a laminar air flow cabinet and 
sterilized equipment (serological pipets and pipet tips), work surfaces were chemically 
disinfected prior to and following work using 70% ethanol and (in Budapest additionally) 
exposed to UV-light at the end of each working day [309–311]. Cells were kept in the 
indicated media at 37 °C, 5% CO2 with a relative humidity of 96%. All used cell lines display 
adherent growth properties. Therefore, the described general cultivation protocol is valid for 
all cell lines used in this study. Dependent on the required cell numbers, cells were grown in 
T-25, T-75, or T-175 culture flasks. The used volumes for the respective culture flask sizes 
are given in the table below (Table 17). Cells were sub-cultivated after reaching a confluency 
level of 80-90%. Briefly, after removal of the culture medium, the cell layer was rinsed with 
PBS buffer, in order to remove traces of serum which contains trypsin inhibitor. The buffer 
was removed and the indicated volume of Trypsin (0.25% (w/v))-EDTA (0.53 mM) (Sigma, 
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Germany / Hungary) solution was added and allowed to incubate until the cell layer started to 
disperse. Cells were aspirated by gently pipetting with fresh growth medium. Cells were 
transferred to falcon tubes and sub-cultivated in a 1:4 to 1:12 ratio or used for assays after 
washing with PBS buffer.  
The general washing procedure consisted of a centrifugation of cell suspension with 281 x g 
for four minutes, following by resuspension of the cell pellet in PBS buffer, a repeated 
centrifugation step, and the resuspension of the pellet in the desired medium (buffer or culture 
medium). Further mentioning of washing steps will refer to this general procedure if not 
stated otherwise. 
 
Table 17: Volumes of Media, Trypsin and buffer used for the different cell culture flasks 
 
Flask 
Surface 
area / 
mm² 
Total 
Volume 
of 
medium / 
mL 
Initial cell 
number / 
Mio Cells 
Harvested 
cell 
number / 
Mio Cells 
Volume 
of PBS 
for 
washing 
Volume 
of 
Trypsin-
EDTA / 
mL 
Volume of 
Medium for 
Resusp. / mL 
T-25 2.500 5-6 0.5-1 3-5 3 mL 0.75 4 
T-75 7.500 15-18 1.5-3 5-10 5 mL 2.0 5 
T-175 17.500 23-26 3-5 15-20 8 mL 3.0 7 
 
 
 
5.3. Determination of cell numbers 
To determine the cell numbers in the suspension after harvesting, two instruments were used. 
For cell counting with the CASY©1 TT (Schärfe, Germany) instrument, 20 µL of the cell 
suspension were transferred to 10 mL of the sterile filtered isosmotic electrolyte solution 
CASY©ton and counted with the indicated instrument. The CASY technology is an electric 
field multi-channel cell counting system that combines the measurements of particle size and 
resistance based on the interaction of the cells with the applied low voltage field in the 
capillary. Based on the number and extent of changes in resistance upon flow of cell 
suspension through the capillary the instrument creates a histogram of cellular size 
distribution. 
 
For determination of the cell numbers using the BioRad TC10™ instrument (Biorad, 
Hungary), samples were prepared by mixing the cell suspension with Trypan Blue 0.4% stock 
solution (Sigma Aldrich, Hungary) in a 1:1 ratio, in order to and exclude stain dead cells. 
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Ten µL of the mixture were transferred to respective counting slides (Biorad TC10 dual-
chamber counting slides (Biorad, Hungary)) and measured. The instrument uses an autofocus 
technology and a digital image analysis algorithm to provide the number of cells and the 
percentage of viability (which is based on the Trypan blue staining).  
 
 
 
5.4. Cryo-conservation and revitalization of cells 
For the long term storage of cellular samples, aliquots of 2-4 Mio Cells were frozen in the 
respective culture medium supplemented with 40% FBS containing 10% DMSO. Aliquots of 
1 mL of the suspensions were filled into screw cap cryo vials (Greiner bio-one, Germany / 
Corning, New York) and cooled down to - 80°C, using a Cryo Freezing Container (Nalgene, 
Sigma, Hungary) filled with isopropanol, which allows a constant cooling rate of 1°C/min. 
After that, vials were transferred to a tank of liquid nitrogen. 
To revitalize the cells, vials were thawed in a 37 °C water bath, transferred into falcon tubes 
containing 5 mL of culture medium and centrifuged to remove the DMSO. After resuspension 
of the cell pellet in fresh medium, cells were transferred to culture flasks and cultured as 
described above. In order to ensure the resistant phenotype of drug selected cell lines, at the 
second passage after thawing, cells were selected for two passages in medium supplemented 
with 500 nM Doxorubicin for A2780adr and Dx5 cells, or 300 nM Vinblastine for KB-V1 
cells. Before using the cells for experiments, cells were grown without selection agents for at 
least one passage. 
 
 
 
5.5. Testing for Mycoplasma 
Mycoplasma are the smallest known Gram-negative bacteria and represent a common kind of 
contamination in cell culture [312]. Firstly noted in the 1950s, until today mycoplasma 
became probably the most prevalent and serious microbial contaminant of cell culture systems 
used in research and industry today [309]. They can pass through pores of more than 0.1 mm 
in diameter and often stay unnoticed due to the lack of visible signs of the infection [309,313]. 
Still they alter many host cell functions including growth, morphology, metabolism, the 
genome and antigenicity, leading to unreliable experimental results [309,310,313,314]. In order 
to ensure that cell lines are free of contamination good tissue culture practice and frequent 
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testing is required [309]. A specific method to test for mycoplasma is the MycoAlert kit 
[309,313]. 
It exploits the activity of certain mycoplasmal enzymes, which are set free upon lysis with the 
assay reagent. The enzymes react with the assay substrate, catalyzing the conversion of ADP 
to ATP: 
 
𝐴𝑇𝑃 + 𝐿𝑢𝑐𝑖𝑓𝑒𝑟𝑖𝑛 + 𝑂2  
𝐿𝑢𝑐𝑖𝑓𝑒𝑟𝑎𝑠𝑒, 𝑀𝑔2+
→             𝑂𝑥𝑦𝑙𝑢𝑐𝑖𝑓𝑒𝑟𝑖𝑛 + 𝐴𝑀𝑃 + 𝑃𝑃𝑖 +𝐶𝑂2 + ℎν 
 
Comparing the ATP levels of a sample before and after the addition of the mycoplasma 
specific MycoAlert™ substrate, a ratio can be obtained which is indicative of the presence or 
absence of mycoplasma [313]. Cells were tested for mycoplasma infections one or two 
passages after thawing using the MycoAlert™ mycoplasma detection kit (Lonza, Hungary) 
[313]. From a confluent culture flask 1 mL medium was transferred to an Eppendorf tube and 
centrifuged for 5 minutes at 129 x g. 35 µL of the upper layer were transferred to an OptiPlate 
(white 96 well plate, Perkin Elmer, Hungary) and 35 µL of MycoAlert reagent was added to 
each well. After 5 minutes of incubation the first luminescence measurement was performed 
(measurement 1). 35 µL of MycoAlert substrate were added to each well and incubated for 
10 minutes. Luminescence was measured (measurement 2) and the ratio of both measurement 
values was calculated: 
 
𝑋 =
𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑚𝑒𝑛𝑡 2
𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑚𝑒𝑛𝑡 1
 
 
If the ratio X was smaller than 1, the sample was negative for mycoplasma. If it was between 
1 and 1.3, the determination should be repeated at the next passage, a ratio higher than 1.3 
indicates an infection of the investigated cell line. Only non-infected cell lines were used. 
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5.6. Measurement of cell viability  
 
5.6.1. MTT viability assay 
The MTT viability assay was developed by Mosmann et al. in 1983 as a quantitative 
colorimetric assay for the measurement of survival and proliferation of mammalian cells 
[315]. Within living cells the pale yellow tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide) is reduced to a dark blue formazan as depicted in Scheme 
5, which can be detected spectrometrically. The amount of formed formazan correlates with 
the number of metabolically active cells over a wide range. The cellular reduction has been 
suggested to involve mitochondrial mechanisms like mitochondrial NADPH and succinate 
[316,317] and mitochondrial enzymes like succinate dehydrogenase [318]. Yet, MTT 
reduction was also detected in other cellular compartments [319] and connected to 
(microsomal) NADH and NADPH [316,320,321]. 
 
 
Scheme 5: Reduction of MTT reagent in living cells 
 
 
MTT viability assays were performed as described earlier with minor modifications [55,322]. 
Briefly, cells were seeded into 96 well tissue culture plates (CytoOne Starlab, Hamburg, 
Germany/ Sarstedt, Newton, USA / Orange, Braine-l'Alleud, Belgium) in the appropriate 
density which was optimized to reach 90% confluence in the untreated wells by the end of the 
incubation time and allowed to attach for 6-12 h. For the different cell lines these cell 
numbers 5000 cells per well for MES-SA and Dx5, as well as for KB-3-1 and KB-V1 cells, 
10000 cells per well for A2780 and A2780adr cells. After attachment of the cells, test 
compounds were added to achieve the required final concentration in a final volume of 
200 µL per well. After an incubation period of 72 h, the supernatant was removed and fresh 
medium supplemented with the MTT reagent (0.83 mg/mL) was added. Incubation with MTT 
142   
 
at 37 °C was terminated after 1 h by removing the supernatants and lysing the cells with 
100 µL DMSO per well. Viability of the cells was measured spectrophotometrically by 
absorbance at 540 nm using either a Perkin Elmer Victor X3, Perkin Elmer EnSpire or a BMG 
POLARstar microplate reader. Data was background corrected by subtraction of the signal 
obtained from unstained cell lysates and normalized to untreated cells.  
 
 
 
5.6.2. Presto Blue viability assay 
An alternative to the measurement of cell viability by MTT assay is the utilization of a 
resazurin based assay [323–325]. Even though resazurin powder is commercially available, 
several assay kits are on the market containing the dye in performance verified quality 
together with additional agents, that stabilize the signal and reduce the background [317]. The 
used assay kit had the brand name PrestoBlue (A-13262, Life technologies, Budapest, 
Hungary). 
Similar to the MTT assay, the PrestoBlue assay is based on an intracellular redox reaction. 
Here, the blue, non-fluorescent 7-hydroxy-10-oxidophenoxazin-10-ium-3-one (resazurin) is 
reduced to the pink, fluorescent 7-hydroxyphenoxazin-3-one (resorufin) as depicted in 
Scheme 6 [326,327]. The product can be detected both by absorbance or fluorescence 
measurements, with the latter method showing a higher sensitivity [317,327–330]. An 
advantage of the PrestoBlue over the MTT assay is, that the cells do not have to be lysed, 
The reduction of resazurin can be mediated by mitochondrial reductases, cytochromes, several 
cytosolic enzymes, as well as by the intracellular reductants NADH, NADPH, FADH, FMNH 
[330]. 
 
 
Scheme 6: Reduction of PrestoBlue reagent in living cells 
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Cells are seeded in plates and treated with test compounds as described for the MTT assay 
(chapter 5.6.1.). After 72 h of incubation with the test compounds, supernatants were either 
removed, and a diluted solution of the PrestoBlue reagent (10%) was added to each well, or in 
the case, where an interaction of the test compound with the resazurin dye could be excluded, 
the reagent was directly added to yield a final concentration of 10% (as in case of Triton-X-
100 viability assays). After incubation with the reagent for one hour at 37 °C emission was 
measured at 579 nm upon excitation at 540 nm using either a Perkin Elmer Victor X3 or 
Perkin Elmer EnSpire microplate reader. 
 
 
 
5.6.3. mCherry, eGFP, DsRed fluorescence assays 
An alternative method which avoids the addition of exogenous assay substrate compounds to 
indicate viability relies on the expression and retention of an intracellular fluorescent protein, 
produced by a transfected cell [331]. Besides of avoiding putative side reactions, another 
advantage of the fluorescent protein labeling is, that cells can be monitored in real time 
without altering the system in any way, other than illuminating with light of the proper 
excitation wavelength [307,331]. Damages in the cell membrane of dying or dead cells will 
cause a leak-out of the soluble fluorescent proteins [332]. The basis of this technique was 
established by Shimomura et al., who isolated the green fluorescent protein (GFP) from the 
jellyfish Aequorea victoria in 1962, characterized its optical properties, and, in 1979, 
identified the chemical nature of the fluorophore [333]. Following the recombinant expression 
of GFP in E. coli Chalfie et al. envisioned that GFP could be used as a vital marker for the in 
situ monitoring of cell growth [334]. Tsien et al. further characterized the fluorophore and 
could engineer further fluorescent proteins with different colors based on GFP and DsRed 
[333,335–337]. The latter protein was isolated from a coral Discosoma species [338,339]. In 
2008, the Nobel Prize in Chemistry was awarded to those three researchers for the discovery 
and development of the green fluorescent protein, GFP [333].  
The fluorescent label proteins used in this study were eGFP, DsRed-II and mCherry. Stable 
transfectants of OVCAR-8-DsRed-II and NCI/ADR-RES-eGFP (kind gifts Dr. Michael M. 
Gottesman, National Institutes of Health, Bethesda) were obtained by lipofectamine 
transfection upon by selection in presence of G418 [307]. MES-SA-mCherry and Dx5-
mCherry cells were created in the laboratory of Katalin Német (Hungarian Academy of 
Sciences, Budapest) by a lentiviral method. Briefly, they inserted the sequence of the 
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fluorescent protein mCherry (kind gift of Erwin Welker, Hungarian Academy of Sciences, 
Budapest) into the pRRL lentiviral plasmid vector containing the EF-1α (human elongation 
factor-1α) promoter (obtained from Didier Trono, Lausanne, Switzerland) using XbaI-SalI 
restriction sites, replacing the originally present GFP sequence. Cells were treated with the 
virus containing supernatant with a multiplicity of infection of four (4 virus particles per cell). 
Stable transfectants were sorted twice with a BD FACS Aria cell sorter (BD, Budapest, 
Hungary), keeping only the cells with high fluorescence intensity. Thus, no antibiotic 
selection was needed to eliminate non transfected cells. 
For the viability assays, the stably transfected cells are seeded in plates and treated with test 
compounds as described for the MTT assay (chapter 5.6.1.). After 72 h of incubation the 
fluorescence of the respective protein was measured with a Perkin Elmer Victor X3 or Perkin 
Elmer EnSpire microplate reader. 
For eGFP transfected cells the emission was measured at 535 nm upon excitation at 490 nm, 
for DsRed-II transfected cells the emission was measured at 579 nm upon excitation at 
540 nm and the fluorescence of mCherry transfected cells was measured at 610 nm upon 
excitation at 585 nm. 
 
 
 
5.6.4. Evaluation of dose response curves 
In order to compare the effectiveness of the investigated compounds, half maximal growth 
inhibitory concentrations (IC50) were determined with the help of Prism software [340]. The 
raw data was normalized to measured controls representing 100% cell viability for untreated 
and 0% viability for dead controls (10% DMSO, or high concentration of toxic compounds, 
respectively). The normalized data was analyzed with a sigmoidal dose-response model using 
the four parameter logistic equation: 
 
𝑦 = 𝐵𝑜𝑡𝑡𝑜𝑚 +
(𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚)
1 + 10(𝐿𝑜𝑔𝐼𝐶50−𝑋)∙𝐻𝑖𝑙𝑙𝑆𝑙𝑜𝑝𝑒
 
 
The Top represents the Y-value at the top plateau, which is reached at 100% cell viability; the 
bottom plateau is reached at 0% viability. The HillSlope describes the steepness of the curve. 
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5.7. Verification of MDR phenotype 
The phenotype of the resistant cells was verified in two ways. In each cytotoxicity assay 
additionally to the test compounds, a P-gp substrate was used as described in 5.7.1. 
Furthermore the MDR phenotype and the P-gp expressing cell population were ascertained by 
the functional Calcein AM assay as detailed in 5.7.2. 
 
 
5.7.1. Using P-gp substrates as control in viability assays 
The phenotype of the resistant cells was verified in each cytotoxicity assay by using at least 
one of the P-gp substrates Doxorubicin, Rhodamine-123 or Vinblastine. Figure 71 shows 
representative dose response curves for the three cell line pairs MES-SA vs. MES-SA/Dx5 
(Figure 71 A), A2780 vs. A2780adr (Figure 71 B) and KB-3-1 vs. KB-V1 (Figure 71 C) 
obtained by MTT assays (see Chapter 5.6.1.). 
It is apparent from the figure, that the dose response curves of the resistant cell lines (filled 
symbols) are shifted to higher concentrations as compared to the curves of the parental cells 
(open symbols). 
 
 
Figure 71: MDR cells show decreased sensitivity toward P-gp substrates Doxorubicin and Vinblastine 
as compared to parental counterparts. Dose-response curves obtained by MTT assay (Chapter 5.6.1.) 
are shown for A: MES-SA (open squares) and MES-SA/Dx5 (filled squares), B: A2780 (open circles) 
and A2780adr (filled circles), C: KB-3-1 (open diamonds) and KB-V1 (filled diamond). 
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5.7.2. Calcein AM accumulation assay 
An alternative diagnostic method to study the function of P-gp is to measure the accumulation 
of the fluorescent cell viability marker, Calcein. Calcein acetoxymethyl ester (AM) is a non-
fluorescent substrate of P-gp. As shown in Scheme 7, upon cleavage of the ester bonds by 
intracellular esterases, the free Calcein has a high fluorescence intensity in the visible range 
and is not transported by P-gp. Thus changes in Calcein uptake can be easily visualized by 
fluorescence measurements using microplate readers or conventional flow cytometry 
[341,342].  
 
 
Scheme 7: Cleavage of Calcein AM ester bonds by intracellular esterases delivers the fluorescent 
Calcein, which can be detected by plate readers and flow cytometers to study the function of P-gp. 
 
 
After counting, a cell suspension was prepared for each cell line, containing 7.5 Mio cells in 
serum free medium, and transferred to a FACS tube. The FACS tubes were centrifuged at 
250 x g for 3 minutes and the supernatant was discarded. Due to the shape of the tube, in this 
procedure 50 µL of supernatant remained, therefore 250 µL of serum free medium were 
added to obtain a total volume of 300 µL of cell suspension. This volume was distributed to 
three FACS tubes, each containing 2.5 Mio cells in 100 µL per FACS tube. Out of the three, 
one sample served as an unstained control for auto-fluorescence of the cells and did not 
receive further treatment. One sample was treated with the P-gp inhibitor Verapamil, while 
the other one served as a vehicle control and obtained the same amount of DMSO as the 
Verapamil sample: Treatment solutions were prepared freshly from 50 µL serum free medium 
per sample supplemented with 1 µL of either a 20 mM Verapamil stock solution in DMSO or 
DMSO alone for the vehicle control. In order to ensure a sufficient amount of treatment 
solution, the amount for one additional sample was prepared in each case. Since the uptake 
and accumulation of Calcein AM are time sensitive processes, a strict time schedule was 
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followed: Upon addition of the 50 µL treatment solution, the sample was vortexed and set into 
a water bath shaker, thermostated to 37 °C. The time that passed between two sample 
treatments was exactly 20 seconds. After the 5 minutes incubation time, the first sample was 
treated with 50 µL of a Calcein AM treatment solution (100 µM in serum free medium), 
vortexed and put back to the water bath shaker. The order and the time shifts between the 
treated samples were kept as in the first treatment. After 10 minutes of incubation, the cellular 
reaction was stopped by addition of 1 mL ice cold PBS per sample (again keeping the 
20 seconds time shifts). Samples were centrifuged at 250 x g and 4 °C for 3 minutes, and after 
one washing step, the supernatant was discarded and the cell pellet was resuspended in 
250 µL of ice cold PBS. Samples were kept on ice until measured by flow cytometry on a 
FACS Calibur instrument (BD Biosciences, USA) or an attune flow cytometer [343]. 
The data was visualized with the help of the program Cell-Quest Pro (BD Biosciences, USA). 
Figure 72 shows an example experiment using MES-SA and MES-SA/Dx5 cells. In the so 
called dot plots cellular detection is aligned with respect to cellular size (Forward scatter, 
FSC: low angle light scatter, the light that strikes the cell) and granularity or structural 
complexity inside the cell (Side scatter, SSC: scattered at larger angles). A “gate” was set, 
selecting only viable cells according in the auto-fluorescence sample. Dead cells generally 
have a lower size and intracellular complexity, and in a simple Calcein AM staining 
experiment they should be low in quantity, but where necessary, they could be detected and 
excluded by staining with the TO-PRO®-3 DNA dye (Life Technologies, USA). 
Histograms, as shown in Figure 72, visualize the frequency distribution of fluorescently 
labelled cells. It can be seen that P-gp expressing MES-SA/Dx5 (Figure 72 F) and KB-V1 
(Figure 72 I) cells accumulate less amount of fluorescent Calcein as compared to their P-gp 
negative MES-SA (Figure 72 E) and KB-3-1 (Figure 72 G) counterparts. The histogram of P-
gp positive cells is shifted to the right. The impact of P-gp on this accumulation is proven by 
the impact of the P-gp inhibitor Verapamil, which shifts the histogram to the direction of P-gp 
negative cells. The described panels show homogenous cell populations, while panel H shows 
the histograms of KB-V1 cells, which partially lost the P-gp upon long term cell culture, 
resulting in a heterogenous cell population. 
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Figure 72: Calcein AM accumulation measurement used as a rapid and sensitive flow cytometric 
assay for studying the function of P-glycoprotein on MES-SA and MES-SA/Dx5 cells. A: 
Visualization of Forward (FSC) and Side Scatter (SSC), modified from [343], B: Dot plot of MES-SA 
cells after staining with Calcein-AM and TO-PRO®-3 DNA dye, C: Gating out dead cells with TO-
PRO®-3 (fluorescence channel FL4) staining, D: Calcein-AM stained cells (fluorescence detection in 
FL1), only living cells (no fluorescence in FL4); Histograms of P-gp negative MES-SA (E) and KB-3-
1 (G) as well as of P-gp positive MES-SA/Dx5 (F) and KB-V1 (H,I) cells. Magenta curves show the 
autofluorescence of unstained cells, cyan curves show histograms of Calcein-AM stained cells, orange 
curves show cells that had been pre-incubated with Verapamil.  
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5.8. ROS determination  
 
5.8.1. DCFDA assay 
The use of DCFDA is the most frequently applied method for the measurement of reactive 
oxygen species. As illustrated in Figure 73, the principle of this assay is based on the 
fluorescence detection of the oxidation product of the non-fluorescent Dichlorofluorescin 
(DCF-H). It is applied in an esterified form as the Diacetate (DCFDA), which is non-
fluorescent and readily taken up by cells. Intracellularly, the reagent is cleaved by esterases to 
DCF-H. Upon oxidation by ROS the fluorescent Dichlorofluorescein (DCF) is formed 
[271,272]. 
 
 
 
Figure 73: Assay principle of ROS detection. The non-fluorescent Dichlorofluorescin diacetate 
(DCFDA) ester is taken up by the cells and cleaved by intracellular esterases to Dichlorofluorescin 
(DCF-H). Upon oxidation by ROS the fluorescent Dichlorofluorescein (DCF) is formed, which can be 
measured with the microplate reader [271,272]. 
  
150   
 
As detailed in the results section, the protocol for the measurement of reactive oxygen species 
(ROS) using DCFDA was thoroughly optimized on the basis of literature reports 
[135,275,283]. After harvesting and washing with PBS buffer, cells were re-suspended in 
PBS in a density of approximately 3 Mio cells per mL and incubated with 10 µM DCFDA (a 
10 mM stock solution was used, preferably prepared freshly or stored at -20 °C, keeping 
freeze-re-thawing cycles at a minimum) in a water bath shaker at 37 °C for 30 min. After 
washing with PBS, cells were plated to 96 well plates in a density of 20,000 cells/well in PBS. 
In each experiment a control reagent was applied, namely hydrogen peroxide or tert-butyl 
hydroperoxide. Additionally, for each tested compound, cell free controls were included using 
DCFDA solution in buffer to test for interaction of the test compounds with DCFDA (on the 
exemplary plate map in Figure 74: columns 1 and 2). Also untreated cells and DCFDA 
solutions were used, in order to distinguish the compound induced signal from unspecific 
signals as detailed in the results section (row A in Figure 74). 
 
 
Figure 74: exemplary plate layout for a typical DCFDA measurement. 
 
 
The fluorescence of DCF was detected at an emission wavelength of 535 nm upon excitation 
at 485 nm. Basal fluorescence was measured at t0 and upon addition of the test compounds in 
different concentrations, the changes in fluorescence were monitored in time intervals of 10 or 
20 min after addition of the test compound. Measurements were perforemed at 14 time points 
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tx where x = 1 referred to the measurement after 10 min or 20 min, and x = 14 to that after 
140 min or 280 min, respectively. Data was expressed as fold change of fluorescence 
compared to the basal levels (measurement of Sample at t0) and to the untreated cell control at 
the respective time-point (measurement of untreated control at tx) by the following 
normalization:  
 
𝑦 =
𝑆𝑎𝑚𝑝𝑙𝑒 𝑑𝑎𝑡𝑎(𝑡𝑥)
𝑆𝑎𝑚𝑝𝑙𝑒 𝑑𝑎𝑡𝑎(𝑡0) ∙ 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑑𝑎𝑡𝑎(𝑡𝑥)
 
 
 
 
5.8.2. HyPer fluorescent protein 
Changes in intracellular H2O2 levels can be tracked in real time using HyPer, a ratiometric 
genetically encoded fluorescent probe [297]. The fluorescence properties of circular permuted 
(cp) fluorescent proteins are sensitive to protein conformation. The fusion of cpYFP (yellow 
fluorescent protein) with the OxyR-RD regulatory domain of E. coli OxyR provides a sensor 
protein, which will show increased fluorescence upon selective oxidation by hydrogen 
peroxide [295]. The spectral properties of the reduced and oxidized sensor enable a 
ratiometric measurement. Stably transfected cell lines would be beneficial for the 
investigation of the effect of compounds on intracellular ROS – or H2O2 – levels, since 
transiently transfected cells have to be assayed within 24 to 48 h after transfection [301]. 
 
 
 
5.8.2.1. Preparation of stably HyPer-expressing cells 
Several people participated in the preparation of stably transfected cell lines, and I would like 
to acknowledge their work. The plasmids encoding the H2O2 sensitive fluorescent proteins 
HyPerC and the mutant HyPerC121s were kind gifts of Dr. Miklós Geiszt (Semmelweis 
University, Budapest, Hungary). I want to thank Zsuzsanna Nagy (working group of Dr. 
Gergely Szakács) for supervising me in performing the gene amplification and purification of 
the plasmids, and Nóra Kucsma (working group of Dr. Gergely Szakács) and Áron Szepesi 
(working group of Dr. Katalin Német) for performing the subsequent steps from the cloning 
of DNA into a lentiviral vector to the transduction and sorting of MES-SA and MES-SA/Dx5 
cells.  
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5.8.2.1.1. Transformation into Top10 competent E.coli cells 
In order to have sufficient DNA material, the first step of the protocol was the amplification 
of the received plasmids. For this purpose the DNA was transformed into Top10 competent E. 
coli cells (Life Technologies, Hungary) [344]. Two vials with each 100 µL cell suspension 
were taken from -80 °C and allowed to thaw on ice. 1 µL of the respective plasmid solution 
(with a DNA content of 1.4 µg/µL in case of HyPerC, and 0.55 µg/µL in case of HyPerC121s 
plasmids) was added to either of the vials and incubated on ice for 30 minutes. A 42 °C heat-
shock was applied to the vials for exactly 2 minutes, following the immediate placement on 
ice for 2 minutes [344,345]. After addition of 900 µL of lysogeny broth (LB) medium [346], 
the vials were incubated in a water bath shaker at 37 °C for 1 hour. 100 µL of the respective 
suspensions were plated out each on a 10 cm diameter kanamycin containing LB agar plate 
and incubated at 37 °C overnight with the agar side up and the lid side down. The remaining 
suspension was stored at 4 °C until the end of the procedure. 
 
 
Figure 75: HyPerC-vector sequence as provided by Evrogen [347]. 
 
 
As depicted in Figure 75, the original plasmids contain a sequence for kanamycin resistance 
[347]. Therefore, only transformed bacteria will be able to grow on the kanamycin containing 
plates. 
On the next day, one colony was picked per plate using a 200 µL pipet tip. The tip was 
transferred into a 50 mL falcon tube containing 10 mL of LB medium. In this (not to tightly 
closed) tube bacteria were allowed to grow at 37 °C for an additional 24 hours. The agar 
plates were stored at 4 °C until the end of the procedure. 
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5.8.2.1.2. Isolation and Purification of amplified plasmid DNA 
Plasmid DNA was isolated and purified from the bacteria using the QIAprep Spin Miniprep 
Kit (QIAGEN, Hungary) [348]. The process is based on the selective alkaline denaturation of 
high molecular weight DNA over closed circular double-stranded DNA. Upon re-
neutralization the chromosomal DNA renaturates to precipitate as a clot, while the plasmid 
DNA stays in the supernatant [349]. 
Underlined buffers and solutions were components of the QIAprep Spin Miniprep Kit 
(QIAGEN, Hungary) [348]. Prior to the procedure, buffers were controlled for precipitations. 
If precipitations were observed, buffers were heated to 37 °C to re-dissolve the components. 
The bacteria (as described in 5.8.2.1.1.) were centrifuged at 4500 x g at 25 °C for 3 min and 
the pellet was resuspended in 500 µL of buffer P1, which was prior supplemented with 
RNase A solution. 500 µL of buffer P2 was added and the vials were mixed thoroughly by 
inverting the tubes 4-6 times. After addition of 700 µL of buffer N3 the vials were mixed 
immediately and thoroughly by inverting the tubes 4-6 times, and centrifuged for 10 min at 
17949 x g and 25 °C. The supernatants were pipetted to QIAprep spin columns, and 
centrifuged (17949 x g, 25 °C) for 1 min. The filtrate was discarded and the columns washed 
with 500 µL buffer PB, following centrifugation for 1 min. After discarding the filtrate, 
columns were washed with 750 µL buffer PE (prior supplemented with ethanol), centrifuged 
for 1 min, and after discarding of the filtrate again centrifuged for 1 min in order to remove 
residual washing buffer. The columns were eluted into a 1.5 mL Eppendorf tube by twice 
adding 50 µL of water and centrifuging for 1 min after a 1 min exposure time.  
 
 
 
5.8.2.1.3. Quantification of DNA  
The amount of DNA in the samples was quantified using a NanoDrop™ 2000 (Thermo 
Scientific, Hungary). This device is a spectrophotometer capable of measuring small sample 
volumes [350]. From the absorbance spectra of a DNA sample, the quantity and purity of 
DNA can be estimated [351]. 
After cleaning of the optical pedestals of the instrument with 3 µL of MilliQ (MQ) water and 
a laboratory wipe, a background spectrum was recorded of 1 µL of the buffer used for the 
DNA-elution (MQ water). Following cleaning, the spectra of the DNA samples were 
measured. The instrument calculates the ratios of absorbance values recorded at 260/280 nm, 
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which is indicative for protein contaminations, and at 260/230 nm, which indicates other 
contaminations [350,351]. Results are given in Table 18. 
 
Table 18: Volumes of Media, Trypsin and buffer used for the different cell culture flasks 
plasmid 
quantity / 
[µg/µL] 
Absorbance 
at λ= 260nm 
Absorbance 
at λ= 280nm 
Ratio 
260/280 nm 
Ratio 
260/230 nm 
purity 
HyPerC 227.5 5.450 2.907 1.87 2.13 ok 
HyPerC121s 276.6 5.531 2.960 1.87 2.12 ok 
 
 
 
5.8.2.1.4. Transient expression and selection in neomycin G418 
A transient transfection with the plasmid was attempted in MES-SA, MES-SA/Dx5 and KB-
3-1 cells following selection in presence of G418 [347]. FuGENE®HD (Promega, Hungary) 
was used as a transfection reagent [301]. 
Cells were seeded into 6 well plates with a density of 0.2 Mio cells/well in 2 mL of culture 
medium. After an overnight incubation, the medium was removed and replaced by 1.5 mL of 
serum free DMEM.  
Per well an solution of 30 ng DNA (7.3 µL of HyPerC DNA and 7.2 µL of HyPerC121s 
DNA) in 100 µL serum free IMDM (Life technology, Hungary) medium was prepared and 
mixed gently with 6 µL of the room temperature thermostated FuGENE®HD reagent. 
Following a 30 minutes incubation time at room temperature the mixtures were added to the 
wells drop by drop and the cells were incubated at 37 °C overnight. At the next day 1.5 mL of 
complete DMEM medium was added per well. After yet another 24 hours incubation time the 
cells were spaced out in two wells in each 1.5 mL of DMEM. To one of them G418 was 
added in a concentration of 1 mg/mL, the other well served as an untreated control.  
At confluence, cells were investigated for fluorescence behavior; the untreated control was 
frozen, while the cells under selection were seeded into a T-25 flask and kept under G418 
selection for the next 10 days. 
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5.8.2.1.5. Lentiviral transfection 
As mentioned previously, the steps in this chapter were performed by Nóra Kucsma (working 
group of Dr. Gergely Szakács) and Áron Szepesi (working group of Dr. Katalin Német). 
The DNA was cloned into a lentiviral vector, and lentiviral particles were produced in 
HEK293T cells transfected by the calcium phosphate co-precipitation method 2nd generation 
lentiviral system. Viral titers were estimated from HEK cells infected with a dilution series of 
HyPerC (259) and HyPerC121s (260) virus supernatants. For the transduction of MES-SA 
and MES-SA/Dx5 cells, cells were seeded into 6 well plates at a density of 250.000 cells per 
well and allowed to attach overnight. At the next day, cells were transduced in 1.5 ml fresh 
DMEM with 75 or 200 µl virus supernatants and 15 µl (0.6 mg/ml) polybrene. At the 
following day, cells were supplied with an additional 1.5 ml of fresh DMEM. The next day 
(day 4), cells were passaged into T-25 (day 8) and subsequently to T-75 (day 10) culture 
flasks. Upon confluency the cells were sorted FACS Aria for fluorescence at 488/530 (±15) 
nm and seeded into T-25 flasks. Upon confluency cells were transferred to T-75 cells. 
Propagated sorted cells were frozen and measured at the attune flow cytometer [343]. The 
histograms characterizing the cells are shown in Figure 76. 
 
 
 
5.8.2.2. Real time measurement of intracellular H2O2-levels 
Additional to the microplate reader experiments (PerkinElmer EnSpire), real time 
measurements were performed with either a PerkinElmer Luminescence Spectrometer LS50B 
or a Varian Cary Eclipse Fluorescence Spectrophotometer in dual wavelengths kinetic mode. 
4x optical acryl cuvettes were used (67.655, Sarstedt, Hungary). A homogenous distribution 
of cells in the suspension was ensured with a mini magnetic stir bar (length: 5 mm, diameter: 
2 mm; 442-0361, VWR, Hungary). Fluorescence was detected simultaneously at the emission 
wavelength of 525 nm upon excitation at 490 and 420 nm and was followed over time. Times 
of compound addition were noted, in order to follow the kinetics of induced effects.  
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Figure 76: Histograms of transfected cells after sorting, detected using two filters to address the two 
excitation maxima (A, C, E, G: 405 nm, B, D, F, H: 488 nm). The auto-fluorescence of non-
transfected cells is shown in magenta, cells transfected with 75 µL viral supernatant are shown in 
violet, and cells transfected with 200 µL are shown in green. A,B show MES-SA cells transfected with 
HyPerC; C,D show MES-SA cells transfected with HyPerC121s; E,F show MES-SA/Dx5 cells 
transfected with HyPerC; G,H show MES-SA/Dx5 cells transfected with HyPerC121s. 
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6. Synthesis and analytical chemical methods 
 
6.1. Synthesis of a focused library 
 
General method: The Schiff bases were obtained by adding an ethanolic solution of the 
hydrazinyl component to the solution of the keto component in equimolar amounts, refluxing 
the mixture in the presence of catalytic amounts of acid. If not indicated otherwise, 
purification was carried out by recrystallization. 
Carbazides were prepared by adding an equimolar amount of hydrazine to the methanolic 
solution of the respective isothiocyanate [221]. Where necessary, purification was carried out 
by recrystallization. 
For the pyridinyl derivatives with ethyl group substitution in 5-position of the pyridine 
moiety (II-e, II-l, IV-c), 5-Ethylpicolinaldehyde (E-5) was prepared from 5-ethyl-2-methyl-
pyridine as reported [89,222]. 
 
 
5-ethyl-2-methyl-pyridine-N-oxid (E-2) 
 35 mL of hydrogenperoxid (35% solution, 0.41 mol) was added to a 
solution of 5-ethyl-2-methyl-pyridine (E-1, 21.76 mL, 0.17 mol) in 
glacial acetic acid (200 mL) and refluxed for 16 hours. After 
concentration, the reaction mixture was neutralized with sodium 
hydroxide and carbonate and the starting material was retrieved by  
extraction with petroleum ether. 5-Ethyl-2-methyl-pyridine-N-oxid was extracted from the 
aqueous phase with chloroform, dried over sodium sulphate and after removal of the solvent 
obtained as a bright yellow liquid in 99% yield. 
1
H-NMR (500 MHz, CDCl3): δ = 8.14 – 8.09 (m, 1Har, H-6), 7.12 (d, 
3
J(H,H) = 7.9 Hz, 1Har, H-3), 
7.00 (dd, 
4
J(H,H) = 1.3 Hz, 
3
J(H,H) = 7.9 Hz, 1Har, H-4), 2.55 (q, 
3
J(H,H) = 7.7 Hz, 2H, CH2CH3), 
2,48 (s, 3H, CH3), 1.20 (t,
 3
J(H,H) = 7.7 Hz, 3H, CH2CH3). 
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5-ethylpyridin-2-yl-methyl acetate (E-3) 
 A solution of 5-ethyl-2-methyl-pyridine-N-oxid (E-2, 22.28 g, 0.16 
mol) and acetic anhydride (28 mL, 0.23 mol) in glacial acetic acid (7 
mL) was refluxed for 3 hours, put on ice, neutralized, and extracted 
with methylene chloride. After removal of the solvent, the extract was 
dissolved in diethyl ether, washed with a saturated solution of sodium 
carbonate and dried over sodium sulphate to give the product in 85% 
yield. 
1
H-NMR (500 MHz, CDCl3): δ = 8.42 (d, 
4
J(H,H) = 2.1 Hz, 1Har, H-6), 7.50 (dd, 
4
J(H,H) = 2.2 Hz, 
3
J(H,H) = 7.9 Hz, 1Har, H-4), 7.24 (d, 
3
J(H,H) = 7.9 Hz, 1Har, H-3), 5.16 (s, 2H, CH2OAc), 2.63 (q, 
3
J(H,H) = 7.6 Hz, 2H, CH2CH3), 2.11 (s, 3H, OOCCH3), 1.22 (t,
 3
J(H,H) = 7.6 Hz, 3H, CH2CH3).  
13
C-NMR (126 MHz, CDCl3): δ = 170.79 (Cq, C=O), 153.04 (Cq,ar , C-2), 149.35 (C-Har, C-6), 138.70 
(Cq,ar, C-5), 136.11 (C-Har, C-4), 121.89 (C-Har, C-3), 66.98 (CH2OAc), 25.89 (CH2CH3), 21.01 
(OOCCH3), 15.36 (CH2CH3). 
 
5-ethylpyridin-2-yl-methanol (E-4) 
 5-ethylpyridin-2-yl-methyl acetate (E-3, 24.29 g, 0.14 mol) was 
dissolved in tetrahydrofuran and refluxed with an aqueous solution of 
sodium hydroxide (8.1 g, 0.20 mol) for 5 hours. After reboiling the 
reaction mixture was reboiled with activated charcoal, it was 
neutralized with glacial acetic acid, filtered. After concentration of the  
crude product under reduced pressure, it was dissolved in a saturated solution of sodium 
hydrogen carbonate, extracted with diethyl ether and dried over sodium sulphate to give the 
product as a brown oil in 80% yield.  
1
H-NMR (500 MHz, CDCl3): δ = 8.32 (d, 
4
J(H,H) = 1.9 Hz, 1Har, H-6), 7.48 (dd, 
4
J(H,H) = 2.2 Hz, 
3
J(H,H) = 7.9 Hz, 1Har, H-4), 7.20 (d, 
3
J(H,H) = 7.9 Hz, 1Har, H-3), 4.70 (s, 2H, CH2OH), 2.60 (q, 
3
J(H,H) = 7.6 Hz, 2H, CH2CH3), 1.20 (t, 
3
J(H,H) = 7.6 Hz, 3H, CH2CH3).  
13
C-NMR (500 MHz, CDCl3): δ = 157.10 (Cq,ar, C-5), 148.12 (C-Har, C-6), 137.99 (Cq,ar, C-2), 136.34 
(C-Har, C-4), 120.55 (C-Har, C-3), 64.29 (CH2OH), 25.81 (CH2CH3), 15.40 (CH2CH3). 
 
  
6. Synthesis and analytical chemical methods  159 
 
 
5-ethylpicolinaldehyde (E-5) 
 Manganese dioxide was prepared freshly by simultaneously adding a 
solution of Manganese(II)sulphate hydrate (14.5 g, 0.09 mol in 25mL 
water) and sodium hydroxide (7.6 g, 0.19 mol in 20 mL water) to a 
warm solution of potassium permanganate KMnO4 (15.5 g, 0.10 mol in 
100 mL water), refluxing the mixture for 6 hours, filtered and dried  
under reduced pressure. 5-ethylpyridin-2-yl-methanol (E-4, 12.82 g, 93.4 mmol) was 
dissolved in chloroform and given to the dried MnO2 (16.24 g, 186.8 mmol). The mixture 
was refluxed in an ultrasonic bath for 5 days, filtered and purified with column 
chromatography using a mixture petroleum ether and ethyl acetate (4:1) on silica gel to give 
the product as a bright yellow liquid in 61% yield.  
1
H-NMR (500 MHz, CDCl3): δ = 10.03 (s, 1H, CHO), 8.60 (d, 
4
J(H,H) = 1.9 Hz, 1Har, H-6), 7.87 (d, 
3
J(H,H) = 8.0 Hz, 1Har, H-3), 7.70 – 7.63 (m, 1Har, H-4), 2.73 (q, 
3
J(H,H) = 7.6 Hz, 2H, CH2CH3), 
1.28 (t, 
3
J(H,H) = 7.6 Hz, 3H, CH2CH3).  
13
C-NMR (500 MHz, CDCl3): δ = 193.30 (CHO), 151.06 (Cq,ar, C-2), 150.18 (C-Har, C-6), 144.67 
(Cq,ar, C-5), 136.28 (C-Har, C-4), 121.72 (C-Har, C-3), 26.43 (CH2CH3), 15.02 (CH2CH3). 
 
 
 
Preparation of Carbazides: 
 
N-(4-methoxyphenyl)hydrazinecarbothioamide (C-1) 
 The reaction of 4-methoxyphenylisothiocyanate (1.000 g, 
6.052 mmol) with hydrazine (0.37 mL 80% aqueous, 
6.052 mmol) resulted in white crystals of the product in 97% 
yield (1.163 g, 5.90 mmol). 
1
H-NMR (500 MHz, DMSO-d6): δ = 9.51 (s, 1H, NH), 8.94 (s, 1H, NH), 7.44 (d, 
3
J(H,H) = 8.2 Hz, 
2Har, H-3, H-5), 6.88 – 6.83 (m, 2Har, H-2, H-6), 4.70 (s, 2H, NH2), 3.74 (s, 3H, OCH3).  
13
C-NMR (126 MHz, DMSO-d6): δ = 179.82 (Cq, C=S), 156.13 (Cq,ar, C-4), 132.17 (Cq,ar, C-1), 
125.51 (2C-Har, C-2, C-6), 113.20 (2C-Har, C-3, C-5), 55.16 (OCH3). 
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N-(4-tolyl)hydrazinecarbothioamide (C-2) 
The reaction of 4-tolylisothiocyanate (500 mg, 3.35 mmol) 
with hydrazine (0.20 mL 80% aqueous, 3.35 mmol) resulted in 
white needles of the product in 98% yield (594 mg, 
3.27 mmol).  
1
H-NMR (500 MHz, DMSO-d6): δ = 9.55 (s, 1H, N-H), 9.00 (s, 1H, N-H), 7.49 (d, 
3
J(H,H) = 7.2 Hz, 
2Har, H-3, H-5), 7.10 (d, 
3
J(H,H) = 8.2 Hz, 2Har, H-2, H-6), 4.74 (s, 2H, NH2), 2.27 (s, 3H, CH3).  
13
C-NMR (126 MHz, DMSO-d6): δ = 179.49 (Cq, C=S), 136.64 (Cq,ar, C-4), 133.14 (Cq,ar, C-1), 
128.45 (2C-Har, C-2, C6), 123.51 (2C-Har, C-3, C5), 20.43 (CH3). 
 
N-(4-nitrophenyl)hydrazinecarbothioamide (C-3) 
 
 
The reaction of 4-nitrophenylisothiocyanate (1.000 g, 
5.56 mmol) with hydrazine (0.34 mL 80% aqueous, 
5.56 mmol), was carried out in a mixture of toluene and 
methanol, due to the low solubility of the starting material and 
resulted in ochre product crystals in 93% yield (1.095 g, 
5.16 mmol).
1
H-NMR (500 MHz, DMSO-d6): δ = 9.55 (s, 1H, N-H), 8.14 (s, 4Har, ), 7.83 (s, 1H, N-H), 6.55 (bs, 
2H, NH2).  
13
C-NMR (126 MHz, DMSO-d6): δ = 178.77 (Cq, C=S), 145.73 (Cq,ar, C-4), 142.49 (Cq,ar, C-1), 
123.80 (2C-Har, C-3, C5), 122.05 (2C-Har, C-2, C6). 
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Preparation of β-isatin thiosemicarbazones (Figure 16, box I): 
 
N-(4’-methoxyphenyl)-2-(2-oxoindoline-3-ylidene)hydrazinecarbothioamide (I-a) [102] 
 The reaction of isatin (147.13 mg, 1.0 mmol) with N-(4-
methoxyphenyl)hydrazinecarbothioamide C-1 (197.26 mg, 
1.0 mmol) in ethanolic solution under HCl-catalysis 
resulted in a yellow fluffy precipitate, which was identified 
as the product in 89% yield (291 mg, 0.89 mmol). 
1
H-NMR (500 MHz, DMSO-d6): δ = 12.75 (s, 1H, N-H), 11.22 (s, 1H, N-H), 10.70 (s, 1H, N-H), 7.76 
(d, 
3
J(H,H) = 7.6 Hz, 1Har, H-4), 7.50 – 7.44 (m, 2Har, H-2’, H-6’), 7.36 (td, 
3
J(H,H) = 7.7 Hz, 
4
J(H,H) = 1.3 Hz, 1Har, H-6), 7.13 – 7.08 (m, 1Har, H-5), 6.99 – 6.95 (m, 2Har, H-3’, H-5’), 6.94 (d, 
3
J(H,H) = 7.9 Hz, 1Har, H-7), 3.78 (s, 3H, OCH3). 
13
C-NMR (126 MHz, DMSO-d6): δ = 176.51 (Cq, C=S), 162.64 (Cq, C=O, C-2), 157.35 (Cq,ar, C-
OCH3, C-4’), 142.37 (Cq,ar, bridge, C-7a), 132.01 (Cq,ar, C-1’), 131.28 (C-Har, C-6), 131.25 (Cq, C=N, 
C-3), 127.14 (C-Har, C-5), 122.30 (C-Har, C-4), 121.26 (2C-Har, C-2’, C-6’), 119.92 (Cq,ar, bridge, C-
3a), 113.54 (2C-Har, C-3’, C-5’), 111.02 (C-Har, C-7), 55.25 (OCH3).  
Anal. Calcd. for C16H14N4SO2: C: 58.88; H: 4.32; N: 17.17. Found: C: 58.58; H: 4.349; N: 16.95. 
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N-(4’-methoxyphenyl)-2-(2-oxo-5-(trifluoromethoxy)-indoline-3-ylidene)hydrazine-
carbothioamide) (I-b) 
 The reaction of 5-trifluoromethoxyisatin (50 mg, 
0.22 mmol) with N-(4-methoxyphenyl)hydrazinecarbothio-
amide C-1 (43 mg, 0.22 mmol) in ethanolic solution under 
HCl-catalysis resulted in a yellow fluffy precipitate, which 
was identified as the product in 70% yield (65.7 mg, 
0.16 mmol). 
1
H-NMR (500 MHz, DMSO-d6): δ = 12.60 (s, 1H, N-H), 11.36 (s, 1H, N-H), 10.78 (s, 1H, N-H), 7.78 
(s, 1Har, H-4), 7.49 – 7.41 (m, 2Har, H-2’, H-6’), 7.41 – 7.31 (m, 1Har, H-6), 7.02 (d, 
3
J(H,H) = 5.0 Hz, 
1Har, H-7), 7.01 – 6.95 (m, 2Har, H-3’, H-5’), 3.78 (s, 3H, OCH3).  
13
C-NMR (126 MHz, DMSO-d6): δ = 176.56 (Cq, C=S), 162.70 (Cq, C=O, C-2), 157.50 (Cq,ar, C-
OCH3, C-4’), 143.53 (Cq,ar, C-OCF3, C-5), 141.23 (Cq,ar, C-1’), 131.06 (Cq,ar, bridge, C-7a), 130.92 
(Cq, C=N, C-3), 127.31 (2C-Har, C-2’, C-6’), 124.03 (C-Har, C-6), 121.45 (Cq,ar, bridge, C-3a), 120.66 
(Cq, d {121.19, 119.15}, 
1
J(C,F) = 255.7 Hz, OCF3), 114.35 (2C-Har, C-3’, C-5’), 113.62 (C-Har, C-4), 
112.10 (C-Har, C-7), 55.27 (OCH3).  
Anal. Calcd. for C17H13N4SO3F3: C: 49.76; H: 3.19; N: 13.65. Found: C: 49.61; H: 3.477; N: 13.53.  
 
N-(4’-tolyl)-2-(2-oxoindoline-3-ylidene)hydrazinecarbothioamide (I-c) [103] 
 The reaction of isatin (147.13 mg, 1.0 mmol) with N-(4-
tolyl)hydrazinecarbothioamide C-2 (181.26 mg, 1.0 mmol) 
in ethanolic solution under acetic acid catalysis resulted in a 
yellow fluffy precipitate, which was identified as the 
product in 53% yield (162.8 mg, 0.53 mmol).
1
H-NMR (500 MHz, DMSO-d6): δ = 12.78 (s, 1H, NH), 11.22 (s, 1H, NH), 10.71 (s, 1H, NH), 7.78 
(d, 
3
J(H,H) = 7.5 Hz, 1H, H-4), 7.49 (d, 
3
J(H,H) = 8.3 Hz, 2Har, H-3’, H-5’), 7.36 (td, 
4
J(H,H) = 
1.2 Hz, 
3
J(H,H) = 7.7 Hz, 1H, H-6), 7.22 (d, 
3
J(H,H) = 8.2 Hz, 2Har, H-2’, H-6’), 7.10 (td, 
4
J(H,H) = 
0.7 Hz, 
3
J(H,H) = 7.6 Hz, 1H, H-5), 6.94 (d, 
3
J(H,H) = 7.8 Hz, 1H, H-7), 2.33 (s, 3H, CH3).  
13
C-NMR (126 MHz, DMSO-d6): δ = 176.26 (Cq, C=S), 162.63 (Cq, C=O), 142.39 (Cq,ar, bridge, C-
7a), 135.85 (Cq,ar, C-4’), 135.27 (Cq,ar, C-1’), 132.06 (Cq, C=N, C-3), 131.29 (C-Har, C-6), 128.77 (2C-
Har, C-3’, C5’), 125.41 (2C-Har, C-2’, C-6’), 122.27 (C-Har, C-4), 121.30 (C-Har, C-5), 119.89 (C-Har, 
C-7), 111.01 (Cq,ar, bridge, C-3a), 20.57 (CH3).  
Anal. Calcd. for C16H14N4SO: C: 61.92; H: 4.55; N: 18.05. Found: C: 62.4; H: 4.402; N: 18.54. 
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N-(4’-nitrophenyl)-2-(2-oxoindoline-3-ylidene)hydrazinecarbothioamide (I-d) [103] 
 The reaction of isatin (147.13 mg, 1.0 mmol) with N-(4-
tolyl)hydrazinecarbothioamide C-3 (212.23 mg, 1.0 mmol) 
in ethanolic solution under acetic acid catalysis resulted in 
an orange-yellowish fluffy precipitate, which was identified 
as the product in 71% yield (242 mg, 0.71 mmol).  
1
H-NMR (500 MHz, DMSO-d6): δ = 13.01 (s, 1H, N-H), 11.28 (s, 1H, N-H), 11.10 (s, 1H, N-H), 8.36 
– 8.24 (m, 2Har, H-3’, H-5’), 8.14 – 8.03 (m, 2Har, H-2’, H-6’), 7.78 (d, 
3
J(H,H) = 7.4 Hz, 1Har, H-4), 
7.40 (td, 
4
J(H,H) = 1.2 Hz,
 3
J(H,H) = 7.7 Hz, 1Har, H-6), 7.13 (td, 
4
J(H,H) = 0.8 Hz, 
3
J(H,H) = 7.6 Hz, 
1Har, H-5), 6.96 (d, 
3
J(H,H) = 7.8 Hz, 1Har, H-7).  
13
C-NMR (126 MHz, DMSO-d6): δ = 176.02 (Cq, C=S), 162.66 (Cq, C=O), 144.59 (Cq,ar , C-1’), 
144.09 (Cq,ar, C-4’), 142.72 (Cq,ar, bridge, C-7a), 133.24 (Cq, C=N, C-3), 131.75 (C-Har, C-6), 124.61 
(2C-Har, C-2’, C6’), 123.91 (2C-Har, C-3’, C5’), 122.38 (C-Har, C-5), 121.54 (C-Har, C-7), 119.63 
(Cq,ar, bridge, C-3a), 111.16 (C-Har, C-4).  
Anal. Calcd. for C15H11N5SO3: C: 52.78; H: 3.25; N: 20.52. Found: C: 53.24; H: 3.57; N: 20.9. 
 
 
 
Preparation of pyridinyl thiosemicarbazones (Figure 16, box II): 
 
N-(4’-methoxyphenyl)-2-(1-(pyridin-2-yl)ethylidene)hydrazinecarbothioamide (II-c) 
 The reaction of 1-(pyridin-2-yl)ethanone (0.15 mL, 
1.325 mmol) with N-(4-tolyl)hydrazinecarbothioamide 
C-2 (250 mg, 1.325 mmol) in ethanolic solution under 
acetic acid catalysis resulted in a white precipitate, 
which was recrystallized to afford the product in 63% yield (250.6 mg, 0.83 mmol).  
1
H-NMR (500 MHz, DMSO-d6): δ = 10.54 (s, 1H, NH), 10.07 (s, 1H, NH), 8.60 (ddd, 
5
J(H,H) = 
0.9 Hz, 
4
J(H,H) = 1.9 Hz, 
3
J(H,H) = 4.7 Hz, 1Har, H-6), 8.54 (d, 
3
J(H,H) = 8.2 Hz, 1Har, H-3), 7.84 – 
7.75 (sm, 1Har, H-4), 7.43 – 7.36 (sm, 3Har, H-5, H-3’, H-5’), 6.97 – 6.91 (sm, 2Har, H-2’, H-6’), 3.78 
(s, 3H, OCH3), 2.46 (s, 3H, CH3). 
13
C-NMR (126 MHz, DMSO-d6): δ = 177.74 (Cq, C=S), 157.24 (Cq,ar, C-4’), 154.71 (Cq,ar, C-2), 49.03 
(Cq C=N), 148.57 (C-Har, C-6), 136.45 (C-Har, C-4), 132.17 (Cq,ar, C-1’), 127.86 (2C-Har, C-2’, C-6’), 
124.16 (C-Har, C-5), 121.34 (C-Har, C-3), 113.45 (2C-Har, C-3’, C-5’), 55.40 (OCH3), 12.50 (CH3).  
Anal. Calcd. for C15H16N4SO: C: 59.98; H: 5.37; N: 18.65. Found: C: 60.0; H: 5.3; N: 18.76. 
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2-((5-ethylpyridin-2-yl)methylene)-N-(4’-methoxyphenyl)hydrazinecarbothioamide (II-
e) 
 The reaction of 5-ethylpicolinaldehyde (E-5, 200 mg, 
1.48 mmol) with N-(4-methoxyphenyl)hydrazinecarbo-
thioamide C-1 (291.9 mg, 1.48 mmol) in ethanolic 
solution under acetic acid catalysis resulted in white 
crystals, of product in 60% yield (229 mg, 0.73 mmol). 
The product seemed to be thermo labile, since it decomposed upon a further recrystallization 
trial. 
1
H-NMR (500 MHz, DMSO-d6): δ = 11.87 (s, 1H, NH), 10.09 (s, 1H, NH), 8.44 (dd, 
5
J(H,H) = 
0.5 Hz, 
4
J(H,H) = 1.9 Hz, 1Har, H-6), 8.35 (d, 
3
J(H,H) = 8.2 Hz, 1Har, H-3), 8.17 (s, 1H, HC=N), 7.69 
(dd, 
4
J(H,H) = 2.2 Hz,
 3
J(H,H) = 8.2 Hz, 1Har, H-4), 7.43 – 7.37 (sm, 2Har, H-3’, H-5’), 6.97 – 6.91 
(sm, 2Har, H-2’, H-6’), 3.77 (s, 3H, OCH3), 2.65 (q, 
3
J(H,H) = 7.6 Hz, 2H, CH2CH3), 1.21 (t, 
3
J(H,H) 
= 7.6 Hz, 3H, CH2CH3). 
13
C-NMR (126 MHz, DMSO-d6): δ = 176.62 (Cq, C=S), 157.00 (Cq,ar, C-4’), 150.93 (Cq,ar, C-2), 
148.72 (C-Har, C-6), 142.93 (HC=N), 139.75 (Cq,ar, C-5), 135.70 (C-Har, C-4), 131.83 (Cq,ar, C-1’), 
127.59 (2C-Har, C-2’, C-6’), 120.20 (C-Har, C-3), 113.26 (2C-Har, C-3’, C-5’), 55.21 (OCH3), 25.22 
(CH2CH3), 15.09 (CH2CH3).  
Purity was determined with HPLC MS to be ≥ 95% (m/z calculated for [M]: 314.41, found 315.2 for 
[M + H]
+
).  
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2-(pyridin-2-ylmethylene)-N-(4’-tolyl)hydrazinecarbothioamide (II-f) 
 The reaction of pyridine-2-carbaldehyde (160.7 mg, 
1.5 mmol) with N-(4-tolyl)hydrazinecarbothioamide C-2 
(271.9 mg, 1.5 mmol) in ethanolic solution under acetic 
acid catalysis resulted in a white fluffy precipitate, which  
was identified as the product in 83% yield (334.5 mg, 1.237 mmol). 
1
H-NMR (500 MHz, DMSO-d6): δ = 11.95 (s, 1H, N-H), 10.15 (s, 1H, N-H), 8.58 (ddd, 
5
J(H,H) = 
1.0 Hz,
 4
J(H,H) = 1.7 Hz,
 3
J(H,H) = 4.9 Hz, 1Har, H-6), 8.43 (d, 
3
J(H,H) = 8.0 Hz, 1Har, H-4), 8.19 (s, 
1H, CHN), 7.84 (ddd, 
5
J(H,H) = 0.9 Hz,
 4
J(H,H) = 1.8 Hz,
 3
J(H,H) = 7.6 Hz, 1Har, H-3), 7.44 – 7.40 
(m, 2Har, H-3’, H-5’), 7.39 (ddd, 
3
J(H,H) = 1.2 Hz, 
3
J(H,H) = 4.9 Hz,
 3
J(H,H) = 7.5 Hz, 1Har, H-5), 
7.18 (d, 
3
J(H,H) = 8.0 Hz, 2Har, H-2’, H-6’), 2.32 (s, 3H, CH3).  
13
C-NMR (126 MHz, DMSO-d6): δ = 176.54 (Cq, C=S), 153.26 (Cq,ar, C-2), 149.36 (C-H, CHN), 
143.00 (C-Har, C-6), 136.48 (C-Har, C-4), 136.45 (Cq,ar, C-CH3, C-4’), 134.74 (Cq,ar, C-1’), 128.61 
(2C-Har, C-3’, C5’), 125.98 (2C-Har, C-2’, C6’) , 124.22 (C-Har, C-5), 120.64 (C-Har, C-3), 20.65 
(CH3).  
Anal. Calcd. for C14H14N4S: C: 62.2; H: 5.22; N: 20.72. Found: C: 62.36; H: 5.228; N: 20.93.  
 
2-(1-(pyridin-2-yl)ethylidene)-N-(4’-tolyl)hydrazinecarbothioamide) (II-g) 
 The reaction of 1-(pyridin-2-yl)ethanone (0.17 mL, 
1.5 mmol) with N-(4-tolyl)hydrazinecarbothioamide C-2 
(271.9 mg, 1.5 mmol) in ethanolic solution under acetic 
acid catalysis resulted in white crystals, which were
recrystallized from a CHCl3:EtOH mixture (1.5:1) to afford the product in 41% yield 
(174 mg, 0.61 mmol).  
1
H-NMR (500 MHz, DMSO-d6): δ = 10.58 (s, 1H, N-H), 10.10 (s, 1H, N-H), 8.60 (ddd, 
5
J(H,H) = 
0.9 Hz, 
4
J(H,H) = 1.7,
 3
J(H,H) = 4.7 Hz, 1Har, H-6), 8.52 (d, 
3
J(H,H) = 8.2 Hz, 1Har, H-3), 7.81 (ddd, 
5
J(H,H) = 1.9 Hz, 
5
J(H,H) = 7.4 Hz, 
5
J(H,H) = 8.2 Hz, 1Har, H-4), 7.45 – 7.37 (m, 3Har, H-5, H-3’, H-
5’), 7.18 (d, 3J(H,H) = 7.9 Hz, 2Har, H-2’, H-6’), 2.46 (s, 3H, C=NCH3), 2.32 (s, 3H, CH3).  
13
C-NMR (126 MHz, DMSO-d6): δ = 177.25 (Cq, C=S), 154.50 (Cq,ar, C-2), 148.98 (Cq, C=N), 148.41 
(C-Har, C-6), 136.52 (Cq,ar, C-4’), 136.30 (C-Har, C-4), 134.65 (Cq,ar, C-1’), 128.50 (2C-Har, C-3’, C-
5’), 125.94 (2C-Har, C-2’, C-6’), 124.01 (C-Har, C-5), 121.16 (C-Har, C-3), 20.56 (CH3), 12.37 
(C=NCH3).  
Anal. Calcd. for C15H16N4S: C: 63.35; H: 5.67; N: 19.70. Found: C: 62.92; H: 5.602; N: 19.81.  
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2-(pyridin-2-ylmethylene)-N-(4-nitrophenyl)hydrazinecarbothioamide (II-j) 
 The reaction of picolinaldehyde (E-5, 160.7 mg, 
1.5 mmol) with N-(4-nitrophenyl)hydrazinecarbothio-
amide C-3 (318.3 mg, 1.5 mmol) in ethanolic solution 
under acetic acid catalysis resulted in a bright yellow
fluffy precipitate, which was recrystallized to afford the product in 97% yield (437 mg, 
1.45 mmol).  
1
H-NMR (500 MHz, DMSO-d6): δ = 12.34 (s, 1H, N-H), 10.53 (s, 1H, N-H), 8.61 (ddd, 
5
J(H,H) = 
0.9 Hz, 
4
J(H,H) = 1.6 Hz, 
3
J(H,H) = 4.8 Hz, 1Har, H-6), 8.41 (d, 
3
J(H,H) = 8.0 Hz, 1Har, H-3), 8.28 – 
8.23 (m, 3H, CHN, H-7, 2Har, H-9, H-9’), 8.08 – 8.03 (m, 2Har, H-8, H-8’), 7.89 (td, 
4
J(H,H) = 
1.5 Hz, 
3
J(H,H) = 7.7 Hz, 1Har, H-4), 7.43 (ddd, 
5
J(H,H) = 1.1 Hz, 
4
J(H,H) = 4.9 Hz, 
3
J(H,H) = 
7.5 Hz, 1Har, H-5).  
13
C-NMR (126 MHz, DMSO-d6): δ = 175.83 (Cq, C=S), 152.78 (Cq,ar, C-2), 149.42 (C-Har, C-6), 
145.19 (Cq,ar, C-4’), 144.23 (CHN), 143.64 (Cq,ar, C-1’), 136.50 (C-Har, C-4), 124.68 (2C-Har, C-3’, C-
5’), 124.46 (C-Har, C-5), 123.68 (2C-Har, C-2’, C-6’), 120.74 (C-Har, C-3). 
Anal. Calcd. for C13H11N5SO2: C: 51.82; H: 3.68; N: 23.24. Found: C: 52.13; H: 3.679; N: 23.51.  
 
2-((5-ethylpyridin-2-yl)methylene)-N-(4’-nitrophenyl)hydrazinecarbothioamide (II-k) 
 The reaction of 5-ethylpicolinaldehyde (E-5, 202.74 mg, 
1.5 mmol) with N-(4-nitrophenyl)hydrazinecarbothio-
amide C-3 (318.3 mg, 1.5 mmol) in ethanolic solution 
under acetic acid catalysis resulted in orange crystals,
which provided the pure product in 49% yield (242 mg, 0.74 mmol) after column 
chromatography and recrystallization.  
1
H-NMR (500 MHz, DMSO-d6): δ = 12.21 (bs, 1H, N-H), 10.52 (bs, 1H, N-H), 8.47 (d, 
4
J(H,H) = 
1.6 Hz, 1Har, H-6), 8.32 (d, 
3
J(H,H) = 7.9 Hz, 1Har, H-3), 8.27 – 8.24 (sm, 2Har, H-3’, H-5’), 8.23 (s, 
1H, HC=N), 8.07 – 8.03 (sm, 2Har, H-2’, H-6’), 7.74 (dd, 
4
J(H,H) = 2.0 Hz,
 3
J(H,H) = 8.4 Hz, 1Har, H-
4), 2.67 (q, 
3
J(H,H) = 7.6 Hz, 2H, CH2CH3), 1.22 (t, 
3
J(H,H) = 7.6 Hz, 3H, CH2CH3).  
13
C-NMR (126 MHz, DMSO-d6): δ = 175.71 (Cq, C=S), 150.53 (Cq,ar, C-2), 148.91 (C-Har, C-6), 
145.31 (Cq,ar, C-1’), 144.39 (C=NH), 143.54 (Cq,ar, C-4’), 140.16 (Cq,ar, C-5), 135.77 (C-Har, C-4), 
124.62 (C-Har, C-3, 123.68 (2C-Har, C-3’, C-5’), 120.44 (2C-Har, C-2’, C-6’), 25.25 (CH2CH3), 15.07 
(CH2CH3).  
Anal. Calcd. for C15H15N5SO2×0.5 H2O: C: 53.24; H: 4.77; N: 20.70. Found: C: 53.44; H: 4.72; N: 
20.75.  
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Preparation of the acetaniline thiosemicarbazone  
(1-(1-(2-aminophenyl)ethylidene)amino)-3-(4’-methoxyphenyl)thiourea (II-p): 
 The reaction of 2-aceto-anilin (0.11 mL, 1.27 mmol) 
with 2-hydrazino-benzothiazole (250 mg, 1.27 mmol) in 
ethanolic solution under acetic acid catalysis delivered 
the product as a bright yellow solid in 10% yield
(38 mg, 0.121 mmol) after column chromatography (PE:EE 4:1) recrystallization.  
1
H-NMR (500 MHz, DMSO-d6): δ = 10.44 (s, 1H, N-H), 9.69 (s, 1H, N-H), 7.46 (d, 
3
J(H,H) = 9.1 Hz, 
2Har, H-2’, H-6’), 7.36 (dd,
 4
J(H,H) = 1.4 Hz, 
3
J(H,H) = 8.0 Hz, 1Har, H-6), 7.06 – 7.01 (sm, 1Har, H-
4), 6.92 – 6.88 (m, 2Har, H-3’, H-5’), 6.71 (dd, 
4
J(H,H) = 1.1 Hz, 
3
J(H,H) = 8.0 Hz, 1Har, H-3), 6.57 – 
6.52 (sm, 1Har, H-5), 3.75 (s, 3H, OCH3), 2.32 (s, 3H, CH3) – NH2 not visible. The purity of the 
compound was determined with HPLC MS to be between 75% (detection at 254 nm) and 85% 
(detection at 280 nm) (m/z calculated for [M]: 314.41, found 315.2 for [M + H]
+
). This amount of 
impurity will lead to an uncertainty of pIC50 estimations, which however lies within the standard error 
of the experiments. In the thesis, compound II-p is compared to its pyridinyl thiosemicarbazone 
counterpart II-c. The toxicities of these two compounds are significantly different: depending on the 
investigated cell lines, II-c is 1.49-2.75 log units more toxic than II-p. Therefore, the drawn 
conclusions might still be considered, despite the remarkable impurity of this compound. 
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Preparation of hydroxyphenyl thiosemicarbazones (Figure 16, box III): 
 
2-(2-hydroxybenzylidene)-N-(4’-methoxyphenyl)hydrazinecarbothioamide (III-b) 
 Salicylic aldehyde (0.135 mL, 1.267 mmol) was reacted 
with N-(4-methoxyphenyl)hydrazinecarbothioamide C-1 
(250 mg, 1.267 mmol) in ethanolic solution under acetic 
acid catalysis. The crude product was purified with
column chromatography (PE:EE 4:1) and allowed to crystallize at -20°C. The product was 
obtained as white crystals in a yield of 62% (236 mg, 0.78 mmol).  
1
H-NMR (500 MHz, CDCl3): δ = 10.92 (s, 1H, N-H), 8.55 (s, 1H, N-H), 7.52 – 7.48 (sm, 2Har, H-3’, 
H-5’), 7.37 – 7.31 (m, 2H, CHN, 1Har, H-4), 7.29 (dd, 
4
J(H,H) = 1.6 Hz, 
3
J(H,H) = 7.6 Hz, 1Har, H-6), 
7.04 (d, 
3
J(H,H) = 7.9 Hz, 1Har, H-3), 6.95 (td, 
4
J(H,H) = 1.1 Hz,
 3
J(H,H) = 7.6 Hz, 1Har, H-5), 6.89 – 
6.84 (sm, 2Har, H-2’, H-6’), 3.79 (s, 3H, OCH3) – OH not visible.  
13
C-NMR (126 MHz, CDCl3): δ = 158.90 (Cq, C=S), 158.83 (CHN), 156.78 (Cq,ar, C-2), 150.04 (Cq,ar, 
C-4’), 132.15 (C-Har, C-4), 131.75 (C-Har, C-6), 131.52 (Cq,ar, C-1’), 122.35 (2C-Har, C-2’, C6’), 
119.82 (C-Har, C-5), 118.31 (Cq,ar, C-1), 116.97 (C-Har, C-3), 114.41 (2C-Har, C-3’, C-5’), 55.67 
(OCH3).  
Anal. Calcd. for C15H15N3SO2: C: 59.78; H: 5.02; N: 13.94. Found: C: 59.75; H: 5.047; N: 14.11. 
 
2-(2-hydroxybenzylidene)-N-(4’-tolyl)hydrazinecarbothioamide (III-c)  
 The reaction of salicylic aldehyde (0.147 mL, 
1.379 mmol) with N-(4-tolyl)hydrazinecarbothioamide 
C-2 (250 mg, 1.267 mmol) in ethanolic solution under 
acetic acid catalysis resulted in yellowish crystals, which  
delivered the pure product in 34% yield (133.8 mg, 0.47 mmol) after recrystallization.  
1
H-NMR (500 MHz, DMSO-d6): δ = 11.67 (s, 1H, OH), 9.94 (s, 2 N-H), 8.48 (s, 1H, CHN), 8.04 (d, 
3
J(H,H) = 7.6 Hz, 1Har, H-6), 7.45 – 7.39 (sm, 2Har, H-3’, H-5’), 7.25 – 7.20 (sm, 1Har, H-4), 7.15 (d, 
3
J(H,H) = 8.1 Hz, 2Har, H-2’, H-6’), 6.87 (dd,
 4
J(H,H) = 0.9 Hz, 
3
J(H,H) = 8.2 Hz, 1Har, H-5), 6.82 (t, 
3
J(H,H) = 7.5 Hz, 1Har, H-3), 2.30 (s, 3H, CH3).  
13
C NMR (101 MHz, DMSO-d6): δ = 175.77 (Cq, C=S), 156.54 (CHN), 139.88 (Cq,ar, C-2), 136.57 
(Cq,ar, C-1’), 134.30 (C-Har, C-4), 131.24 (C-Har, C-6), 128.47 (2C-Har, C-3’, C-5’), 127.05 (Cq,ar, C-
4’), 125.64 (2C-Har, C-2’, C6’), 120.27 (Cq,ar, C-1), 119.19 (C-Har, C-5), 116.01 (C-Har, C-3), 20.58 
(CH3).  
Anal. Calcd. for C15H15N3SO: C: 63.13; H: 5.30; N: 14.73. Found: C: 63.12; H: 5.249; N: 14.89.  
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Preparation of arylhydrazones (Figure 16, box IV): 
4-hydrazinyl-6-methoxypyrimidine necessary for the synthesis of the arylhydrazones IV-a-c 
and VII-d was prepared in a two-step approach starting from 4,6-dichloropyrimidine 
[89,222].  
 
4-chloro-6-methoxypyrimidine (E-7)
 To a cooled solution (-10 °C) of 4,6-dichloropyrimidine (E-6, 5 g, 33.56 
mmol) in dry methanol one equivalent of sodium hydride (titrated solution 
in dry methanol) was added, the solution was allowed to warm to room 
temperature and react for 48 hours. The solvent was removed, 
the crude product dissolved in brine and extracted with chloroform and used without further 
purification.  
1
H-NMR (500 MHz, DMSO-d6): δ = 8.68 (d, 
5
J(H,H) = 0.8 Hz, 1Har, H-2), 7.18 (d, 
5
J(H,H) = 0.9 Hz, 
1Har, H-5), 3.96 (s, 3H, OCH3). 
 
4-hydrazinyl-6-methoxypyrimidine (E-8) 
 To a solution of 4-chloro-6-methoxypyrimidine (2.5 g crude product) in 
methanol an aqueous solution of hydrazine (80 %, 6.1 mL) was added 
and refluxed. After evaporation of the solvent, the aqueous solution of 
the crude product was alkalized with sodium hydroxide and extracted  
with methylene chloride to give the product as an ochre powder in 60% yield.  
1
H-NMR (500 MHz, CDCl3): δ = 8.26 (s, 1Har, H-2), 6.42 (bs, 1H, NH), 6.07 (s, 1Har, H-5), 3.92 (s, 
3H, OCH3), 3.42 (bs, 2H, NH2). 
13
C-NMR (126 MHz, CDCl3): δ = 170.72 (Cq ar, C-6), 167.17 (Cq ar, 
C-4), 157.68 (C-Har, C-2), 84.90 (C-Har, C-5), 53.87 (OCH3). 
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4’-methoxy-6’-(2-(pyridin-2-ylmethylene)hydrazinyl)pyrimidine (IV-a) 
 The reaction of 2-pyridinecarboxaldehyde (191.1 mg, 1.78 
mmol) with 4-hydrazinyl-6-methoxypyrimidine (250 mg, 1.78 
mmol) resulted in brightly rosy crystals of the product in 72% 
yield (293 mg, 1.28 mmol). 
1
H-NMR (300 MHz, CDCl3): δ = 8.78 (bs, 1H, NH), 8.60 (d, 
3
J(H,H) = 4.8 Hz, 1Har, H-6), 8.38 (d, 
5
J(H,H) = 0.6 Hz, 1Har, H-2’), 8.00 (d, 
3
J(H,H) = 8.0 Hz, 1Har, H-3), 7.93 (s, 1H, C=NH), 7.75 (t, 
3
J(H,H) = 7.3 Hz, 1Har, H-4), 6.63 (d, 
5
J(H,H) = 0.7 Hz, 1Har, H-5’), 3.99 (s, 3H, OCH3).  
13
C-NMR (126 MHz, DMSO-d6): δ = 170.00 (Cq,ar, C-4’), 162.78 (Cq,ar, C-6’), 157.77 (C-Har, C-2), 
153.47 (Cq,ar, C-2), 149.28 (C-Har, C-6), 142.77 (HC=N), 136.59 (C-Har, C-4), 123.62 (C-Har, C-5), 
119.44 (C-Har, C-3), 85.38 (C-Har, C-5’), 53.54 (OCH3).  
Anal. Calcd. for C11H11N5O×0.75 H2O: C, 54.43; H, 5.19; N, 28.85. Found: C, 54.36; H, 4.49; N, 
28.94.  
ESI-MS: m/z Calcd. for [M]: 229.0964. Found: 230.0979 for [M+H]
+
, 252.0798 for [M+Na]
+
. 
 
4’-methoxy-6’-(2-(1-(pyridin-2-yl)ethylidene)hydrazinyl)pyrimidine (IV-b) 
 The reaction of 2-acetylpyridine (0.2 mL, 1.78 mmol) with 4-
hydrazinyl-6-methoxypyrimidine (250 mg, 1.78 mmol) 
resulted in brightly rosy crystals of the product in 79% yield 
(342 mg, 1.41 mmol).  
1
H-NMR (500 MHz, DMSO-d6): δ = 10.43 (s, 1H, NH), 8.57 (ddd, 
5
J(H,H) = 0.9 Hz, 
4
J(H,H) = 
1.7 Hz, 
3
J(H,H) = 4.8 Hz, 1Har, H-6), 8.37 (d, 
5
J(H,H) = 0.9 Hz, 1Har, H-2’), 8.15 (dt, 
5
J(H,H) = 
0.9 Hz, 
3
J(H,H) = 8.1 Hz, 1Har, H-3), 7.85 – 7.75 (sm, 1Har, H-4), 7.35 (ddd, 
4
J(H,H) = 1.1 Hz, 
3
J(H,H) = 4.8 Hz, 
3
J(H,H) = 7.4 Hz, 1H, H-5), 6.57 (d, 
5
J(H,H) = 0.9 Hz, 1H, H-5’), 3.89 (s, 3H, 
OCH3), 2.40 (s, 3H, C=NCH3).  
13
C-NMR (126 MHz, DMSO-d6): δ = 170.04 (Cq,ar, C-4’), 163.51(Cq,ar, C-6’), 157.53 (C-Har, C-2’), 
155.24 (Cq,ar, C-2), 148.42 (C-Har, C-6), 147.91 (Cq, C=N), 136.44 (C-Har, C-4), 123.40 (C-Har, C-5), 
119.93 (C-Har, C-3), 86.10 (C-Har, C-5’), 53.50 (OCH3), 11.76 (C=NCH3).  
Anal. Calcd. for C12H13N5O×0.5 H2O: C, 57.13; H, 5.59; N, 27.76. Found: C, 57.23; H, 5.46; N, 
27.09.  
ESI-MS: m/z Calcd. for [M]: 243.1120. Found: 244.1128 for [M+H]
+
, 266.0953 for [M+Na]
+
.  
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4’-[2-[(5-ethylpyridin-2-yl)methylidene]hydrazin-1-yl]-6’-methoxypyrimidine (IV-c) 
 The reaction of 5-ethylpicolinaldehyde (E-5, 241.1 mg, 1.78 
mmol) with 4-hydrazinyl-6-methoxypyrimidine (E-8, 250 mg, 
1.78 mmol) resulted in brightly rosy crystals of the product in 
63% yield (288.7 mg, 1,12 mmol).  
1
H-NMR (500 MHz, DMSO-d6): δ = 11.45 (s, 1H, NH), 8.43 (d, 
4
J(H,H) = 1.6 Hz, 1Har, H-6), 8.33 
(d, 
5
J(H,H) = 0.9 Hz, 1Har, H-2’), 8.12 (s, 1H, C=NH), 7.93 (d, 
3
J(H,H) = 8.1 Hz, 1Har, H-3), 7.68 (dd, 
4
J(H,H) = 2.1 Hz, 
3
J(H,H) = 8.2 Hz, 1Har, H-4), 6.49 (d, 
5
J(H,H) = 0.6 Hz, 1Har, H-5’), 3.89 (s, 3H, 
OCH3), 2.64 (q, 
3
J(H,H) = 7.6 Hz, 2H, CH2CH3), 1.20 (t, 
3
J(H,H) = 7.6 Hz, 3H, CH2CH3).  
13
C-NMR (126 MHz, DMSO-d6): δ = 169.96 (Cq,ar, C-6’), 162.78 (Cq,ar, C-4’), 157.74 (C-Har, C-2’), 
151.22 (Cq,ar, C-2), 148.73 (C-Har, C-6), 142.91 (C-H, HC=N), 139.16 (Cq,ar, C-5), 135.87 (C-Har, C-
4), 119.11(C-Har, C-3), 85.26 (C-Har, C-5’), 53.50 (OCH3), 25.15 (CH2CH3), 15.08 (CH2CH3).  
Anal. Calcd. for C13H15N5O: C, 60.69; H, 5.88; N, 27.22. Found: C, 60.32; H, 5.76; N, 27.28. 
ESI-MS: m/z Calcd. for [M]: 257.1277. Found: 258.1272 for [M+H]
+
, 280.1074 for [M+Na]
+
. 
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Preparation of pyridinyl hydrazino-benzothiazoles (Figure 16, box V): 
As a general comment on the hydrazino-benzothiazole derivatives from boxes V, VI and VII, 
in the 
13
C NMR spectra (especially measured by attached proton test (APT) method) some 
signals were not detectable. Mainly this occurred for the bridging quaternary carbons C-3’a 
and C-7’a, but dependent on the respective compounds also for some other signals. Those are 
indicated below. 
 
2’-(2-(pyridin-2-yl)methylene)hydrazinyl)-1’,3’-benzothiazole (V-a) 
 The reaction of picolinaldehyde (E-5, 0.144 mL, 
1.513 mmol) with 2-hydrazino-benzothiazole (250 mg, 
1.513 mmol) in ethanolic solution under acetic acid 
catalysis resulted in bright yellowish shining crystals, which  
delivered the pure product in 75% yield (287.7 mg, 1.132 mmol) after recrystallization. 
1
H-NMR (500 MHz, DMSO-d6): δ = 12.48 (bs, 1H, NH), 8.60 (ddd, 
5
J(H,H) = 1.0 Hz, 
4
J(H,H) = 
1.7 Hz, 
3
J(H,H) = 5.0 Hz, 1Har, H-6), 8.14 (s, 1H, C=NH, H-7), 7.91 (d, 
3
J(H,H) = 7.9 Hz, 1Har, H-4’), 
7.87 (m, 1Har, H-3), 7.80 (d, 
3
J(H,H) = 7.9 Hz, 1Har, H-7’), 7.49 (d, 
3
J(H,H) = 5.9 Hz, 1Har, H-4), 7.38 
(ddd, 
4
J(H,H) = 1.6 Hz, 
3
J(H,H) = 4.9 Hz, 
3
J(H,H) = 7.3 Hz, 1Har, H-5), 7.35 – 7.29 (sm, 1Har, H-5’ or 
H-6’), 7.17 – 7.10 (sm, 1Har, H-6’ or H-5’). 
13
C-NMR (101 MHz, DMSO-d6): δ = 167.07 (Cq,ar, C-2’), 153.09 (Cq,ar, C-2), 149.52 (C-Har, C-6), 
136.79 (C-Har, C-4), 126.04 (C-Har, C-5’), 123.88 (C-Har, C-5), 121.94 (C-Har, C-6’), 121.58 (C-Har, 
C-7’), 119.39 (C-Har, C-4’). Signals for HC=N, C-3, C-3’a and C-7’a were not detectable.  
Anal. Calcd. for C13H10N4S: C: 61.4; H: 3.96; N: 22.03. Found: C: 61.81; H: 3.936; N: 22.4. 
Purity was additionally determined with HPLC MS to be ≥ 95% (m/z calculated for [M]: 254.31, 
found 255.2 for [M + H]
+
). 
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2’-(2-(1-(pyridin-2-yl)ethylidene)hydrazinyl)-1’,3’-benzothiazole (V-b) 
 The reaction of 1-(pyridin-2-yl)ethanone (0.17 mL, 
1.513 mmol) with 2-hydrazino-benzothiazole (250 mg, 
1.513 mmol) in ethanolic solution under acetic acid 
catalysis resulted in beige precipitate, which delivered the 
pure product after recrystallization. The yield was not determined. NMRs revealed the 
presence of acetic acid in the crystals, therefore EA analysis was adapted accordingly. 
1
H-NMR (500 MHz, DMSO-d6): δ = 11.86 (bs, N-H), 8.59 (ddd, 
5
J(H,H) = 0.9 Hz, 
4
J(H,H) = 1.6 Hz, 
3
J(H,H) = 4.7 Hz, 1Har, H-6), 8.08 (d, 
3
J(H,H) = 8.2 Hz, 1Har, H-4’), 7.90 – 7.83 (sm, 1Har, H-4), 7.74 
(d, 
3
J(H,H) = 7.6 Hz, 1Har, H-7’), 7.41 – 7.36 (sm, 2Har, H-5, H-3), 7.33 – 7.27 (sm, 1Har, H-5’), 7.11 
(td, 
4
J(H,H) = 0.9 Hz, 
3
J(H,H) = 7.8 Hz, 1Har, H-6’), 2.43 (s, 3H, CH3, H-8).  
13
C-NMR (126 MHz, DMSO-d6): δ = 168.17 (Cq,ar, C-2’), 155.07(Cq,ar, C-2), 148.59 (C-Har, C-6), 
136.39 (C-Har, C-4), 125.98 (C-Har, C-5’), 123.53 (C-Har, C-5), 121.70 (C-Har, C-6’ or C7’), 121.67 
(C-Har, C-7’ or C-6’), 119.69 (C-Har, C-4’), 12.68 (CH3) – the signals for CH3C=N, C-3, C-3’a, C-7’a 
were not detectable.  
Anal. Calcd. for C14H12N4S×0.7 C2H4O2: C: 59.6; H: 4.8; N: 18.1. Found: C: 59.1; H: 4.9; N: 18.0.  
Additionally purity was determined with HPLC MS to be ≥ 95% (m/z calculated for [M]: 268.34, 
found 268.8 for [M + H]
+
, 291.3 for [M + Na]
+
). 
 
  
174   
 
2’-(2-(5-ethylpyridin-2-yl)methylene)hydrazinyl)-1’,3’-benzothiazole (V-c) 
 The reaction of 5-ethyl-picolinaldehyde (E-5, 200 mg, 
1.48 mmol) with 2-hydrazino-benzothiazole (244.5 mg, 
1.480 mmol) in ethanolic solution under acetic acid 
catalysis resulted in cream-colored precipitate, which 
delivered the pure product in 46% yield (192.2 mg, 0.681 mmol) after recrystallization.  
1
H-NMR (500 MHz, DMSO-d6): δ = 12.41 (bs, 1H, NH), 8.46 (dd, 
5
J(H,H) = 0.6 Hz, 
4
J(H,H) = 
2.1 Hz, 1Har, H-6), 8.13 (s, 1H, C=NH), 7.84 (d, 
3
J(H,H) = 7.9 Hz, 1Har, H-4’), 7.79 (d, 
3
J(H,H) = 
7.9 Hz, 1Har, H-7’), 7.73 (ddd, 
3
J(H,H) = 0.5 Hz, 
3
J(H,H) = 2.1 Hz, 
3
J(H,H) = 8.2 Hz,1Har, H-3), 7.48 
(d, 
3
J(H,H) = 4.8, 1Har, H-4), 7.31 (td, 
3
J(H,H) = 1.3 Hz, 
3
J(H,H) = 8.0 Hz, 1Har, H-5’ or H-6’), 7.17 – 
7.10 (sm, 1Har, H-6’ or H-5’), 2.66 (q, 
3
J(H,H) = 7.7 Hz, 2H, CH2CH3), 1.21 (t, 
3
J(H,H) = 7.7 Hz, 3H, 
CH2CH3). 
13
C-NMR (126 MHz, DMSO-d6): 166.99 (Cq,ar, C-2’), 150.82 (Cq,ar, C-2), 148.93 (C-Har, C-6), 139.41 
(Cq,ar, C-5), 135.98 (C-Har, C-4), 125.95 (C-Har, C-5’), 121.80 (C-Har, C-6’), 121.49 (C-Har, C-7’), 
119.04 (C-Har, C-4’), 25.17 (CH2CH3), 15.07 (CH2CH3) – the signals for HC=N, C-3, C-3’a, C-7’a 
were not visible.  
Anal. Calcd. for C15H14N4S: C: 63.80; H: 5.00; N: 19.84. Found: C: 63.47; H: 4.886; N: 19.81.  
 
Preparation of the acetaniline hydrazino-benzothiazole 2-(1-(2-(1’,3’-benzothiazol-2’-
yl)hydrazine-1-ylidene)ethyl)aniline (V-d) 
 
 
The reaction of 2-aceto-anilin (0.10 mL, 1.21 mmol) with 
2-hydrazino-benzothiazole (200 mg, 1.21 mmol) in 
ethanolic solution under acetic acid catalysis delivered the 
product as a greyish brownish solid after recrystallization. 
  
1
H-NMR (500 MHz, DMSO-d6): δ = 11.62 (s, 1H, NH), 7.67 (d, 
3
J(H,H) = 7.9 Hz, 1Har, H-4’), 7.43 
(dd, 
4
J(H,H) = 1.4 Hz,
 3
J(H,H) = 8.0 Hz, 1Har, H-7’), 7.30 – 7.19 (m, 2Har, H-3, H-5), 7.10 – 7.00 (m, 
2Har, H-5’, H-6’), 6.82 (s, 2H, NH2), 6.76 (dd, 
4
J(H,H) = 1.3 Hz,
 3
J(H,H) = 8.2 Hz, 1Har, H-4), 6.61 – 
6.51 (sm, 1Har, H-6), 2.43 (s, 3H, CH3). 
13
C-NMR (126 MHz, DMSO-d6): δ = 165.34 (Cq,ar, C-2’), 156.54 (Cq, CH3C=N), 147.38 (Cq,ar, CNH2, 
C-1), 129.18 (C-Har, C-5), 129.03 (C-Har, C-5’), 126.22 (C-Har, C-3), 121.94 (C-Har, C-6’), 121.24 (C-
Har, C-7’), 118.07 (Cq,ar, C-2), 115.96 (C-Har, C-), 114.95 (C-Har, C-4), 114.07 (C-Har, C-4’), 15.67 
(CH3). The signals for C-3’a and C-7’a were not detectable. 
Purity of the compound was determined with HPLC MS to be ≥ 95% (m/z calculated for [M]: 282.36, 
found 283.1 for [M + H]
+
).  
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Preparation of hydroxyphenyl hydrazino-benzothiazoles (Figure 16, box VI): 
 
2-((2-(1’,3’-benzothiazol-2’-yl)hydrazine-1-ylidene)methyl)phenol (VI-a) 
The reaction of salicylic aldehyde (0.13 mL, 1.21 mmol) 
with 2-hydrazino-benzothiazole (200 mg, 1.21 mmol) in 
ethanolic solution under acetic acid catalysis delivered the
pure product as a white precipitate in 93% yield (306 mg, 1.13 mmol) after recrystallization. 
1
H-NMR (500 MHz, DMSO-d6): δ = 12.14 (s, 1H, NH), 10.44 (s, 1H, OH), 8.45 (s, 1H, C=NH), 7.74 
(d,
 3
J(H,H) = 7.9 Hz, 1Har, H-4’), 7.61 (d, 
3
J(H,H) = 6.6 Hz, 1Har, H-7’), 7.41 – 7.32 (m, 1Har, H-3), 
7.31 – 7.27 (sm, 1Har, H-6’), 7.27 – 7.24 (sm, 1Har, H-5’), 7.09 (td, 
4
J(H,H) = 1.3 Hz,
 3
J(H,H) = 
7.9 Hz, 1Har, H-5),6.95 – 6.88 (m, 2Har, H-6, H-4). 
13
C-NMR (126 MHz, DMSO-d6): δ = 166.40 (Cq,ar, C-2’), 156.59 (Cq,ar, C-OH, C-1), 146.98 (HC=N), 
130.80 (C-Har, C-4), 127.71 (C-Har, C-6), 126.15 (C-Har, C-5’), 121.77 (C-Har, C-7’), 121.51 (C-Har, 
C-5), 119.61(Cq,ar, C-2), 119.42 (C-Har, C-4’), 116.12 (C-Har, C-3) – the signals for C-6’, C-3’a and C-
7’a were not visible.  
Anal. Calcd. for C14H11N3O: C: 62.43; H: 4.12; N: 15.60. Found: C: 62.56; H: 4.086; N: 15.76.  
Purity was additionally determined with HPLC MS to be ≥ 95% (m/z calculated for [M]: 269.32, 
found 315.2 for [M + H]
+
). 
 
2-(1-(2-(1’,3’-benzothiazol-2’-yl)hydrazine-1-ylidene)ethyl)phenol (VI-b) 
 The reaction of 2-hydroxyacetophenon (0.15 mL, 
1.21 mmol) with 2-hydrazino-benzothiazole (200 mg, 
1.21 mmol) in ethanolic solution under acetic acid catalysis 
delivered the pure product as a yellow precipitate in 92% 
yield (315 mg, 1.11 mmol) after recrystallization.  
1
H-NMR (500 MHz, DMSO-d6): δ = 12.52 (bs, 1H, NH), 7.66 (d, 
3
J(H,H) = 7.7 Hz, 1Har, H-7’), 7.59 
(dd, 
4
J(H,H) = 1.0 Hz, 
3
J(H,H) = 7.8 Hz, 1Har, H4’), 7.30 – 7.24 (m, 2Har, H-5’, H-6’), 7.19 (d, 
3
J(H,H) = 7.8 Hz, 1Har, H-3), 7.06 (t, 
3
J(H,H) = 7.5 Hz, 1Har, H-5), 6.93 – 6.87 (m, 2Har, H-4, H-6), 
6.50 (bs, 1H, OH), 2.50 (s, 3H, CH3).  
13
C-NMR (126 MHz, DMSO-d6): δ = 165.12 (Cq,ar, C-2’), 159.60 (Cq,ar, C-OH, C-1), 158.23 (Cq,ar, C-
3’a), 141.17 (Cq, CH3C=N), 130.58 (C-Har, C-5), 128.40 (C-Har, C-3), 126.66 (C-Har, C-5’), 123.72 
(Cq,ar, C-7’a), 122.45 (C-Har, C-6’), 121.62 (C-Har, C-7’), 119.91 (Cq,ar, C-2), 118.72 (C-Har, C-4), 
116.70 (C-Har, C-4’), 112.35 (C-Har, C-6), 14.41 (CH3).  
Anal. Calcd. for C15H13N3SO×1.25 H2O: C: 58.9; H: 5.11; N: 13.74. Found: C: 58.7; H: 4.728; N: 
13.85.   
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Preparation of combined structures (Figure 16, box VII): 
 
N,N-bis(4-methoxyphenyl)hydrazine-1,2-bis(carbothioamide) (VII-a) 
The reaction of 4-methoxyphenylisothiocyanate 
(413.1 mg, 2.5 mmol) with hydrazine (0.06 mL 80% 
aqueous, 1.25 mmol) in ethanolic solution delivered the 
pure product as a white solid in 69% yield (310 mg, 
0.856 mmol) after recrystallization. 
1
H-NMR (500 MHz, DMSO-d6): δ = 9.69 (s, 2H, 2 NH), 9.52 (s, 2H, 2 NH), 7.38 (d, 
3
J(H,H) = 
8.8 Hz, 4Har, H-3, H-3’, H-5, H-5’), 6.93 – 6.86 (m, 4Har, H-2, H-2’, H-6, H-6’), 3.75 (s, 6H, 2 
OCH3).  
13
C-NMR (126 MHz, DMSO-d6): δ = 156.82 (2Cq,ar, C-4, C-4’), 132.11 (2Cq,ar, C-1, C-1’), 126.77 
(4C-Har, (even though with very low intensity) C-2, C-2’, C-6, C-6’), 113.48 (4C-Har, C-3, C-3’, C-5, 
C-5’), 55.35 (2 OCH3). – for the quaternary C=S no signal was visible in APT test, the signal for C-2, 
C-2’, C-6 and C-6’ had a remarkably low intensity.  
Anal. Calcd. for C16H18N4S2O2: C: 53.02; H: 5.01; N: 15.46. Found: C: 53.18; H: 5.047; N: 15.66.  
 
3-[(1’,3’-benzothiazol-2’yl)amino]-1-(4-methoxyphenyl)thiourea (VII-b) 
 The reaction of N-(4-methoxyphenyl)hydrazinecarbo-
thioamide C-1 (250 mg, 1.513 mmol) with 2-hydrazino-
benzothiazole (250 mg, 1.513 mmol) in ethanolic 
solution delivered the pure product as a yellow solid in 
75% yield (357.2 mg, 1.139 mmol) after recrystalli-
zation. 
1
H-NMR (500 MHz, DMSO-d6): δ = 13.38 (s, 1H, N-H), 7.66 (s, 1H, N-H), 7.60 (dd, 
3
J(H,H) = 
1.3 Hz, 
3
J(H,H) = 8.2 Hz, 1Har, H-4’), 7.37 – 7.31 (sm, 1Har, H-5’), 7.30 – 7.25 (sm, 2Har, H-3, H-5), 
7.19 (dd, 
3
J(H,H) = 1.4 Hz, 
3
J(H,H) = 7.7 Hz, 1Har, H-7’), 7.10 – 7.06 (sm, 2Har, H-2, H-6), 6.93 (td, 
3
J(H,H) = 1.4 Hz, 
3
J(H,H) = 7.7 Hz, 1Har, H-6’), 3.82 (s, 3H, OCH3). For one NH no signal was 
visible.  
13
C-NMR (101 MHz, DMSO-d6): δ = 165.69 (Cq,ar, C=S), 159.89 (Cq,ar, C-2’), 148.39 (Cq,ar, C-4), 
139.48 (Cq,ar, C-3’a), 133.49 (C-Har, C-5’), 130.64 (C-Har, C-6’), 129.73 (2C-Har, C-2, C-6), 124.55 
(Cq,ar, C-7’a), 124.48 (Cq,ar, C-1), 123.29 (C-Har, C-7’), 119.64 (C-Har, C-4’), 114.78 (2C-Har, C-3, C-
5), 55.56 (OCH3). 
Anal. Calcd. for C15H14N4S2O: C: 54.52; H: 4.27; N: 16.96. Found: C: 54.26; H: 4.082; N: 16.7.  
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3-(2-(1’,3’-benzothiazol-2’-yl)hydrazine-1-ylidene)-2,3-dihydro-indol-2-one (VII-c) 
 
 
The reaction of isatin (222.6 mg, 1.513 mmol) with 2-
hydrazino-benzothiazole (250 mg, 1.513 mmol) in ethanolic 
solution under acetic acid catalysis delivered the pure product 
as a yellow precipitate after recrystallization (The yield was 
not determined).  
1
H-NMR (500 MHz, DMSO-d6): δ = 13.38 (s, 1H, N-H), 11.24 (s, 1H, N-H), 7.94 (d, 
3
J(H,H) = 
7.6 Hz, 1Har, H-4’), 7.67 (d, 
3
J(H,H) = 7.6 Hz, 1Har, H-7’), 7.55 (d, 
3
J(H,H) = 7.3 Hz, 1Har, H-7), 7.44 
– 7.39 (sm, 1Har, H-6’ or H-5’), 7.39 – 7.34 (sm, 1Har, H-5’ or H-6’), 7.30 – 7.25 (m, 1Har, H-4), 7.10 
(t, 
3
J(H,H) = 7.7 Hz, 1Har, H-6), 6.97 (d, 
3
J(H,H) = 7.9 Hz, 1Har, H-5).
  
13
C-NMR (126 MHz, DMSO-d6): δ = 141.64 (Cq,ar, C-7a), 130.85 (C-Har, C-6), 126.36 (C-Har, C-5’), 
123.29 (C-Har, C-6’), 122.43 (C-Har, C-5), 121.93 (C-Har, C-7’), 120.48 (C-Har, C-4), 120.01 (C-Har, 
C-4’), 119.74 (Cq,ar, C-3a), 111.09 (C-Har, C-7). Signals for C-3, C-3a’, and C-7a’ were not visible in 
the APT test.  
Purity of the compound was determined with HPLC MS to be ≥ 95% (m/z calculated for [M]: 294.33, 
found 295.2 for [M + H]
+
). 
 
3-(2’-(6’-methoxypyrimidin-4’-yl)hydrazono)inulin-2-one (VII-d) 
 4-hydrazinyl-6-methoxypyrimidine (E-8, 150 mg, 1.04 mmol) 
was than reacted with isatin (152.7 mg, 1.04 mmol) in 
ethanolic solution under acetic acid catalysis. The reaction 
delivered the pure product as a yellow powder after column 
chromatography and recrystallization in 24% yield (68 mg, 
0.248 mmol).  
1
H-NMR (500 MHz, DMSO-d6): δ = 11.09 (bs, 1H, N-H), 10.70 (s, 1H, N-H), 8.51 (s, 1Har, H-2’), 
8.11 (d, 
3
J(H,H) = 7.9 Hz, 1Har, H-7), 7.35 (td, 
4
J(H,H) = 0.9 Hz,
 3
J(H,H) = 7.7 Hz, 1Har, H-6), 7.04 
(td, 
4
J(H,H) = 0.9 Hz, 
3
J(H,H) = 7.6 Hz, 1Har, H-5), 6.89 (d, 
3
J(H,H) = 7.9 Hz, 1Har, H-4), 6.63 (s, 
1Har, H-5’), 3.93 (s, 3H, OCH3).  
13
C-NMR (126 MHz, DMSO-d6): δ = 170.22 (Cq,ar, C-6’), 164.64 (Cq, C=O), 163.06 (Cq,ar, C-4’), 
158.15 (C-Har, C-2’), 143.07 (Cq, C-7a), 135.81 (Cq,ar, C-3), 131.72 (C-Har, C-6), 125.67 (C-Har, C-5), 
121.49 (C-Har, C-4), 120.00 (Cq,ar, C-3a), 110.92 (C-Har, C-7), 87.83 (C-Har, C-5’), 53.90 (OCH3).  
Anal. Calcd. for C13H11N5O×H2O: C: 54.35; H: 4.56; N: 24.38. Found: C: 54.85; H: 4.517; N: 23.26.  
Additionally purity was determined with HPLC MS to be ≥ 95% (m/z calculated for [M]: 269.26, 
found 270.0 for [M + H]
+
). 
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6.2. UV‒Vis spectrophotometric measurements for complex stability evaluation 
The interaction of metal ions and ligands can be quantified by means of stability constants 
βp,q,r that give information about the thermodynamic stability of metal complexes [352,353]. 
In a system containing a metal ion M
z+
 and a ligand HnL, the following solution equilibrium 
can be formulated: 
 
𝑝𝐻+ + 𝑞𝑀𝑧+ + 𝑟𝐻𝑛𝐿 𝐻𝑝𝑀𝑞(𝐻𝑛𝐿)𝑟
𝑝+𝑞𝑧  
 
The stoichiometric coefficients for the metal ion (q) and the ligand (r) are higher or equal to 
zero, while the coefficient p can be positive for protons, but can also take negative values for 
hydroxide ions [353]. According to the law of mass action the stability constant βp,q,r can be 
expressed as the quotient of the activities of the participating species {Xi}, which is define as 
the product of their activity coefficients fi with their concentrations [Xi]: 
 
𝛽𝑝,𝑞,𝑟 =
{𝐻𝑝𝑀𝑞(𝐻𝑛𝐿)𝑟
𝑝+𝑞𝑧}
 {𝐻+}𝑝{𝑀𝑧+}𝑞{𝐻𝑛𝐿}𝑟
=
𝑓𝐻𝑝𝑀𝑞(𝐻𝑛𝐿)𝑟
𝑝+𝑞𝑧
 𝑓
𝐻+
𝑝 ∙ 𝑓
𝑀𝑧+
𝑞 ∙ 𝑓𝐻𝑛𝐿
𝑟  
∙
[𝐻𝑝𝑀𝑞(𝐻𝑛𝐿)𝑟
𝑝+𝑞𝑧]
[𝐻+]𝑝[𝑀𝑧+]𝑞[𝐻𝑛𝐿]𝑟
 
 
The excess of a low-valent electrolyte salt ensures constant activity coefficients for all ions 
and molecules in the system under investigation. This allows the incorporation of activity 
coefficients into the stability constant and therefore the approximatively usage of 
concentrations instead of activities [352–354]. Accordingly, an ionic strength of 0.20 M was 
adjusted using KCl salt in the samples. 
Spectrophotometric titrations were performed on samples of the ligands alone or in the 
presence of FeCl3 or CuCl2. The applied metal-to-ligand ratios were 1:1, 1:2 and 1:3. 
Generally the concentration of the ligand was set to 50 µM. Due to its’ lower water solubility 
ligand Q-4 is an exception to this general procedure. Here a more diluted sample preparation 
was required; therefore titrations with this ligand were performed at 10 µM ligand 
concentrations. The initial pH of the samples was 2, the initial volume 10.00 mL. pH values 
were determined using an Orion 710A pH-meter equipped with a Metrohm combined 
electrode (type 6.0234.100). The electrode system was calibrated to the pH scale by means of 
blank titrations (strong acid vs. strong base; HCl vs. KOH) according to the method suggested 
by Irving et al. [355]. Samples were deoxygenated by bubbling purified argon for ca. 10 min 
prior to the measurements. Defined volumes of a 0.10 M carbonate-free KOH solution 
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containing 0.10 M KCl were applied to the sample using a Metrohm 665 Dosimat burette until 
a pH of 11.5 was reached. The reaction vial was thermostated to 25.0 ± 0.1 
o
C and kept under 
argon atmosphere.  
In case of ligand IV-b additional samples were prepared for the 1:1 Fe (III) to ligand ratio at 
lower pH values. In this individual samples KCl was partially or completely replaced by HCl, 
and pH values in the range between 0.7 and 2.0 were calculated from the HCl content. 
 
In the evaluation of the equilibrium model 𝑝𝐻+ + 𝑞𝑀𝑧+ + 𝑟𝐻𝑛𝐿 𝐻𝑝𝑀𝑞(𝐻𝑛𝐿)𝑟
𝑝+𝑞𝑧 for the 
calculation of the stability constants βp,q,r it is good practice to analyze the two subsystems, in 
which one or the other stoichiometric coefficient is set to zero. βp,q,0, in which r is zero, 
describes the acid-base equilibria for the metal ion, βp,0,r the one for the free ligand. Therefore 
from the latter system, the ligand’s pKa values can be determined. In case of the metal 
hydroxido species, literature data was used [356].  
 
Spectral changes upon addition of the base were recorded in the wavelength interval between 
200 and 800 nm using a Hewlett Packard 8452A diode array spectrophotometer. Quartz glass 
cuvettes with path lengths (l) of 1 or 2 cm were used (Hellma), depending on the molar 
absorptivity (ε) of the applied ligand samples. During one titration spectra of approximately 
30 samples were measured. 
According to the Lambert-Beer law the absorption A of the sample (s) at a wavelength (λ) is 
composed of the additive contributions of each single species Xi that is present in the solution 
[353]: 
 
𝐴𝑠,𝜆 =∑𝐴𝑖,𝑠,𝜆
𝑁
𝑖=1
= 𝑙 ∙∑𝜀𝑖,𝜆 ∙ 𝑐𝑖,𝑠
𝑁
𝑖=1
 
 
With the help of the program PSEQUAD the molar absorbance spectra of the individual 
species Xi were calculated on the basis of deconvolution of the measured spectra. This is done 
in two steps by first solving the matrices of data describing the equilibrium system through 
the mass-balance equations at the applied pH values for the unknown free concentrations. The 
second step includes refinement and minimizing steps in order to obtain the formation 
constants βp,q,r and molar absorptivity values εi that best fit to the measured data and the 
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applied equilibrium model [357]. These calculations were done by Professor Éva A. Enyedy 
(Department of Inorganic and Analytical Chemistry, University of Szeged, Hungary).  
 
With the help of the computer program MEDUSA [358] the calculated data can be used to 
predict further chemical equilibrium and distribution diagrams at given conditions.  
βp,q,r is the overall stability constant, which is also called cumulative stability constant, since it 
can be formulated as the product of stepwise stability constants [359]. For simplicity reasons 
the following considerations are given for an example system of a ligand like Q-1, which 
coordinates to the metal ion in its deprotonated form L
-1
. With iron
III
 (z = 3) three putative 
complexes can be formed, which are described by the following equations: 
 
𝑀𝑧+ + 𝐿−1 [𝑀𝐿](𝑧−1)  with  𝐾1 =
[[𝑀𝐿](𝑧−1)]
[𝑀𝑧+][𝐿−1]
 
 
[𝑀𝐿](𝑧−1) + 𝐿−1 [𝑀𝐿2]
(𝑧−2)  with  𝐾2 =
[[𝑀𝐿2]
(𝑧−2)]
[[𝑀𝐿](𝑧−1)][𝐿−1]
  
and 𝛽[𝑀𝐿2](𝑧−2) = 𝐾1𝐾2 =
[[𝑀𝐿2]
(𝑧−2)]
[𝑀𝑧+][𝐿−1]2
 
 
[𝑀𝐿2]
(𝑧−2) + 𝐿−1 [𝑀𝐿3]
(𝑧−3) with 𝐾3 =
[[𝑀𝐿3]
(𝑧−3)]
[[𝑀𝐿2](𝑧−2)][𝐿−1]
  
and 𝛽[𝑀𝐿3](𝑧−3) = 𝐾1𝐾2𝐾3 =
[[𝑀𝐿3]
(𝑧−3)]
[𝑀𝑧+][𝐿−1]3
 
 
Concentrations and distributions of the different species can be calculated based on the total 
metal ion concentration [M
z+
]Σ: 
 
[𝑀𝑧+]Σ = [𝑀
𝑧+] + [[𝑀𝐿](𝑧−1)] + [[𝑀𝐿2]
(𝑧−2)] + [[𝑀𝐿3]
(𝑧−3)] 
 
applying the above listed equilibria this can be written as: 
 
[𝑀𝑧+]Σ = [𝑀
𝑧+] ∙ {1 + 𝐾1[𝐿] + 𝐾1 ∙ 𝐾2[𝐿]
2 + 𝐾1 ∙ 𝐾2 ∙ 𝐾3[𝐿]
3} =  [𝑀𝑧+] ∙ ξ 
 
the expression within the curly brackets can be summarized in ξ and is defined as the 
reciprocal fraction of a species, which was not converted into another one. Applying these 
formulas, the free metal ion concentration can be described as  
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[𝑀𝑧+] =
[𝑀𝑧+]𝛴
𝜉
 
Accordingly, the concentrations of the other species can be formulated as  
[[𝑀𝐿](𝑧−1)] =
[𝑀𝑧+]𝛴
𝜉
∙ 𝐾1[𝐿] 
[[𝑀𝐿2]
(𝑧−2)] =
[𝑀𝑧+]𝛴
𝜉
∙ 𝐾1 ∙ 𝐾2[𝐿]
2 
[[𝑀𝐿3]
(𝑧−3)] =
[𝑀𝑧+]𝛴
𝜉
∙  𝐾1 ∙ 𝐾2 ∙ 𝐾3[𝐿]
3 
These basic relations are incorporated in the two applied programs (PSEQUAD and 
MEDUSA). 
 
 
 
6.3. Electrochemical Studies 
 
6.3.1. Cyclic voltammetry 
The thermodynamics and kinetics of redox reactions, which take place at the interface of an 
electrode and an ionic conductor, can be investigated with dynamic electroanalytical methods, 
such as cyclic voltammetry. The interaction of electrical energy and chemical change within 
the observed heterogeneous electron transfer reactions causes voltammograms with 
characteristic shapes. The unequivocal positions of the voltammetric waves on the potential 
scale are characteristic for the individual electrochemical properties of redox systems, like a 
virtual fingerprint. Therefore the technique has been labelled “electrochemical spectroscopy” 
[360–362].  
The experimental setup is built by an electrochemical cell consisting of three electrodes as 
shown in Figure 77 A. Potentials of the working electrode are given against a non-polarized 
reference electrode. In order to protect the reference electrode against large currents, an 
additional auxiliary electrode is used [362]. The electrochemical cell is connected to a 
potentiostat with voltage scan generator and recorder. A linear potential ramp is applied to the 
working electrode with a constant sweep rate =
𝑑𝐸
𝑑𝑡
 .  
After reaching the switching potential Eλ the direction of the potential ramp is reversed and 
the potential returns linearly to its initial value, thus forming a triangular voltage as depicted 
in Figure 77 B.  
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The system utilized in this thesis consisted of a PC controlled electrochemical measurement 
system (EF 451, Szeged, Hungary) with a glassy carbon disc electrode as working electrode, a 
platinum electrode as auxiliary electrode and a Ag/AgCl/KCl (1 M) reference electrode. 
Electrochemical potentials were converted into the normal hydrogen electrode (NHE) scale by 
addition of 0.236 V [363].  
The water jacket of the electrochemical cell (see Figure 77 A) ensured a constant temperature 
of 25.0 ± 0.1 °C. Due to low solubility in aqueous solution, samples containing either 1.0 mM 
metal ion or 1 mM ligand were prepared in a 90% (v/v) DMSO-water mixture. 10 mM of tert-
butylammonium chloride (TBACl) was used as a supporting electrolyte and a sweep rate of 
v = 100 mV/s was applied in the range of –1.5 to +1.2 V. 
Measurements were performed under argon atmosphere after purging the samples for 15 min 
with argon. 
 
 
Figure 77: Experimental setup of CV measurements A: thermostated reaction vial with an Ag/AgCl 
(1M KCl) reference electrode, a Pt-reference electrode and a Glassy Carbon disc electrode as a 
working electrode. CVs were performed in 90% (v/v) DMSO with TBACl (10 mM) as supporting 
electrolyte. B: time course of the triangular voltage applied in the three electrode system. 
 
 
Ferrocene in 90 % (v/v) DMSO-water was used as an external standard to reconcile the 
electrochemical system (E1/2 = +0.428 ± 0.012 V). Figure 78 shows a representative 
voltammogram of the applied standard.  
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At the initial potential (A) no electrochemical processes take place, yet [361]. Changing the 
potential (from A to B), only capacitive currents flow, which are caused by the formation of 
the Helmholtz double layer without charge transfer between electrode and electrolyte [362]. 
As soon as the electrochemical double layer is formed, the oxidation takes place (B), and a 
Faradaic current occurs based on the heterogeneous charge transfer at the phase boundary 
[362]. 
𝑋𝑟𝑒𝑑 𝑋𝑜𝑥 + 𝑧 𝑒
− 
The current I flowing as a result of this reaction with the transfer of z electrons is “diffusion 
controlled”: It is proportional to the concentration gradient of the produced oxidized species 
Xox at the electrode surface (x=0): 
I = zFA ∙ 𝐷[𝑋𝑜𝑥] (
𝜕[𝑋𝑜𝑥]
𝜕𝑥
)
𝑥=0
= 𝑗[𝑋𝑟𝑒𝑑] ∙ 𝑧𝐹𝐴  
with F being the Faraday constant, A being the electrode surface and D being the diffusion 
coefficient. The charge flux at this reaction j[X] is proportional to the concentration gradient at 
the electrode surface [362]: 
𝑗[𝑋𝑟𝑒𝑑] = −𝐷[𝑋𝑟𝑒𝑑] (
𝜕[𝑋𝑟𝑒𝑑]
𝜕𝑥
)
𝑥=0
= 𝐷[𝑋𝑜𝑥] (
𝜕[𝑋𝑜𝑥]
𝜕𝑥
)
𝑥=0
 
Therefore the current can be expressed as  
I = 𝑗[𝑋𝑟𝑒𝑑] ∙ 𝑧𝐹𝐴. 
The oxidation of the reduced species takes place, with its peak in position (C) in Figure 78. As 
a consequence of the occurring reaction, the concentration of the reduced species at the 
electrode surface decreases following the Nernst equation [361]: 
𝐸 = 𝐸° −
𝑅𝑇
𝑧𝐹
∙ 𝑙𝑛
[𝑋𝑟𝑒𝑑]
[𝑋𝑜𝑥]
 
This decrease in concentration results in a decrease of the diffusion dependent current, as seen 
in the voltammogram from points (C) to (D). A slight increase in the current might be 
observed from point (D) to the anodic switching potential Eλ,anodic, which is reached at point 
(E) in Figure 78. This might indicate a new redox process – in aqueous solutions at 1.23 V 
against NHE formation of O2 might be observed for example. 
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Reversing the sweep after the switching potential causes an inversion of the Helmholtz double 
layer, resulting in capacitive currents [361,362]. Is the double layer established, as in point F 
in Figure 78, the diffusion controlled reduction of the oxidized species starts with its 
maximum resulting in the peak current at positon G Figure 78. Due to a decrease in 
concentration of the oxidized species at the electrode surface, the current decreases again 
from (G) to (H). The cycle is continued to the cathodic switching potential at (J), and repeated 
from there. 
 
Figure 78: Representative voltammogram of a 1.0 mM Ferrocene solution in 90% (v/v) DMSO, 
supplemented with 10 mM TBACl at a sweep rate of v = 100 mV/s in the range of –0.5 to +1.0 V, 
Eλ,cathodic, Eλ,anodic: switching potentials; Ep,red, Ep,ox: peak potentials, Ip,red, Ip,ox: peak currents. 
 
 
Two factors influence the current at the working electrode, namely the heterogeneous charge 
transfer (as defined in the equation describing j[X]) and the transport of mass, that builds up a 
concentration gradient at the electrode surface [362]. In the described voltammogram, the 
current is diffusion controlled, that means the charge transfer occurs at such a high rate, that a 
dynamic equilibrium is established at the phase boundary and the Nernst equation is satisfied. 
This is the case for reversible systems [362]. On the contrary, in some cases the rate of the 
charge transfer is very slow, so that only one of the heterogeneous reactions (oxidation or 
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reduction) can be measured. In that cases the current depends on this rate and is charge-
transfer controlled. These reactions are irreversible and the Nernst equation does not describe 
these processes [362]. A third case can be distinguished, in which charge-transfer and 
diffusion influence the measured current. In these reactions, which are termed “quasi-
reversible” the Nernst equation is approximately satisfied [362]. 
Correlating the described kinetics with observed experimental parameters, diagnostic criteria 
could be identified for the characterization of electrochemical systems. For example the ratio 
of anodic to cathodic peak currents has been found to be close to 1 for reversible processes 
[360]. Also the half-peak potentials of a reversible process should have a distance of ΔE = 
58 mV [361]. 
 
 
 
6.3.2. Oxidation of ascorbic acid (ASC) and glutathione (GSH) 
The redox activity of compounds can also be investigated by monitoring reactions with 
biologically relevant antioxidants. At pH 7.4 two powerful intracellular reducing agents are 
glutathione (GSH) and ascorbate (ASC), with formals potential of the GSSG/GSH and the 
dehydro-L-ascorbic acid/ASC redox pairs are -0.26 V and +0.05 V, respectively [255,256]. 
The changes in characteristic regions of the compounds’ spectra (especially those of metal 
complexes) that occur upon reaction with the antioxidants were followed over time [89,263]. 
In order to address the reversibility of the observed reactions, hydrogen peroxide was added at 
the end of the reaction with the antioxidants to re-oxidize the reduced products [89]. UV‒Vis 
spectrophotometric measurements were performed under aseptic conditions using a Hewlett 
Packard 8452A diode array spectrophotometer and a special, tightly closed tandem cuvette 
(Hellma Tandem Cell, 238-QS, path length: 1 cm, Figure 79).  
 
 
Figure 79: Tandem Cuvette used for GSH and ASC oxidation assay. 
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The reagents were separated until the reaction was triggered. The pH of the solutions was 
adjusted to 7.40 by 50 mM HEPES and an ionic strength of 0.1 M (KCl) was applied at 25.0 ± 
0.1 °C. In case of the IVa-Fe system, a pH of 5.45 was adjusted by 50 mM MES buffer. One 
of the isolated pockets contained the reducing agent (ASC or GSH) at ten times higher 
concentrations than that of the metal ions. The other pocket contained the ligand in the 
presence of equimolar amounts of metal ions. The used concentrations were 25 µM in case of 
the IVa-Cu (II) system, 50 µM for the IVa-Fe (III) system, and 100 µM for the Q-1, Q-2, Q-
3 and Q-4 systems with both metal ions. Both isolated pockets of the cuvette were completely 
deoxygenated by carefully bubbling a stream of argon for 10 min before mixing the reactants. 
Spectra were recorded before and immediately after mixing, and changes were followed for 
up to 90 min. At the end of the measurements cc. H2O2 (35%, 50 µL to 1.4 mL) was added to 
the samples. 
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7. List of Abbreviations 
 
6PGδL 6-phosphoglucono-δ-lactone 
ABC ATP-binding-cassette 
ADP Adenosine diphosphate 
Akt1 threonine-protein kinase (PKB) 
ASK1 apoptosis signal-regulating kinase-1 
ATCC American tissue culture collection 
ATP  Adenosine triphosphate 
Bad Bcl-2-associated death promoter 
Bax Bcl-2-associated X protein 
BCRP Breast Cancer Resistance Protein 
bs NMR signal, broad singlet 
Cat catalase 
CDK2 Cyclin-dependent kinase 2 
CHO Chinese Hamster ovary 
CP ceruloplasmin 
Cq NMR signal, quaternary carbon 
Cq,ar NMR signal, quaternary aromatic carbon 
CS collateral sensitivity 
CTR1 copper transporter 
d NMR signal, duplet 
DCF Dichlorofluorescein 
DCFDA 2’7’-Dichlorofluoresceindiacetate 
DCF-H Dichlorofluorescin 
dd NMR signal, duplet of duplets 
ddd NMR signal, duplet of duplets of duplets 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO dimethyl sulfoxide 
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DMT1 divalent metal transporter 
DNA Deoxyribonucleic acid 
dt NMR signal, duplet of triplets 
DTP Developmental Therapeutics Program 
DTT dithiothreitol 
ECAR extracellular acidification rates 
FACS Fluorescence-activated cell sorting 
FBS fetal bovine serum 
FPN1 ferroportin 
G6P glucose-6-phosphate 
G6PDH glucose-6-phosphate dehydrogenase 
GPx glutathione peroxidase 
GPx glutathione peroxidase 
GR glutathione reductase 
GRX glutaredoxin 
GSH reduced glutathione 
GS-SG oxidized glutathione 
GSTπ Glutathione S-transferase π 
HIF-1α Hypoxia-inducible factor 1-alpha 
HSAB hard and soft acids and bases  
IKK IκB-kinase 
IRE-IRP iron-response element and iron-regulatory protein (1/2) 
ISC iron sulfur cluster 
IκB inhibitor of NFκB 
J NMR signal, coupling constant 
JNK c-Jun N-terminal kinase 
Keap1 Kelch-like ECH-associated protein 1 
m NMR signal, multiplet 
MCX-I mitochondrial complex I 
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MDR Multidrug Resistance 
MRP1 Multidrug resistance-associated protein 1 
MTFR mitotransferrin 
mTOR mammalian target of rapamycin 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
NAC N-acetylcysteine 
NADP
+
 oxidized nicotinamide adenine dinucleotide phosphate 
NADPH reduced nicotinamide adenine dinucleotide phosphate 
NCI National Cancer Institute 
NDRG1 N-myc downstream-regulated gene 1 
NFκB nuclear factor κB 
Nrf2 Nuclear factor (erythroid-derived 2)-like 2 
OX oxidases 
PBS phosphate buffered saline 
PDK1 3’-phosphoinositide-dependent kinase-1 
PG Plumbagin 
P-gp P-glycoprotein 
PI3K phosphatidylinositol-3-kinase 
PI3K/AKT/mTOR 
Phosphatidylinositol-4,5-bisphosphate 3-kinase /  
Protein kinase B (PKB) / mammalian target of rapamycin 
PKC protein kinase C 
PKD protein kinase D 
PTEN phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase 
pyr pyruvate 
q NMR signal, quartet 
ROS reactive oxygen species 
RPMI Roswell Park Memorial Institute medium, 
RR Ribonucleotide reductase 
s NMR signal, singlet 
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sm NMR signal, symmetrical multiplet 
SNP single-nucleotide polymorphism 
SOD superoxide dismutase 
SR Selectivity ratio 
STEAP3 six transmembrane epithelial antigen of the prostate 3 (ferrireductase) 
t NMR signal, triplet 
TBACl tert-butylammonium chloride 
t
BHP tert-butyl hydroperoxide 
td NMR signal, triplet of duplets 
tet-off tetracycline-repressible 
Tf Transferrin 
TfR transferrin receptor 
TPx thioredoxin peroxidase 
Trx thioredoxin 
Trx-(SH)2 reduced thioredoxin 
TrxR thioredoxin reductase 
Trx-S2 oxidized thioredoxin 
TSC thiosemicarbazone 
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Table A1. Predicted physicochemical properties and measured biological data (IC50 values in µM) of isatin β-TSCs  
Compound code 
MW / 
g/mol 
logD TPSA 
calc 
pKa 
calc 
pKb 
IC50 
(MES-
SA) 
IC50 
(MES-
SA/Dx5) 
IC50 
(MES-
SA_ 
mCh) 
IC50 
(MES-
SA/Dx5
_mCh) 
IC50 
(KB-3-1) 
IC50 
(KB-V1) 
IC50 
(A2780) 
IC50 
(A2780 
adr) 
 
I-a (NSC73306) 
326.37 3.01 74.75 9.28 -1.48 
6.10  
± 0.942 
3.59  
± 1.01 
12.06  
± 3.32 
4.15  
± 0.895 
7.82  
± 2.06 
3.78  
± 0.433 
7.49  
± 0.297 
4.84  
± 1.21 
 I-b 410.37 4.44 83.98 9.31 -2.38 
6.14  
± 2.41 
2.78  
± 1.21 
8.14  
± 2.34 
2.52  
± 0.862 
6.56  
± 2.69 
3.92  
± 0.642 
3.39  
± 0.932 
3.77  
± 1.34 
 I-c 310.37 3.68 65.52 9.33 -1.23 
5.33  
± 1.43 
3.27  
± 0.751 
11.31  
± 2.53 
3.27  
± 0.850 
4.44  
± 1.47 
4.00  
± 0.618 
9.70  
± 1.50 
8.75  
± 1.94 
 I-d 341.35 3.11 108.66 9.17 -1.91 
9.17  
± 3.64 
4.74 
± 1.10 
15.76  
± 7.57 
7.55  
± 6.73 
8.196  
± 1.52 
4.58  
± 0.900 
25.70  
± 6.92 
8.78  
± 2.35 
 I-e 364.35 4.04 65.52 9.22 -2.14 
2.06  
± 0.360 
1.40  
± 0.349 
3.34  
± 0.694 
1.95  
± 0.905 
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Table A2. Predicted physicochemical properties and measured biological data (IC50 values in µM) of pyridinecarbaldehyde TSCs: 
Compound code 
MW / 
g/mol 
logD TPSA 
calc 
pKa 
calc 
pKb 
IC50 
(MES-
SA) 
IC50 
(MES-
SA/Dx5) 
IC50 
(MES-
SA_ 
mCh) 
IC50 
(MES-
SA/Dx5
_mCh) 
IC50 
(KB-3-1) 
IC50 
(KB-V1) 
IC50 
(A2780) 
IC50 
(A2780 
adr) 
 triapine 195.25 0.29 89.32 11.67 4.95   
1.305  
± 0.396 
2.523  
± 0.802 
    
 II-a 256.33 3.36 49.31 9.44 3.05     
0.715  
± 0.153 
0.585  
± 0.161 
        
 II-c 300.38 2.76 58.54 9.4 2.88 
0.340  
± 0.056 
0.0142 
± 0.0023 
0.252  
± 0.117 
0.0635 
± 0.0311 
0.951 
± 0.900 
1.75  
± 2.38 
0.0457 
± 0.00064 
0.0306 
± 0.0139 
 II-d 300.38 3.33 58.54 9.4 3.77     
4.715 
± 0.323 
4.22  
± 0.479 
    
 II-e 314.41 4.16 58.54 9.4 3.43 
0.423  
± 0.0812 
0.0718 
± 0.0388 
0.096  
± 0.022 
0.0559  
± 0.00126 
    
 II-f 270.35 3.87 49.31 9.46 3.05 
0.396 
± 0.184 
0.0762 
± 0.0230 
0.794  
± 0.244 
0.766  
± 0.710 
0.744  
± 0.135 
0.915  
± 0.252 
0.0480  
± 0.00214 
0.0635  
± 0.0045 
 II-g 284.38 3.43 49.31 9.46 2.88 
0.0163  
± 0.0086 
0.00178 
± 0.00054 
0.0654  
± 0.0798 
0.0294 
± 0.0166 
0.0404 
± 0.0169 
0.0360  
± 0.0149 
0.0172  
± 0.00578 
0.0210 
± 0.0054 
 II-h 284.38 3.43 49.31 9.4 2.88   
0.0317  
± 0.00281 
0.0632 
± 0.0167 
    
 II-i 284.38 3.43 49.31 9.43 2.88     
0.0299  
± 0.00631 
0.0922  
± 0.0330 
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Table A2. continued 
Compound code 
MW / 
g/mol 
logD TPSA 
calc 
pKa 
calc 
pKb 
IC50 
(MES-
SA) 
IC50 
(MES-
SA/Dx5) 
IC50 
(MES-
SA_ 
mCh) 
IC50 
(MES-
SA/Dx5
_mCh) 
IC50 
(KB-3-1) 
IC50 
(KB-V1) 
IC50 
(A2780) 
IC50 
(A2780 
adr) 
 II-j 301.32 3.3 92.45 9.25 3.05 
2.70 
± 0.88 
1.83  
± 0.469 
2.74  
± 1.43 
2.74  
± 0.0786 
1.05  
± 0.274 
1.99  
± 1.02 
0.666 
± 0.277 
1.37  
± 0.192 
 II-k 329.38 4.26 92.45 9.25 3.43 
10.88 
± 2.19 
8.02 
± 4.70 
10.47  
± 1.17 
11.05 
± 1.98 
8.03  
± 0.91 
8.93  
± 0.96 
no fit 
possible 
 
 II-l 324.32 4.24 49.31 9.31 3.05     
0.849  
± 0.125 
0.720 
± 0.201 
    
 II-m 338.35 3.79 49.31 9.31 2.88     
9.59 
± 1.32 
11.72 
± 0.2123 
    
 II-n 324.32 4.23 49.31 9.09 3.05   
0.125 
± 0.0364 
0.159  
± 0.0928 
    
 II-o 338.35 3.79 49.31 9.09 2.88     
0.0332  
± 0.00659 
0.161  
± 0.0845 
        
 II-q 314.41 2.74 71.67 9.40 6.10 
10.67  
± 2.36 
8.02  
± 1.49 
18.48  
± 1.14 
17.66  
± 5.47 
20.58  
± 6.29 
22.26  
± 1.40 
4.35  
± 0.683 
4.87  
± 0.527 
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Table A3. Predicted physicochemical properties and measured biological data (IC50 values in µM) of salicylaldehyde TSCs and an aniline 
derivative: 
Compound code 
MW / 
g/mol 
logD TPSA 
calc 
pKa 
calc 
pKb 
IC50 
(MES-
SA) 
IC50 
(MES-
SA/Dx5) 
IC50 
(MES-
SA_ 
mCh) 
IC50 
(MES-
SA/Dx5
_mCh) 
IC50 
(KB-3-1) 
IC50 
(KB-V1) 
IC50 
(A2780) 
IC50 
(A2780 
adr) 
 III-a 271.34 3.58 56.65 8.68 1.91   
14.04 
± 9.61 
6.45 
± 5.81 
    
 III-b 301.36 3.42 65.88 8.67 1.71 
3.91  
± 0.969 
3.50  
± 0.672 
2.67  
± 0.689 
1.85  
± 0.177 
5.02  
± 0.320 
4.87 
± 1.63 
5.47  
± 0.707 
6.95  
± 0.826 
 III-c 285.36 4.09 56.65 8.68 1.99 3.97  
± 1.47 
5.36  
± 2.09 
1.44  
± 0.249 
1.87  
± 0.468 
3.36  
± 0.395 
3.69  
± 1.06 
5.15  
± 1.04 
6.01  
± 0.788 
 III-d 299.39 3.94 56.65 8.63 1.74   10.86  
± 2.64 
3.46  
± 1.93 
    
 III-e 339.34 4.46 56.65 8.65 0.97   5.07  
± 1.86 
4.08  
± 1.50 
    
 III-f 384.33 3.41 99.79 6.40 0.35   
16.36  
± 3.38 
11.92 
± 1.66 
    
 III-g 384.33 3.41 99.79 6.40 0.35   
21.13  
± 2.86 
13.88  
± 1.65   
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Table A4. Predicted physicochemical properties and measured biological data (IC50 values in µM) of arylhydrazones. 
Compound code 
MW / 
g/mol 
logD TPSA 
calc 
pKa 
calc 
pKb 
IC50 
(MES-
SA) 
IC50 
(MES-
SA/Dx5) 
IC50 
(MES-
SA_ 
mCh) 
IC50 
(MES-
SA/Dx5
_mCh) 
IC50 
(KB-3-1) 
IC50 
(KB-V1) 
IC50 
(A2780) 
IC50 
(A2780 
adr) 
  IV-a 229.24 2.36 72.29 11.57 3.50 
2.82  
± 0.535 
2.49  
± 0.552 
2.45  
± 0.813 
2.71 
± 0.96 
1.95  
± 0.294 
2.83  
± 0.382 
1.73  
± 0.0560 
1.95  
± 0.0934 
  IV-b 243.26 1.92 72.29 11.18 3.43 
0.265  
± 0.0785 
0.0953 
± 0.0289 
0.261  
± 0.0603 
0.22  
± 0.0044 
0.358  
± 0.0490 
0.494  
± 0.0798 
0.144  
± 0.0337 
0.0272  
± 0.00756 
  IV-c 257.29 3.32 72.29 11.65 3.71 
1.55  
± 0.285 
1.11  
± 0.198 
2.33  
± 0.388 
2.11  
± 0.72 
1.23  
± 0.0257 
1.57  
± 0.238 
1.30  
± 0.169 
0.630  
± 0.0962 
 IV-d 212.25 1.98 50.17 12.66 4.34   
0.102 
± 0.0869 
0.0591  
± 0.0071 
    
 IV-e 248.28 4.00 50.17 12.95 4.04   
0.820  
± 0.286 
0.435  
± 0.109 
    
 IV-f 262.31 3.55 50.17 12.59 3.97   
0.483  
± 0.987 
0.382  
± 0.186 
    
 IV-g 262.31 4.49 50.17 13.03 4.74   
0.559  
± 0.146 
0.397  
± 0.0371 
    
 IV-h 276.34 4.00 50.17 12.71 4.67   
0.298  
± 0.0672 
0.294 
± 0.0153 
    
 VII-d 269.26 2.15 88.5 8.73 3.21   
Not 
toxic 
  
Not 
toxic 
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Table A5. Predicted physicochemical properties and measured biological data (IC50 values in µM) of pyridinyl hydrazinobenzothiazoles and an 
acetaniline derivative 
Compound code 
MW / 
g/mol 
logD TPSA 
calc 
pKa 
calc 
pKb 
IC50 
(MES-
SA) 
IC50 
(MES-
SA/Dx5) 
IC50 
(MES-
SA_ 
mCh) 
IC50 
(MES-
SA/Dx5
_mCh) 
IC50 
(KB-3-1) 
IC50 
(KB-V1) 
IC50 
(A2780) 
IC50 
(A2780 
adr) 
 V-a 254.31 4.05 50.17 8.80 3.88 
1.42  
± 0.223 
1.02  
± 0.154 
2.70  
± 0.258 
3.36  
± 1.36 
0.646  
± 0.066 
0.840  
± 0.194 
0.587  
± 0.0867 
0.455  
± 0.111 
 V-b 268.34 3.58 50.17 8.37 3.68 
0.201  
± 0.0856 
0.0142  
± 0.00193 
0.252  
± 0.0714 
0.104  
± 0.0224 
0.344  
± 0.0353 
0.279  
± 0.0480 
0.0944  
± 0.0330 
0.0312  
± 0.00886 
 V-c 282.36 5.00 50.17 8.90 4.14 3.24  
± 0.0548 
1.85  
± 0.0391 
4.26  
± 0.054 
3.83  
± 1.47 
0.612  
± 0.116 
1.14  
± 0.0804 
0.814  
± 0.0446 
0.619  
± 0.185 
 V-d 282.36 1.59 63.3 5.48 13.86 45.58  
± 8.81 
28.00  
± 4.22 
46.16  
± 9.10 
19.01  
± 2.87 
        
 VII-c 294.33 2.47 66.38 5.73 2.30   
Not 
toxic 
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Table A5. Predicted physicochemical properties and measured biological data (IC50 values in µM) of hydroxyphenyl hydrazinobenzothiazoles 
Compound code 
MW / 
g/mol 
logD TPSA 
calc 
pKa 
calc 
pKb 
IC50 
(MES-
SA) 
IC50 
(MES-
SA/Dx5) 
IC50 
(MES-
SA_ 
mCh) 
IC50 
(MES-
SA/Dx5
_mCh) 
IC50 
(KB-3-1) 
IC50 
(KB-V1) 
IC50 
(A2780) 
IC50 
(A2780 
adr) 
 VI-a 269.32 4.20 57.51 8.61 4.76 
24.68  
± 8.55 
10.45  
± 4.60 
23.18  
± 11.39 
4.55  
± 1.89 
18.07  
± 9.94 
11.73  
± 1.23 
3.16  
± 0.630 
6.01  
± 1.43 
 VI-b 283.35 4.07 57.51 8.57 4.56 
12.51  
± 1.67 
5.52  
± 1.77 
21.61  
± 3.23 
11.64  
± 4.76 
14.29  
± 3.65 
12.07  
± 3.51 
8.74  
± 2.80 
9.95  
± 1.33 
 VI-c 299.35 4.09 66.74 9.04 4.55   
14.91  
± 7.89 
11.57  
± 8.55 
    
 VI-d 313.37 3.95 66.74 8.93 4.35   
50.67  
± 9.37 
15.37  
± 6.58 
    
 VI-e 
283.35 4.70 57.51 8.92 4.83   
89.10  
± 27.50 
15.60  
± 8.05 
    
 VI-f 314.32 3.21 100.65 6.38 4.02   
4.07  
± 1.59 
1.99 
± 0.714 
     
 VI-g 283.35 4.36 46.51 10.09 4.80   
Not 
toxic 
Not 
toxic 
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